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ABSTRACT 
While physical rehabilitation facilitates some recovery, it is uncommon for 
patients to recover completely from stroke. Cell based therapies derived from stem cells 
have produced promising results in enhancing recovery in pre-clinical studies, but the 
mechanism is not yet completely understood. We previously evaluated human umbilical 
tissue-derived cells (hUTC) in our non-human primate model of cortical injury, limited to 
the hand area of primary motor cortex. hUTC treatment, injected intravenously 24 hours 
after injury, resulted in significantly greater recovery of fine motor function compared to 
treatment with vehicle. Based on these striking findings, in the current study, we 
investigated the hypothesis that hUTC treatment leads to functional recovery through 
reducing cytotoxic responses and enhancing neurorestorative processes following cortical 
injury. Brain sections were assessed using histological techniques to quantify perilesional 
oxidative damage, hemosiderin accumulation, microglial activation, Betz cell number, 
synaptic density, and astrocytic complexity. Brain sections outside of the primary area of 
injury were also assessed for microglial activation in white matter pathways, cell 
activation through c-Fos in premotor cortices, and neurogenesis in neurogenic niches. 
  x 
Finally, blood samples from throughout the recovery period and CSF samples from 16 
weeks after injury were analyzed for BDNF levels. In the perilesional area, hUTC 
treatment was associated with lower oxidative damage and hemosiderin accumulation, 
but not with a difference in microglial activation. hUTC also resulted in a trend toward 
higher astrocyte complexity and synaptic density in the lesion area, but no difference in 
ipsilesional Betz cell number. Further, hUTC treatment led to more microglia in white 
matter pathways, higher c-Fos activation in ventral premotor cortex, and a trend toward 
higher neurogenesis in the hippocampus. Finally, BDNF levels were higher in blood with 
hUTC treatment one week after injury, but there was no change beyond one week in 
blood serum or in CSF, when compared with vehicle. Taken together, these results 
suggest that hUTC treatment modulates immune responses, limits perilesional damage 
and cell death, enables neuroplasticity and reorganization, and enhances acute 
neurotrophic factor secretion. While many cell therapies are currently undergoing clinical 
trials, this study advances our understanding of the mechanism of cell based therapies. 
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CHAPTER ONE: INTRODUCTION AND SPECIFIC AIMS 
Stroke Related Disability 
Every year 795,000 Americans suffer a stroke which results in permanent cortical 
damage and functional disability (Go et al., 2013). Thrombolytic therapy is the only FDA 
approved treatment for ischemic stroke (Koroshetz, 1996). It functions in a 
neuroprotective role, but only if given within 4.5 hours of stroke onset (Cronin, 2010; 
Carpenter et al., 2011) and therefore, only a minority of patients are treated with 
thrombolytics due to limited time constraints or other contraindications. However, with 
physical rehabilitation, many patients do recover some degree of function in the first four 
weeks after stroke (Grefkes and Ward, 2014), but it is uncommon for patients to recover 
completely to pre-stroke functioning (Gowland, 1987).  Currently, there are no treatments 
to enhance recovery from stroke and a neurorestorative treatment is needed that enhances 
endogenous restorative mechanisms that occur following stroke and balances pro- and 
anti-inflammatory responses to injury. 
Stroke Pathophysiology 
Ischemic Cascade 
Following an ischemic event, such as a stroke, the tissue normally perfused by the 
blocked blood vessel undergoes deprivation of oxygen and glucose triggering a sequence 
of events termed the “ischemic cascade” that involves cellular bioenergetic failure and 
irreversible cell injury to all cell types (Brouns and De Deyn, 2009). Wherein, available 
adenosine triphosphate (ATP) depletes, increasing the need for oxidative 
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phosphorylation, which produces reactive oxygen species (ROS) in the cells undergoing 
ischemia (Lipton, 1999). Next, the disruption of ion channels causes an influx of Na+ and 
an outflux of K+, which depolarizes the membrane, thus opening Ca2+ channels and 
leading to rapid influx of Ca2+ and release of glutamate into synaptic clefts (Graham and 
Hickey, 2002). Neighboring cells are depolarized when glutamate binds to N-methyl-D-
aspartate (NMDA) or α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptors, leading to wide spread peri-infarct depolarizations (Lipton, 1999). The 
continued influx of Ca2+ into the cell leads to membrane and protein degradation and 
mitochondrial damage (Lipton, 1999).  
Cytotoxic Mechanisms and Blood Breakdown 
Following disruption of the mitochondria, both cytochrome c and reactive oxygen 
species are released into the cell (Lipton, 1999). Excess reactive oxygen species intra- 
and extracellularly in the area of ischemia leads to necrosis in the ischemic core through 
lipid peroxidation and apoptosis in neighboring neurons. Lipid peroxidation is the 
breakdown of polyunsaturated fatty acids, such as those found in the bilayer phospholipid 
membrane or myelin, initiated by reactive oxygen species. Fatty acid radicals are 
propagated through a series of reactions ultimately being broken down to stable end 
products including 4-hydroxynonenal (4-HNE) and malondialdehyde (MDA) (Allen and 
Bayraktutan, 2009). Both end products are detected using immunohistochemistry to 
estimate the extent of oxidative damage to have occurred in the tissue (Ravera et al., 
2015).  
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Lipid peroxidation is further catalyzed in the presence of unbound iron 
(Gutteridge, 2006). Following ischemic injury, iron homeostasis is disrupted resulting in 
an increase of total brain iron (Selim and Ratan, 2004). In the case of injury, such as a 
stroke, ferritin accumulates intracellularly and extracellularly with fragments of cell 
membrane and hemoglobin bound to ferric iron forming the protein aggregate, 
hemosiderin (Selim and Ratan, 2004). Hemosiderin deposits accumulate with age 
especially in the globus pallidus (Brass et al., 2006) and iron bound to hemosiderin is 
poorly available for use (Gutteridge and Hou, 1986). The Fenton reaction and Haber-
Weiss cycle perpetuate iron homeostasis disruption, also producing an increasing pool of 
hydroxyl free radicals. These hydroxyl free radicals may contribute to the initiation of 
further lipid peroxidation and other oxidative damage in the area of ischemia 
(Winterbourn, 1995). Iron mediated lipid peroxidation persists beyond the initial 
reperfusion injury (Kondo et al., 1997).  
Acute Responses of Peripheral and Central Immune System 
Following injury to the brain, the neuroimmune and peripheral immune systems 
are activated. Acutely, microglia undergo a differential activation, home to the site of 
injury through chemotaxis, and recruit peripheral immune cells, including neutrophils, 
lymphocytes, and macrophages (Kreutzberg, 1996; Fumagalli et al., 2015). Classic 
activation (pro-inflammation) of these cells promote neurotoxicity through the release of 
pro-inflammatory cytokines, proteases, and ROS (Patel et al., 2013). In response to pro-
inflammatory cytokines, astrocytes become reactive and exhibit hypertrophy (Pekny, 
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Wilhelmsson and Pekna, 2014), localize to the lesion (Li et al., 2014), and produce 
proteases and more pro-inflammatory cytokines (Amantea et al., 2015). 
Reactive astrocytes disrupt the blood brain barrier (BBB) and inhibit axonal 
outgrowth, while also limiting damage through elimination of glutamate and ROS (Li et 
al., 2014; Pekny, Wilhelmsson and Pekna, 2014). Phagocytic microglia and macrophages 
clear cellular debris including degraded cellular components and iron complexes 
(Fumagalli et al., 2015). The lesion core is formed where irreversible injury takes place 
through the cytotoxic processes described above. The periphery of the lesion core, termed 
the penumbra, is a transitional area that is vulnerable to damage (Furlan et al., 1996; 
Moustafa and Baron, 2009). Elongated astrocytes assemble with chondritic sulfate 
proteoglycan to form the glial scar around the lesion core (Suzuki et al., 2012; Li et al., 
2014). The glial scar acts to reduce the spreading secondary injury from the area of 
irreversible cell damage and to enable plasticity in surviving penumbral structures (Li et 
al., 2014; Pekny, Wilhelmsson and Pekna, 2014). 
Chronic Responses of Glia 
Simultaneous and long-lasting anti-inflammatory processes counteract damage 
resulting from pro-inflammation. It remains unclear exactly how and when pro-
inflammation converts to resolution and neuroprotection (Shichita, Ito and Yoshimura, 
2014). However, through resolution of inflammatory event, microglia, phagocytes, and 
astrocytes polarize from classically (cytotoxic) to alternatively (cytoprotective) activated 
phenotypes (Zanier et al., 2011; Fumagalli et al., 2015). In alternative activation, 
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microglia secrete growth factors and anti-inflammatory cytokines promoting lesion repair 
and further removal of cell debris (Fumagalli et al., 2015). While, chronic inflammation 
after ischemia is well characterized up to 30 days following injury, less is known about 
the inflammatory processes after 30 days in long-term recovery. However, there is 
evidence of endogenous neurorestorative processes in the chronic phase including 
remodeling of axons, synapses, and blood vessels in the perilesional area.  
Neurorestorative Processes in the Penumbra 
Injury to the primary motor cortex results in neuronal loss through oxidative 
damage, apoptosis, and inflammation (Brouns and De Deyn, 2009). The penumbra 
borders the lesion core where irreversible damage occurs and is defined by the decreased 
level of blood flow to the area (Astrup, Siesjö and Symon, 1979) in an ischemic event 
and the area of secondary injury (Stoffel et al., 1997) in a traumatic event. Regeneration 
of the core of the lesion is uncommon leaving the perilesional structures both vulnerable 
to damage and in the proximity to reorganize surviving structures (Furlan et al., 1996; 
Moustafa and Baron, 2009). As inflammation in the penumbra area resolves, surviving 
structures contribute to remodeling damaged circuits leading to functional improvements 
after injury (Carmichael, 2003; Nudo, 2007). This perilesional reorganization is related 
spatially and temporally to the growth and retraction of new blood vessels (Brown et al., 
2007). 
In the developing brain and following pathological events, microglia strip 
synapses, both microglia and astrocytes assist in neurite guidance, and astrocytes aid in 
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synaptogenesis and stabilizing new synapses (Powell, Fawcett and Geller, 1997; Eyo and 
Dailey, 2013; Li et al., 2014). Studies report that microglia near the penumbra may be 
neuroprotective and enhance plasticity through the release of neurotrophic factors 
(Lalancette-Hebert et al., 2007; Narantuya et al., 2010; Liguz-Lecznar and Kossut, 2013; 
Anttila et al., 2016). Further, a growing body of literature suggests that astrocytes are 
responsible for axonal guidance and enhancing functional recovery after injury (Barker 
and Ullian, 2010; Li et al., 2014) through release of neurotrophic factors such as brain 
derived neurotrophic factor (BDNF) (Béjot, Mossiat, et al., 2011).  
Contribution of Neurorestorative Adult Neurogenesis  
It has been demonstrated that cortical injury stimulates the formation of new 
neurons and glia in the adult brain located in two regions: the subventricular zone and the 
subgranular zone of the dentate gyrus (Anderson, 2001; Arvidsson et al., 2002; Jin et al., 
2006; Minger et al., 2007; Zhang et al., 2011, 2013; Lindvall and Kokaia, 2015). A pool 
of newly generated cells is formed throughout the recovery period and up to four months 
after injury (Thored et al., 2006). However, it is unknown whether these observed 
proliferating cells incorporate into the damaged circuits to replace damaged or dead cells 
(Burda and Sofroniew, 2014). However, newly generated neurons are unable to quickly 
and accurately integrate into damaged circuits (Wieloch and Nikolich, 2006). Therefore, 
studies suggest instead that neuroglioblasts in the same areas may act as mediators for 
enhanced recovery of function from cortical injury (Zhang and Chopp, 2016; Zhang, 
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Zhang and Chopp, 2016) by increasing growth factor expression of parenchymal cells in 
the lesion area.  
Facilitation of Spontaneous Recovery Following M1 Injury  
In both animal models and human stroke patients with motor impairments, 
physical therapy involving rehabilitative motor tasks can lead to significant improvement 
over a period of months following stroke (Calautti and Baron, 2003; Frost et al., 2003). 
Nevertheless, complete recovery to pre-stroke function is rare (Gowland, 1987), despite 
the CNS having a limited ability to repair or regenerate neurons (Yiu and He, 2006). 
Therefore, functional recovery is more likely due to a variety of neuroplasticity 
mechanisms such as axonal sprouting, dendritic remodeling, synaptic plasticity, and 
changes in myelination (Wieloch and Nikolich, 2006; Minger et al., 2007; Pascual-Leone 
et al., 2012; Fields, 2015; Mensch et al., 2015; Armstrong et al., 2016). In fact, there is 
evidence for cortical neuroplasticity and reorganization following CNS lesions in both 
humans and animal models (Pons et al., 1988; Kaas, 1991; Seitz et al., 1995). This 
reorganization occurs most notably in the perilesional area, though changes also occur 
throughout the brain after stroke (Ward and Cohen, 2004; Cotrina et al., 2016), especially 
in undamaged motor areas (Frost et al., 2003; Nudo, 2007; Nudo and McNeal, 2013). For 
example, following primary motor cortex (M1) injury, reorganization is frequently 
observed in premotor cortex and corticospinal tract neurons (Frost et al., 2003; Liu et al., 
2013; Sist, Fouad and Winship, 2014). With the secondary motor areas projecting to M1 
and corticospinal tract, it is possible that the functional connections that compensate for 
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M1 are strengthened or unmasked rather than completely rebuilt to assist in functional 
recovery. 
Neuroanatomical Basis of Motor Movements of the Hand 
Upper motor neurons originating in the primary motor cortex project into the 
corticospinal tract and synapse with lower motor neurons that directly activate muscles 
controlling movement (Groos et al., 1978). However, beyond upper and lower motor 
neurons, a complex system of cortical and subcortical structures enables voluntary motor 
movements. Control for the motor system includes a bilateral neural network that 
integrates visual, sensorimotor, and cognitive feedback to contribute to the planning and 
execution of motor movements (Brugger et al., 2015; Mayhew et al., 2017). While the 
complexity of the motor system is not entirely understood, it is thought that the network 
forms internal representations of motor actions to generate and imitate these represented 
actions (Giacomo Rizzolatti and Luppino, 2001). Secondary motor areas involved in this 
motor system include the premotor, supplementary motor, cingulate motor, and posterior 
parietal cortices along with subcortical structures of the basal ganglia, thalamus, and 
cerebellum.  
Cortical motor areas can be divided into two groups based on their relation to 
visual and somatosensory information (parietal dependent motor areas) or cognitive 
information (prefrontal dependent motor areas) (Giacomo Rizzolatti and Luppino, 2001). 
Parietal dependent motor areas (primary motor, premotor, and supplementary motor 
areas) contain representative somatotopic maps and send direct projections the spinal 
cord (Giacomo Rizzolatti and Luppino, 2001). The premotor cortices, supplementary 
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motor area, and somatosensory cortices are the source of afferents to M1 (Dum and 
Strick, 1991; Luppino et al., 1993). In contrast, prefrontal dependent motor areas (pre-
supplementary motor area and rostral dorsal premotor cortex) do not project to the M1 or 
spinal cord, but instead project to secondary motor areas and the brainstem (Luppino et 
al., 1993; He, Dum and Strick, 1995; G Rizzolatti and Luppino, 2001). Parietal 
dependent input includes specific motor activity needed for goal directed movements and 
prefrontal dependent input involves decisions about the goal directed movement (G 
Rizzolatti and Luppino, 2001). 
The primary motor cortex (M1) is defined as Broadman’s area 4 in the human 
brain (Brodmann, 1999), but a similar homologous M1 is found in monkey. M1 is 
organized with somatotopic representations of the entire body. Supragranular layers (I-
III) receive input from other cortical areas and project to cortical areas in the contra- and 
ipsilateral hemispheres. Infragranular layers (V-VI) consist of the long projection 
neurons, the upper motor neurons, of layer V termed Betz cells (Rivara et al., 2003), and 
the corticothalamic connections originating in layer VI. Early anatomical studies have 
classified motor cortex as agranular based on the absence of a typical layer IV (Matelli, 
Luppino and Rizzolatti, 1985). However, recent studies are challenging the long-standing 
dogma with anatomical and physiological evidence of a distinct layer IV (Yamawaki et 
al., 2014), which receives motor thalamocortical input from the motor thalamus (Barbas 
and García-Cabezas, 2015). 
The dorsal and ventral premotor cortices (PMd and PMv) are defined as 
Brodmann’s area 6 (Brodmann, 1999) and their lamination structure, having a weakly-
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delineated layer IV, is intermediate between the agranular and granular (Barbas and 
García-Cabezas, 2015). The premotor cortices encode representations of potential motor 
actions based on previous visual information and process new visual information to 
determine an appropriate motor action (G Rizzolatti and Luppino, 2001). PMv has code 
specific movements with hand shaping (Rizzolatti et al., 1988) related to the goal and 
temporal aspects of movement (Murata et al., 1997). Anterior intraparietal area (AIP) is a 
parietal structure that represents visual information before sending it to PMv for motor 
planning (Murata et al., 2000). Following processing, PMv sends motor activity plans 
with visual and temporal aspects of movements to M1 for activity (Murata et al., 2000). 
The mirror neurons that exhibit firing activity correlated with both executing and viewing 
motor actions, are found within PMv (Rizzolatti, Fadiga, Gallese, et al., 1996). These 
neurons are thought to interact with the superior temporal sulcus via the inferior parietal 
lobule (Perrett et al., 1989) to enable action recognition and imitation through visual 
input (G Rizzolatti and Luppino, 2001). 
 Motor areas located in the depths of the sagittal sulcus include supplementary 
motor area (SMA), pre-supplementary motor area (pre-SMA), and cingulate motor area 
(CMA). The SMA is involved in processing somatosensory information to plan for 
complex movements and execute learned sequences of movements (Luppino et al., 
1993). Neurons in SMA are related to specific types of movements and are active shortly 
before movement performance (G Rizzolatti and Luppino, 2001). In contrast to SMA, 
pre-SMA relays prefrontal input to PMv about the goal of the motor action and is 
activated long before movement occurs allowing change of direction of action before 
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activity (Luppino et al., 1993; Shima and Tanji, 2000). Pre-SMA is involved in learning 
sequences of movement and making decisions about the sequence (G Rizzolatti and 
Luppino, 2001). Next, CMA is involved in assigning value to an action based on context 
and outcome (Iwata et al., 2013) and adjusting future behavior based on previous 
consequence (Shima and Tanji, 2000). Additionally, part of CMA is involved in bilateral 
hand movements with a homogenous distribution of neurons (Nakayama, Yokoyama and 
Hoshi, 2015), in direct contrast to SMA which is organized in clusters and controls the 
contralateral hand much like M1 (Yokoyama, Nakayama and Hoshi, 2016). Overall these 
midline supplementary motor areas comprise the supplementary motor cortex (SMC) that 
together integrate cognitive input to inform parietal dependent motor areas prior to 
movement initiation (Brugger et al., 2015). 
Subcortical motor areas, basal ganglia and cerebellum, relay all projections 
through the thalamus to reach the cortical motor areas. The basal ganglia functions as a 
network to integrate inputs from cortical and subcortical areas to gate the output in motor 
cortices through the thalamus to allow goal-directed movement or prevent unintended 
movements (Hikosaka, Takikawa and Kawagoe, 2000). While the basal ganglia are 
involved in modulation of motor output, these structures are also involved in procedural 
learning, skill execution, and value based behavior through dopaminergic neurons 
(Hikosaka et al., 2017).  The cerebellum is active in proprioception of position and 
motion during limb movement while also being involved in higher cognitive processes 
(Weeks, Therrien and Bastian, 2017). 
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Corticospinal tract fibers project to the spinal cord to enable activation or 
inhibition of lower motor neurons. Betz cell projections from the primary motor cortex 
make up only part of the projections to the corticospinal tract. The remaining fibers 
originate in the premotor cortices (Dum and Strick, 1991), the supplementary and 
cingulate motor areas (He, Dum and Strick, 1995), and the somatosensory cortex (3a) 
(Rathelot and Strick, 2006). Most of the corticospinal tract fibers decussate in the 
medulla and ultimately activate contralateral limb associated muscles. Together these 
corticospinal, primary motor cortex, and brainstem connections comprise the motor 
systems. Within the system, the primary motor cortex is involved in the control and 
execution of motor movements. The precision grasping of an object during goal directed 
hand movements is mediated by the PMd and PMv. Specifically, the PMd is involved in 
the direction and amplitude of reaching towards an object to be grasped (Kantak et al., 
2012). In contrast, the PMv mediates the actual grasping component of goal directed 
hand movements including the appropriate shaping of the hand posture to grasp objects 
(Rizzolatti et al., 1988, 1990; Rizzolatti, Fadiga, Matelli, et al., 1996; Murata et al., 1997; 
Kantak et al., 2012). Learning and execution of complex sequences of motor tasks is 
mediated through the pre-SMA and SMA (Luppino et al., 1993). Finally, value and 
reward systems associated with motor movements are mediated through the CMA and 
basal ganglia (Iwata et al., 2013; Hikosaka et al., 2017). 
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Pre-Clinical Models of Stroke 
Modeling Human Stroke 
 Ischemic stroke occurs spontaneously in human patients and there is considerable 
variability in the localization and size of the infarct. The molecular mechanism of 
ischemic stroke differs significantly between different types including cases due to large 
vessel atherosclerosis and rupture of plaque, cardioembolism, and small vessel disease 
(Sommer, 2017). To develop translatable neurorestorative treatments for human patients 
following stroke, extensive preclinical testing of new therapeutics is needed using animal 
models. Models for human stroke ideally exhibit the diversity of human stroke in age and 
sex differences (Hall, Pazara and Linseman, 1991; Bacigaluppi, Comi and Hermann, 
2010) as well as location and size of infarct. However, to produce reliable results, 
preclinical models of stroke need to exhibit reproducible infarcts and have low variability 
between experimental groups. Further experimental stroke surgery must be performed 
under anesthesia and the confounding effects of anesthesia must be considered. Models in 
pre-clinical stroke research range from in vitro models to in vivo models in rodents and 
non-human primates. Each step has its utility in the pre-clinical flow. However, as 
treatments progress forward toward clinical trials, the differences between pre-clinical 
models and human patients must be considered.  
In Vitro Studies to Model Stroke 
 In vitro studies of stroke provide an opportunity for high-throughput analysis and 
pinpointing biochemical and molecular mechanisms of oxygen deficiency. Specifically, 
 14  
factors and enzymes can be neutralized to confirm whether they are integral to 
mechanism of a therapeutic. The ischemic environment is replicated in vitro using 
oxygen and glucose derivation or enzymatic blockage of cell metabolism (Choi, 1993; 
Sommer, 2017). In vitro studies are performed using primary cell culture, which allows 
for visualization of the dynamic interactions between brain cells, or with organotypic 
slices, which allow for visualization of the anatomic proximity of such cells in the brain 
(Dirnagl, 2012; Sommer, 2017). However, the synthesized environment may miss key 
components of the in vivo processes.  
Rodent Models of Stroke 
 Preclinical models in rodents are most commonly middle cerebral artery occlusion 
(MCAO) models. The MCA, often affected in human patients, is either permanently or 
transiently occluded. This occlusion can be accomplished through an intraluminar suture 
(Longa et al., 1989), ligation (Robinson et al., 1975), or electrocoagulation (Brint et al., 
1988). Another route of occlusion is through the placement of an embolus, such as a 
thromboembolic clot (Kudo et al., 1982) or microsphere (Mayzel-Oreg et al., 2004), in 
the MCA, which can later be lysed or removed. Both the intraluminar suture and embolus 
methods model occlusion without requiring a craniotomy that adds blunt skull trauma and 
disruption of the BBB to the milieu of stroke pathophysiology (Sommer, 2017). 
However, entering the lumen of a blood vessel may result in endothelial cell damage. 
Overall, MCAO models result in a large lesion with variable and significant impairments 
and a high mortality rate (Carmichael, 2005). However, the evolution of damage results 
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in an easily discernable core and penumbra, which are important aspects of modeling 
human stroke (Sommer, 2017).  
 Other methods of ischemia induction include the use of endothelin-1, which 
evokes long lasting but temporary vasoconstriction (Yanagisawa et al., 1988). Following 
craniotomy, endothelin-1 is applied to an exposed blood vessel or directly on the surface 
of the brain (Robinson and McCulloch, 1990). Vasoconstriction follows that eventually 
subsides as the endothelin-1 is cleared and results in a slow ischemia onset and slow 
reperfusion (Sommer, 2017). Receptors for endothelin-1 are on endothelial cells of blood 
vessels, resulting in vasoconstriction, but these receptors are also found on neurons and 
astrocytes, which must be considered (Carmichael, 2005). 
Another model is the photochemical stroke, which targets distal branches of MCA 
and can be performed without a craniotomy (Watson et al., 1985). Following injection of 
a photosensitive dye, illumination through the skull at a specific wavelength activates 
ROS in the blood vessels containing the dye through photooxidation (Carmichael, 2005). 
Through ROS activation, the endothelial lining of the blood vessel is damaged, resulting 
in platelet activation and aggregation and thus ischemia (Watson et al., 1985; Sommer, 
2017). While this model is non-invasive and targeted to specific areas, it results in a large 
degree of endothelial cell damage and vasogenic edema (Carmichael, 2005). 
Spontaneous strokes can be investigated in rat models of hypertension, which 
exhibit human-like symptoms including a higher risk for ischemic stroke (Okamoto et al., 
1966). However, intrinsically the experimental model is much more unpredictable with 
increased variability in the population. Further, while hypertensive rats do represent the 
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human condition, the resulting pathologies or outcome measures are difficult to attribute 
to hypertension, stroke, or other causes (Sommer, 2017). Overall, rodent models of stroke 
provide an in vivo assessment of experimental therapeutics, but the model used and its 
caveats must be considered when interpreting the results of the study. Other important 
considerations include anatomical differences between rodents and humans such as a 
smooth cortex, lissencephaly, and a low extent of white matter. 
Monkey Models of Stroke 
 While many neurorestorative treatments have shown promise in rodent models of 
stroke, none have successfully translated to human stroke patients. In order to bridge the 
clinical gap, the Stroke Therapy Academic Industry Roundtable (STAIR) report 
recommends that promising therapies be tested in gyrencephalic species, such as non-
human primates (NHP) prior to human trials (Stroke Therapy Academic Industry 
Roundtable (STAIR), 1999; Fisher et al., 2009). Of the available laboratory animals, 
NHPs have a brain structure most similar to humans including white matter volume and 
organization of the cortex and NHP exhibit a greater degree of fine dexterity, allowing 
for more thorough outcome measures. Importantly, financial and ethical considerations 
require a therapeutic to be promising in other pre-clinical models before NHP trials.  
Similar to rodents, there exists several NHP models of stroke. The first NHP 
stroke models were developed in baboons using balloon inflation to occlude the MCA 
(Spetzler et al., 1980, 1983) or lenticulostriate arteries (Del Zoppo et al., 1986). Since 
these initial models, cortical injury models have been developed in other NHP species 
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including both lissencephalic species such as the marmoset, squirrel monkey, owl 
monkey, and Senegal bush baby as well as gyrencephalic species such as the macaque 
monkey (rhesus, cynomolgus, and Japanese), African green monkey, and vervet monkey 
(Cook and Tymianski, 2012). Historically, baboons were the most common NHP species 
used for stroke modeling (Sommer, 2017). It is important to note the greater degree of 
collateralization in NHP cerebral vasculature, especially in the baboon, requiring careful 
techniques to insure complete occlusion (Cook and Tymianski, 2012). The macaque 
monkeys have collateral blood vessels in the MCA, but to a lesser degree, making their 
vasculature more similar to that of humans (Cook and Tymianski, 2012).  
Models of stroke in NHP are often adaptations from rodent models. A common 
model of stroke in NHP involves a similar MCAO using clip, ligation, 
electrocoagulation, balloon inflation, endovascular microcatheter, or endovascular 
embolus (Sommer, 2017), resulting in a large ischemic injury. Isolation of the MCA 
occurs either through a pterion craniotomy (Roitberg et al., 2003) or a transorbital 
approach (Spetzler et al., 1980). The transorbital approach was developed in baboons 
(Spetzler et al., 1980, 1983; Del Zoppo et al., 1986) and has been adapted in rhesus 
monkey models (Jones et al., 1981; Murphy et al., 2008), but requires the enucleation of 
the eye, restricting post-operative behavioral outcome measures. Endovascular routes to 
MCAO are also common, but result in a high mortality rate (Cook and Tymianski, 2012). 
Finally, the photothrombotic model has also been adapted in limited NHP studies (Li et 
al., 2010; Ikeda et al., 2013). 
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Another route of ischemic stroke induction is through focal ischemic lesions 
involving an electrophysiologically guided lesion in the arm or hand area of M1 
(Hoffman and Strick, 1995; Pizzimenti et al., 2007; Moore et al., 2012, 2013, 2016; 
Darling et al., 2013). This model enables a reliable outcome measure of motor activity 
with one arm or hand. Following pterion craniotomy, the lesion is created using a 
micropipette in the arm or hand area either to gently remove subpial arterioles penetrating 
the surface of the cortex (Moore et al., 2012, 2013, 2016) or remove the entirety of the 
gray matter (Hoffman and Strick, 1995; Pizzimenti et al., 2007; Darling et al., 2013). 
These focal lesions are consistent, but even with careful suction some blood infiltrates 
into brain parenchyma and adds another dimension of pathology more similar to a 
hemorrhagic stroke. This suggests that the focal cortical injury model, such as that used 
in the current study, is a hybrid between ischemic and hemorrhagic stroke. 
Cell Based Therapy 
Defining Stem Cells 
 Cell based therapies contain a variety of multipotent cell types from different 
anatomical sources. Stem cells are an undifferentiated and self-renewing cell population 
with potency, defined as the ability to differentiate into specialized cells (Burns and Zon, 
2002). Stem cells are found in developing embryos and in many regions throughout the 
adult body. During embryonic development, embryonic stem cells (ESC) of the morula 
(day 3 post-fertilization) are totipotent, able to form an embryo and extraembryonic 
structures, and ESC of the blastocyst (day 5 post-fertilization) are pluripotent, able to 
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form cells of all three germ layers (ectoderm, mesoderm, and endoderm) (Kalladka and 
Muir, 2014). While stem cell research began investigating the potential of ESC as a 
therapeutic, ethical concerns and legislature has halted further research into embryonic 
stem cells, beyond the use of preexisting ESC lines (Kalladka and Muir, 2014). Due to 
these changes, adult derived stem cells have become the focus of cell-based therapy in 
recent years (Hsuan et al., 2016). 
In the adult, stem cells are either hematopoietic or mesenchymal in lineage. 
Hematopoietic stem cells (HSC) are multipotent cells that give rise to blood cells of both 
myeloid and lymphoid origin (Cai, Weiss and Rao, 2004). Mesenchymal stem/stromal 
cells (MSC) are multipotent and differentiate into cells of mesodermal origin (Preston et 
al., 2003). MSC support hematopoiesis (Lindner et al., 2010) and become activated 
following injury or infection to enable reparation of tissue (Preston et al., 2003). MSC are 
a heterogenous population and vary in potency based on different source regions (Fazzina 
et al., 2016), but the International Society for Cellular Therapy proposed minimum 
criteria to define multipotent mesenchymal stromal cells. MSC must be plastic adherent 
and express CD105, CD73, and CD90 while not expressing hematopoietic markers such 
as CD45, CD34, CD14, CD11b, CD79α, CD19, or HLA-DR (Dominici et al., 2006). 
Stem Cell Use in Cell Based Therapy 
In the adult, MSC are found in adipose, bone marrow, neurogenic niches, dental 
pulp, olfactory mucosa, basal layer of the epidermis, extraembryonic membranes, and 
other sites of high cell turnover (Fazzina et al., 2016). Adipose cells are a common 
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harvest procedure from liposuction or tissue resection (Schreml et al., 2009) and yield 
multipotent self-renewing cells in culture. Bone marrow are a common site of harvest for 
both HSC and MSC. In fact, bone marrow transplantation of HSC is the only clinically 
used cell-based therapy (Thomas et al., 1957). However, bone marrow samples are a 
painful procedure with a low yield of viable cells. During pregnancy, extraembryonic 
membranes including the placenta, amnion, amniotic fluid, umbilical cord, and umbilical 
cord blood are rich in both HSC and MSC (Chen et al., 2015). The extraembryonic 
membranes are typically disposed of following birth, leaving them readily available with 
proper consent, and without any ethical or safety concerns (Weiss and Troyer, 2006). Of 
extraembryonic membranes, umbilical cord tissue and blood have a larger population 
with higher proliferation potential (Chen et al., 2015). 
Umbilical Cord as a Source of Therapeutic Cells 
Embryology and Anatomy of the Umbilical Cord 
In the developing embryo, the connecting stalk derives from the yolk sac and 
contains the allantois as well as the umbilical arteries and vein (Benirschke, Burton and 
Baergen, 2012). The umbilical cord contains mucoid connective tissue, termed Wharton’s 
jelly (WJ), that is covered with a single layer of amniotic epithelium (Benirschke, Burton 
and Baergen, 2012). The mucoid portion of the WJ is composed of ground substance of 
mucopolysaccharides, mainly chondroitin sulfate and hyaluronic acid (Kim et al., 2013). 
Spindle shaped cells are distributed throughout the ground substance and supportive 
collagen matrix (Benirschke, Burton and Baergen, 2012). Spindle shaped cells resemble 
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fibroblasts, but also express actin and produce elastic fibers suggesting a myofibroblast-
like phenotype (Baum and Duffy, 2011). Others refer to the spindle shaped cells as 
simply MSC (Watson et al., 2015). For consistency, all the spindle shaped cells within 
the cord tissue will now be referred to as umbilical cord tissue cells or UTC. UTC exhibit 
stemness and when contrasting with the typical adult MSC, UTC have a greater 
expansion capacity, higher doubling time, and higher potency (Troyer and Weiss, 2008). 
Further, the immunophenotype of UTC is similar to the typical MSC in terms of CD73+, 
CD90+, CD34-, CD45-, and HLA-DR-, however they differ in that UTC express HLA-
ABC, involved with MHC Class I surface receptor (Lund et al., 2007; Zhang et al., 2011; 
Arbab et al., 2012; Noone et al., 2013). These observations suggest that UTC represent a 
population of cells distinct from both adult and embryonic stem cells, but with features of 
each (Troyer and Weiss, 2008; Maslova, Novak and Kruzliak, 2015). 
Studies have shown that greater proportions of HSC are localized in the cord 
blood and greater proportions of MSC are located in the cord tissue (Maslova, Novak and 
Kruzliak, 2015). Umbilical cord tissue consists of amniotic epithelium, subamniotic 
region, WJ, intervascular region, perivascular region, and umbilical blood vessels (Troyer 
and Weiss, 2008) that are sources of UTC, but their embryonic origin is not completely 
understood. There are two hypotheses for their origin including an entrapment of 
migrating stem cells in the umbilical cord tissue during development or from 
mesenchyme that is part of the developing umbilical cord directly giving rise to UTC 
(Kim et al., 2013). Additionally, there are no clear histological delineations between the 
tissue compartments (Kim et al., 2013). However, the phenotype of UTC from each 
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tissue compartment differ in a graduated way. The more external tissue compartments 
(sub-amnion and intervascular) contain UTC that have higher potency than those in the 
internal tissue compartments (perivascular and subendothelial) (Troyer and Weiss, 2008). 
Umbilical Cord Derived Cell Use in Cell Based Therapy 
Cord blood has been considered as a therapeutic since 1990 with the first 
transplant into patients with Fanconi’s anemia (Gluckman et al., 1990). To date, there are 
13,400 patents containing “umbilical cord blood” in the title when searching Google 
Scholar. Research has shifted to also investigate the therapeutic potential of umbilical 
tissue. Currently, there are a multitude of options to preserve both umbilical cord blood 
and tissue after pregnancy for use by the mother, child, or immediate family members. 
While umbilical cord tissue has been investigated for a shorter time, there are 1,120 
patents containing “umbilical cord tissue” in the title when searching Google Scholar. 
The cells used in the current study are called human umbilical cord tissue derived cells 
(hUTC) and were obtained under the Patent # US20050054098 (Mistry et al., 2005). 
Under the patent, cells are derived from the human umbilical cord tissue that are self-
renewing. However, these cells are explicitly not cord blood or endothelial cells from the 
blood vessels of the cord. 
 Isolation protocols and characterization of hUTC are detailed in the patent, but 
briefly summarized here (Mistry et al., 2005). To isolate hUTC, umbilical cord tissue is 
washed to remove blood, mechanically dissociated, treated with digestion enzymes, and 
centrifuged multiple rounds. Next, cells are cultured and allowed to grow to confluence. 
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Then, the hUTC are collected and cryoprotected for later use. When allowed to grow for 
60 days, hUTC expanded through more than 40 passages and yielded more cells than 
human bone marrow derived mesenchymal stem cells (BM-MSC), fibroblasts, or adipose 
derived cells. As previously mentioned, UTC express markers of MSC including CD73+, 
CD90+, and do not express markers of HSC including CD34-, CD45-, and HLA-DR-, 
and finally expresses HLA-ABC, MHC Class I surface receptor (Lund et al., 2007; 
Zhang et al., 2011; Arbab et al., 2012; Noone et al., 2013). Additional cell surface 
markers include those involved in regulation of cell migration and proliferation (CD10, 
PDGFr-alpha), angiogenesis (CD13), and tissue remodeling (CD44) (Mistry et al., 2005). 
Importantly, the cell surface expression did not differ significantly between cells that had 
undergone differing number of passages or cells from different donors (Mistry et al., 
2005). 
Through gene expression, hUTC were identified as genetically different from 
BM-MSC, bone marrow derived cells, fibroblasts, and placenta derived cells. The genetic 
signature of hUTC includes IL-8 (CXCL8), reticulon 1, renin, and oxidized LDL receptor 
1 (OLR-1), confirmed at the mRNA level (Mistry et al., 2005). These genes are 
expressed on extraembryonic derived (placenta, decidua, amnion, umbilical cord, 
Wharton's jelly) stem cells (Hsieh et al., 2010; Fong et al., 2011) and are involved in 
regulating hematopoietic differentiation.  
hUTC secrete trophic factors in vitro including angiogenic factors (HGF, MCP-1, 
bFGF, and IL-8) and neurotrophic factors (BDNF and IL-6) (Mistry et al., 2005; Lund et 
al., 2007; Alder et al., 2012). Additionally, in vitro mixed lymphocyte reaction revealed 
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that hUTC do not stimulate allogenic lymphocytes, allogenic T-cells, naïve T-cells, 
peripheral blood mononuclear cells, or any adverse immunological response. Further, 
they do not express proteins involved in T-cell mediated cytotoxicity and apoptosis 
(CD178), costimulatory factors for T cell activation (CD80, CD86, B7-H2), MHC Class 
II antigen presentation (HLA-DR, HLA-DQ), or MHC Class I antigen presentation 
(HLA-G). However, hUTC do express a costimulatory ligand for T cell proliferation and 
Interferon Gamma production (PD-L2) (Mistry et al., 2005).  
hUTC are less active in promoting plasma clotting than BM-MSC, fibroblasts, or 
adipose derived cells. (Mistry et al., 2005). Tissue factor is the only clotting factor 
secreted, but it is secreted in an inactive form that only activates under mechanical or 
chemical stress. While tissue factor promotes clotting, it is also involved in angiogenic 
activity. Further, hUTC stimulate endothelial cells to form blood vessel networks in vitro. 
Finally, preliminary results also show that hUTC transplantation in rat models of disease 
result in reduced damage following myocardial infarction and a preservation of 
photoreceptors following Retinitis Pigmentosa (Mistry et al., 2005). 
Stem Cell Therapy as an Emerging Paradigm for Stroke (STEPS) 
With the increasing attention on cell based therapies such as hUTC, pre-clinical 
studies are needed to assess safety and efficacy (Stem Cell Therapies as an Emerging 
Paradigm in Stroke Participants, 2009). Alongside rodent models, large animal models 
are necessary to validate rodent study results and better mimic the human condition in a 
gyrencephalic brain (Stem Cell Therapies as an Emerging Paradigm in Stroke 
Participants, 2009; Savitz et al., 2011). Also, it is necessary to evaluate appropriate, 
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modality specific outcome measures in a long-term fashion (Stem Cell Therapies as an 
Emerging Paradigm in Stroke Participants, 2009). In the case of intravenous infusion of 
cell based therapy, monitoring of ectopic tissue growth or cell clumping in spleen, liver, 
and lungs is necessary to determine any detrimental effects of the infusion (Stem Cell 
Therapies as an Emerging Paradigm in Stroke Participants, 2009). Further, abnormal 
behavior or vital signs should be monitored throughout the recovery period (Savitz et al., 
2011). More specifically, lung function via respiratory rate or blood oxygen content 
should be monitored (Savitz et al., 2011). It is important to do appropriate histological 
studies at least 4 weeks after stroke by examining the effect of the cell based therapy on 
the immune system, parenchymal brain cells, and the remodeling of surviving structures 
(Savitz et al., 2011). 
Following many years of promising neuroprotective treatments failing to translate 
to human stroke patients, the Stroke Program Review Group recommends identifying 
neurorestorative agents after stroke (Grotta et al., 2008). Many cell therapies have shown 
promise as delayed neurorestorative treatments and it has been shown that these 
exogenous stem cells do not incorporate into neural circuits directly. While the 
mechanism of cell-based therapies remains unclear, studies suggest that cell based 
therapies modulate the immune response to reduce secondary injury and enhance 
endogenous repair mechanisms to increase brain plasticity and enhance synaptic 
remodeling (Savitz et al., 2014). Exogenous stem cells enhance the functioning of 
endogenous stem cells and surviving neurons and glia in the area of ischemia. Further, it 
has been suggested that some cell based therapies may not enter the central nervous 
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system, but instead may act through peripheral organs (Savitz et al., 2014). Finally, 
evidence suggests that the cell therapy works as an adjuvant to rehabilitation therapy and 
may depend on active rehabilitation for its mechanism of action (Savitz et al., 2014). The 
non-progressive nature of stroke pathophysiology creates an opportunity to enhance 
endogenous restoration and modulate inflammation (Kalladka and Muir, 2014; Hsuan et 
al., 2016)  
Findings from Preclinical Studies of hUTC Treatment 
 Previous studies have demonstrated enhanced motor recovery with human 
umbilical tissue derived cell (hUTC) infusion following stroke-induced motor 
impairment in rodent models (Zhang et al., 2011, 2012, 2013; Jiang et al., 2012; Yang et 
al., 2012; Shehadah et al., 2013; Shams Ara et al., 2015) and non-human primate models 
(Moore et al., 2013). Motor recovery in these studies is accompanied by no change in the 
lesion volume (Zhang et al., 2011, 2012, 2013; Yang et al., 2012; Moore et al., 2013; 
Shehadah et al., 2013; Shams Ara et al., 2015). However, studies demonstrated a 
decrease in apoptotic cells (Zhang et al., 2011, 2012) and fewer necrotic cells (Shams 
Ara et al., 2015) after treatment. Also, an increase in vascular density and synaptic 
density in the ischemic boundary zone (Zhang et al., 2011, 2012, 2013; Arbab et al., 
2012; Jiang et al., 2012; Yang et al., 2012; Shehadah et al., 2013) and an increase in cell 
proliferation in the subventricular zone (Yang et al., 2012; Zhang et al., 2012, 2013) was 
observed in rodent models of stroke. Furthermore, using diffusion tensor imaging, rats 
receiving hUTC treatment after stroke had higher fractional anisotropy values (directional 
diffusion) indicating healthier white matter in the lesion area (Jiang et al., 2012). 
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However, human tissue derived cells in these studies did not migrate in large numbers 
into the cortex or lesion area suggesting that cells act peripherally and are likely 
eliminated from the body over time (Zhang et al., 2011, 2012; Shams Ara et al., 2015). It 
is hypothesized that the mechanism of action of the hUTC is the release of neurotrophic 
factors such as BDNF and basic fibroblast growth factor (bFGF). 
 In our study assessing the efficacy of hUTC in rhesus monkeys, results 
demonstrated that intravenous administration, 24 hours after damage to the hand area of 
monkey primary motor cortex, significantly improved fine motor function of the impaired 
hand compared to vehicle controls (Moore et al., 2013). Specifically, monkeys that 
received hUTC infusion, demonstrated significant recovery on measures of fine motor 
function and strength of the hand during the first 14 days after surgery as compared to 
monkeys that received a vehicle. Furthermore, there was a significant difference between 
groups on the mean time to retrieve the food reward on our motor task across the 12-
week post-operative assessment with the treated group showing a shorter time to retrieve. 
Finally, in terms of grasp pattern, there was significantly improved finger-thumb grasp 
rating across the post-operative period in the monkeys treated with hUTC. 
Approach to Current Research 
 The goal of the current research is to determine how intravenous infusion of cell 
therapy containing hUTC improved motor recovery in rhesus monkeys. On gross 
inspection of the post-mortem brain, the composition of the lesion appeared different 
between groups in that the lesion area of the vehicle controls was much darker in color. 
Following this observation, oxidative damage and iron accumulation were measured in 
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the area of the lesion. Further, in conjunction with oxidative damage and iron, activated 
microglia, the resident immune cells of the brain, were quantified. Next, the surviving 
Betz cells in layer V of primary motor cortex and the density of synapses in the 
perilesional area were considered. In combination with the rewiring of the perilesional 
area, reactive astrocytes in this area were quantified and their branching patterns 
elucidated. Additionally, BDNF was measured in blood throughout the recovery period 
and in blood and CSF at the completion of the study. In the premotor cortices, activation 
of c-Fos and the density of synapses were quantified. Finally, cell proliferation in 
neurogenic niches was quantified to represent general neuroplasticity of the recovering 
brain. This study was conducted by investigating the following research goals: 
1. To determine the effect of hUTC infusion on oxidative stress, hemosiderin, and 
microglial activation following cortical injury and their impact on recovery of 
function.  
2. To determine the effect of hUTC infusion on neuronal survival, synaptic 
remodeling, and reactive astrocytes in the perilesional area and BDNF levels in 
serum and CSF following cortical injury and their impact on recovery of function. 
3. To determine the effect of hUTC infusion on activation and synaptic density in 
premotor cortices and general neuroplasticity in the brain and their impact on 
recovery of function. 
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CHAPTER TWO: METHODS APPLYING TO ALL CHAPTERS 
Overview 
Archived tissue sections, serum, and CSF available from the eight adult male 
rhesus monkeys (Macaca mulatta; Table 2) (Moore et al., 2013) were used in the three 
projects outlined above. Four monkeys received cell therapy (isolated from human 
umbilical tissue derived cells) and four monkeys received a vehicle control, both 
administered intravenously 24 hours after onset of cortical damage. The investigators 
were blind to the subject descriptions and cell therapy conditions in all the following 
experiments.  
Subjects 
Monkeys ranged from 8-12 years of age (approximately equivalent to humans 
from 24 to 36 years of age) (Tigges et al., 1988) and were obtained from the Caribbean 
Primate Research Center (San Juan, PR) or Yerkes National Primate Center (Atlanta, 
GA). Prior to entering the study, all monkeys were examined and screened for abnormal 
health history and were given initial pre-operative MRI scans to ensure no occult brain 
abnormality. Once enrolled in the study, the monkeys were housed in the Laboratory 
Animal Science Center of Boston University Medical Campus, which is accredited by the 
Association for the Assessment and Accreditation of Laboratory Animal Care 
(AAALAC). Experiments were conducted in accordance with the Guide for the Care and 
Use of Laboratory Animals from the National Institute of Health’s Office of Laboratory 
Animal Welfare and were approved by the Institutional Animal Care and Use Committee 
(IACUC) of the Boston University Medical Campus. 
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Pre-operative Training on Fine Motor Function Tasks 
As previously described (Moore et al., 2010, 2012, 2013, 2016) monkeys were 
pre-trained on our Hand Dexterity Task (HDT) for a total of 15 days (Monday, 
Wednesday and Friday each week for 5 weeks). The HDT is a modified version of a 
Klüver board (Klüver, 1935) and requires precise control of the digits, specifically 
apposition of the thumb and forefinger, to retrieve a small, visible food reward (M&M’s, 
Mars, Inc) from two different sized wells in a Plexiglas tray. Food rewards were round 
and approximately 1 cm in diameter. Both wells were 1 cm deep. The large well was 25 
mm wide and the small well was 18 mm wide. Time to retrieve the food reward is 
recorded by a timer that is connected to photocells that are in the openings on each side 
of the apparatus. The timer starts when the monkey puts a hand through one of the 
openings, triggering the photocells to start the timer. The timer stops when the monkey 
removes his hand. An experimenter records whether the reward was successfully 
retrieved and the response time to retrieve. The HDT has been used to assess fine motor 
function of the hand and digits in adult monkeys with and without injury to the hand 
representation in the motor cortex as well as to compare the performance of middle-aged 
rhesus monkeys to young adult monkeys  (Moore et al., 2010, 2012, 2013, 2016).  Each 
test day consists of 16 trials for each of the two well sizes as well as for each hand 
resulting in a total of 32 trials. The order of trials for each hand and well follows a 
pseudorandom balanced sequence to eliminate any order effects. Monkeys are given 30 
seconds to complete a trial. If they do not or would not complete a trial in 30 seconds, the 
trial is terminated and the monkey is given one additional opportunity to complete that 
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trial. After a second failed attempt, a non-response is recorded, the monkey’s difficulties 
are noted in the study record and the next trial is initiated. 
Hand Preference 
 At the completion of pre-training on the HDT, free choice trials with both sides of 
the apparatus baited and accessible to both hands were administered to determine which 
hand was ‘‘preferred’’ or dominant. This assessment was also compared with the pre-
operative acquisition rates for each hand. Based on this assessment, the lesion was 
targeted to the hemisphere controlling the dominant hand to ensure that even with 
impairment, monkeys would be motivated to use the impaired hand during post-operative 
testing. 
Electrophysiological Mapping and Lesion of the M1 Hand Area 
 As previously reported  (Moore et al., 2012, 2013, 2016) to induce reproducible 
limited cortical damage to impair motor function of one hand, a craniotomy was 
performed to expose the precentral gyrus of the hemisphere contralateral to the preferred 
hand.  Then, a small monopolar silver ball electrode was placed gently on the pia and 
electrical stimulation applied to determine the area from which hand movements could be 
evoked at the lowest threshold. The electrode was moved systematically in rows from the 
dorsal to the ventral aspect of the pre-central gyrus to identify loci activating the fingers, 
thumb, and wrist. These were transcribed onto a calibrated photograph of the region.  
This map was used to guide creation of a lesion limited to the hand representation by 
making a small incision in the pia at the dorsal limit of the hand representation area and 
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then inserting a small glass suction pipette under the pia to bluntly dissect the small 
penetrating arterioles as they enter the underlying cortex. This approach removes the 
blood supply to the cortex of the mapped hand representation but does not directly 
damage cortical gray matter. This produces an ischemic lesion of the gray matter with 
preservation of underlying white matter (Moore et al, 2013). 
Human Umbilical Tissue Derived Cell Therapy Infusion 
 Intravenous (IV) administration of the human umbilical tissue derived cell therapy 
(hUTC; CNTO0007, Advanced Technologies and Regenerative Medicine, LLC, Johnson 
& Johnson, New Brunswick, NJ) was performed between 23 and 24 hours following 
surgery. Briefly, cells were removed from liquid nitrogen storage, thawed and assessed 
for viability. They were then aliquoted into a sterile syringe and 10 million cells/kg were 
administered intravenously at a concentration of 10 million cells/mL and a rate of 0.5 mL 
per minute using a syringe pump. The control monkeys received vehicle that was 
administered at the same volume and rate. 
Post-operative Testing 
 Post-operative testing began two weeks after surgery and was conducted on 
Monday, Wednesday, and Friday for 12 weeks. To ensure that each monkey used the 
impaired hand, 70% of the trials required the use of the impaired hand (contralateral to 
the lesion) while 30% were given to the unaffected hand. The forced use of the impaired 
hand is similar to the idea of constraint-induced therapy used in human rehabilitation 
strategies (Corbetta et al., 2015; Souza et al., 2015; Kwakkel et al., 2016). 
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Grasp Pattern Assessment 
 Performance on the HDT during pre-operative and post-operative testing was 
videotaped and a licensed Occupational Therapist (Dr. Monica Pessina) who specializes 
in upper extremity recovery following stroke, analyzed the videos using our Grasp 
Assessment Scale for NHP (Moore et al., 2012) which was adapted from the Eshkol-
Wachman Movement Notation (Carr et al., 1985; Whishaw et al., 2002) and the Fugl-
Meyer Motor Assessment scale (Fugl-Meyer et al., 1975).  Our NHP scale consists of 
hierarchical categories from 0 (no movement) to 8 (normal grasp) with half steps (0.5) 
between 3 and 8. Thus a maximum score of 8 reflects normal grasp with functional pinch 
between thumb and a finger. Each stage includes distinctive features of grasp such as the 
shaping of the hand and digits for grasp and the pattern of grasp and release, providing a 
semi-quantitative measure of grasp function. A value between 0-8 is assigned to their 
performance each day during post-operative testing and the median score across the 
entire post-operative period was determined. 
Perfusion and Tissue Processing 
 Blood samples were taken pre-operatively, 1 week after injury, 4-6 weeks after 
injury, and 9-10 weeks after injury to monitor changes over the recovery period. CSF and 
blood samples were collected at the point of sacrifice, 14 weeks after injury. For 
perfusion-fixation of the brain, monkeys were sedated with Ketamine (10 mg/kg IM) 
deeply anesthetized with sodium pentobarbital (25 mg/kg IV to effect) and were 
euthanized by exsanguination during transcardial perfusion-fixation of the brain. This 
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began first with no more than 5 minutes of cold Krebs-Heinsleit buffer (4°C, pH 7.4) 
followed immediately by fixation with 8 liters of warm 4% paraformaldehyde, (30°C, pH 
7.4) over 10 minutes. The brain was blocked, in situ, in the coronal plane to ensure 
reproducible planes of section during later processing and then removed from the skull, 
weighed and post-fixed overnight in 4% paraformaldehyde (no more than 18 hours). It 
was then transferred to cryoprotectant solution to eliminate freezing artifact (Rosene, Roy 
and Davis, 1986). Cryoprotected blocks were flash frozen at -75°C and stored at -80°C 
until they were cut on a microtome into interrupted series of coronal sections (eight series 
of 30 μm thick sections and one 60 μm thick series) with a spacing between sections 
within a series of 300 μm. The 60 μm series was immediately mounted on microscope 
slides and stained with thionin for lesion reconstruction. The other series were collected 
in phosphate buffer with 15% glycerol and stored at -80°C. 
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Subject Sex Age (years) 
Treatment 
Group 
Lesion 
Hemisphere 
Recovery 
Time 
(days) 
Mean 
Grasp 
Rating 
Lesion 
Volume 
(mm3) 
BrdU 
Survival 
Time 
(days) 
Supplier 
SM014j M 8.5 Vehicle L 54 7.68 87 110 CPRC 
SM018j M 9.6 Vehicle L 96 6.46 84 92 CPRC 
SM020j M 9.3 Vehicle R 96 6.58 123 106 CPRC 
SM022j M 10.6 Vehicle R 96 6.46 59 138 CPRC 
SM016j M 10.1 
hUTC 
Treated 
L 56 7.88 63 116 CPRC 
SM017j M 8.6 
hUTC 
Treated 
L 35 7.72 58 99 CPRC 
SM021j M 11.5 
hUTC 
Treated 
R 51 7.80 114 111 CPRC 
SM024j M 12.1 
hUTC 
Treated 
L 48 7.86 106 n/a YNPRC 
Table 1: Subject data 
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Abstract 
Cortical injury elicits long-term cytotoxic and cytoprotective mechanisms within 
the brain, the balance and shift of which determines the functional outcome for the 
individual. Cytotoxicity is exacerbated through the secretion of pro-inflammatory 
cytokines, production of reactive oxygen species, accumulation of unbound iron, and 
lipid peroxidation of cell membranes and myelin. In contrast, cytoprotective mechanisms 
are promoted through the resolution of inflammation and oxidative stress, growth factors 
and anti-inflammatory cytokines to encourage a return to homeostasis, and the 
reorganization of surviving structures.  There are currently no neurorestorative treatments 
to aid in balancing the cytotoxic and cytoprotective mechanisms following cortical injury. 
However, cell based therapies are an emerging treatment that may function in 
immunomodulation, reduction of secondary damage, and reorganization of surviving 
structures. We previously evaluated human umbilical tissue-derived cells (hUTC) in our 
non-human primate model of injury limited to the hand area of primary motor cortex. 
hUTC or vehicle was injected intravenously 24 hours after injury and resulted in 
significantly greater recovery of fine motor function compared to vehicle treated controls 
(Moore et al., 2013). Here we investigate the hypothesis that hUTC treatment modulates 
the immune response and reduces the cytotoxic response to injury thus leading to 
functional recovery. To test our hypothesis, brain sections from monkeys in the previous 
study were processed using immunohistochemistry to label oxidative damage (4-
hydroxynonenal) and activated microglia (LN3) and using histology to label iron 
(Prussian Blue). Oxidative damage in the sublesional white matter and perilesional iron 
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accumulation decrease with hUTC treatment. Microglial activation is significantly higher 
in the downstream white matter areas in hUTC treated monkeys compared to vehicle 
controls. Interestingly, lesion volume and perilesional oxidative damage increases with 
increased perilesional iron accumulation. These findings support the hypothesis that 
hUTC decreases the cytotoxic response to cortical injury while increasing the activation 
and recruitment of microglia to promote cytoprotective mechanisms.  
Introduction 
Cell based therapies are an attractive neurorestorative treatment for cortical injury 
that have shown largely promising results in preclinical studies. While the mechanism of 
these therapies remains unclear, studies suggest that cell based therapies modulate post-
injury inflammation and reduce secondary damage (Savitz et al., 2014). While such 
neurorestorative treatments for stroke have been assessed preclinically, none have 
successfully translated to human patients. The Stroke Therapy Academic Industry 
Roundtable (STAIR) (Fisher et al., 2009) and Stem Cells as an Emerging Paradigm in 
Stroke (STEPS) (Savitz et al., 2011) meetings convened to address the transition between 
preclinical and clinical studies. Both the STAIR and STEPS reports recommend the use 
of non-human primate models to validate and further assess efficacy and safety of 
promising cell based therapies. Previously, we assessed a cell based therapy containing 
human umbilical tissue derived cells (hUTC) in our reproducible non-human primate 
model of cortical injury (Moore et al., 2013). Results demonstrate that intravenous 
administration of hUTC, 24 hours after cortical damage, significantly improves function 
and strength of the impaired hand in the first two weeks of recovery and improves finger-
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thumb grasp rating during the 12-week post-operative assessment as compared to vehicle 
treated controls. 
In this study, we aim to assess the effect of hUTC on inflammatory processes and 
secondary damage. Metabolic stress following cortical injury such as ischemic stroke 
results in neuronal death, accumulation of reactive oxygen species (ROS), disruption of 
iron homeostasis, and recruitment of immune cells (Lipton, 1999). Excess reactive 
oxygen species intra- and extracellularly in the area of ischemia leads to necrosis via lipid 
peroxidation in the ischemic core and apoptosis in neighboring neurons (Brouns and De 
Deyn, 2009). Lipid peroxidation is further catalyzed in the presence of unbound iron 
(Gutteridge, 2006). Following ischemic injury, iron homeostasis is disrupted resulting in 
an increase of total brain iron (Selim and Ratan, 2004). The Fenton reaction and Haber-
Weiss cycle perpetuate this disruption in iron homeostasis thus producing an increasing 
pool of hydroxyl free radicals (Winterbourn, 1995). These hydroxyl free radicals may 
contribute to the initiation of further lipid peroxidation and other oxidative damage in the 
area of ischemia (Bresgen and Eckl, 2015). Subsequently, microglia, the immune cells of 
the brain, are activated and recruited following cortical injury. Activated microglia 
produce ROS and pro- and anti-inflammatory cytokines, to both contribute to and resolve 
inflammation after cortical injury (Kreutzberg, 1996).  
Studies assessing numerous cell therapy treatments similar to hUTC infusion have 
observed an immunomodulatory effect. Specifically, cell therapy is related to a reduction 
in oxidative stress (Calió et al., 2014) and polarization of microglia and macrophages to a 
protective phenotype (Fumagalli et al., 2015). Therefore, we hypothesized that hUTC 
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infusion modulates the glial response and reduces cytotoxic responses to cortical injury, 
by interrupting the cycle of ROS production and oxidative stress. In this study, we 
examined and quantified markers of oxidative damage, iron, and activated microglia in 
brain tissue from 16 weeks after injury in hUTC treated and vehicle treated controls to 
assess their effects on recovery of function. To our knowledge, this is the first study to 
investigate the relationship of oxidative damage, iron accumulation, and activated 
microglia following cortical injury with a cell based therapy. 
Methods  
Immunohistochemistry 
Markers chosen for immunohistochemistry were LN3, representing MHC II 
expressing microglia and macrophages and 4-hydroxynonenal (4-HNE), a byproduct of 
lipid peroxidation. Two series of 30 μm sections spaced 1200 μm (LN-3) or 2400 μm (4-
HNE) containing the motor cortex in both hemispheres were removed from storage and 
thawed to room temperature for immunohistochemistry. Sections were batch-processed 
for each experiment in the same reagents according to the following steps. First, sections 
were rinsed in 0.05M Tris-buffered saline (TBS) to remove the glycerol. To increase 
antigenicity of 4-HNE, tissue sections were first incubated in 9.1 mM citrate buffer at 500 
Watts at 40ºC for 5 minutes then at room temperature for 30 minutes. To quench 
endogenous peroxidases, all sections were incubated for 30 minutes in TBS containing 
1% sodium borohydride (4-HNE) or 3% H2O2 (LN3) followed by washes in TBS. 
Sections were then incubated for one hour in a blocking solution of 10% Normal Goat 
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Serum (NGS) and 0.4% Triton-X in TBS. The sections were incubated for 48 hours at 
4ºC with gentle agitation in monoclonal primary antibodies to 4-HNE (anti-4HNE in 
mouse; 1:500, R&D Systems, Minneapolis, MN) and LN3 (anti-LN3 in mouse; 1:1000, 
MP Biomedicals, Santa Ana, CA) in a solution containing 2% NGS and 0.1% Triton-X in 
TBS. Several sections of brain tissue were left out of the primary antibody to control for 
immunoreactivity. Following incubation with the primary antibody, the sections were 
washed in a solution containing 2% NGS and 0.1% Triton-X in TBS, followed by a 2-
hour incubation in biotinylated secondary antibody (1:600; Vector Laboratories, 
Burlingame, CA) in TBS containing 2% NGS, and 0.4% Triton-X. The sections were 
then washed in TBS and subsequently incubated with an avidin biotinylated horseradish 
peroxidase complex (ABC Elite; Vector Laboratories, Burlingame, CA) for 1 hour. The 
sections were then washed in TBS followed by rinses in 0.175M sodium acetate solution. 
For visualization, all sections were incubated together in sodium acetate containing 
0.55mM 3-3’-diaminobenzidine (DAB; Sigma-Aldrich, St. Louis, MO), nickel sulfate 
(0.095M), and 0.0025% H2O2. The sections were washed in sodium acetate to stop the 
DAB reaction, followed by rinses in TBS. Finally, sections were mounted on gelatin-
coated slides, air dried, and cover-slipped using Permount mounting medium (Thermo 
Fisher Scientific, Waltham, MA). 
Sections stained with the antibody to LN3 were counterstained with 0.5% thionin 
(Fisher Scientific, Pittsburgh, PA) to define the boundary between the gray and white 
matter. Briefly, slides containing LN3 stained sections were incubated in a 1:1 mixture of 
Chloroform and 100% Ethanol for 2 hours to remove lipids and increase penetration of 
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the stain in subsequent steps. Then slides were rehydrated through a graded series of 
ethanol (100%, 100%, 95%, 70%, 50%) and reverse osmosis H2O (dH2O). Next, slides 
were incubated for 2 minutes in filtered 0.05% thionin solution (pH 5.5) containing 
sodium acetate and glacial acetic acid. Following, slides were moved through two rounds 
of dH2O and dehydrated through a graded series of ethanol (70%, 95%, 100%, 100%). 
Finally, slides were cleared in Xylene (Fisher Scientific, Pittsburgh, PA) and 
coverslipped using Permount mounting medium (Thermo Fisher Scientific, Waltham, 
MA). 
Iron Histology 
Perl’s Prussian blue histology was performed to visualize intra- and extracellular 
iron, often in a complex of hemosiderin, in the area of the lesion. A series of 30 μm 
sections spaced 1200 μm containing the motor cortex in both hemispheres was removed 
from storage and mounted on gelatin subbed microscope slides and allowed to dry 
completely. For Perl’s Prussian Blue histology, all microscope slides were placed in each 
solution together in a rack. First, slides containing sections were immersed in dH2O for 
one minute. Next, a solution of 5% Hydrochloric Acid (HCl; Fisher Scientific, Pittsburgh, 
PA) and 5% Potassium Ferrocyanide (Sigma-Aldrich, St. Louis, MO) in dH2O (Prussian 
Blue Solution) was combined immediately before use. All slides were incubated in the 
Prussian Blue solution for 35 minutes. Following this, slides were moved through two 
rounds of dH2O and dehydrated through a graded series of ethanol (70%, 95%, 100%, 
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100%). Finally, slides were cleared in Xylene (Fisher Scientific, Pittsburgh, PA) and 
coverslipped using Permount (Thermo Fisher Scientific, Waltham, MA). 
Regions of Interest for Stereology and Densitometry 
As with all the other procedures, data collection and analyses were done with the 
experimenter blind to the treatment condition of each monkey. Sections containing the 
lesion were determined by the disturbance of the cortical surface in the area of the motor 
cortex. Regions of interest (ROI) for 4-HNE densitometry and LN3 stereology were 
determined at the 4x objective on a Nikon E600 light microscope and included 
perilesional gray matter (PLG) and sublesional white matter (SLW) (Figure 1). SLW was 
defined by first drawing a straight line from the depths of the cingulate sulcus to the 
depths of the lateral sulcus. Next, lines perpendicular to the cortical surface were drawn 
from the straight line between sulci to the gray-white boundary. Finally, the ROI was 
completed by connecting the lateral and medial boundaries of the SLW by a line 
following the gray-white boundary. PLG was defined using the lateral and medial 
boundaries of SLW and the gray-white boundary. Next, parallel lines to the SLW lateral 
and medial boundaries were followed to the cortical surface. These boundaries were 
connected by lines tracing the cortical surface and the gray-white boundary to complete 
the PLG ROI. The ROI for iron histology densitometry was determined at the 10x 
objective on a Nikon E600 light microscope. The lesion area ROI for iron histology was 
defined as the presence of strong Prussian Blue staining around the lesion to its medial 
and lateral boundaries and as deep into the white matter as the strong staining extended. 
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Densitometry for 4-HNE 
The percent area of staining was quantified for 4-HNE. Mounted sections stained 
for 4-HNE were visualized on a Nikon E600 light microscope equipped with a motorized 
stage and Surveyor software with TurboScan (Objective Imaging, Kansasville, WI). Two 
equally spaced sections near the site of the lesion were selected per animal. The 
ipsilesional hemisphere was visualized in Surveyor using the 4x objective, bright field 
correction, and manual focus. Using TurboScan Stepped, tiled images were acquired and 
saved as TIFF files. These images were imported into Fiji software (NIH, version 1.50i), 
(Schindelin et al., 2012) and scale was set using distance in pixels determined for the 
specific objective on the specific microscope. ROIs (PLG and SLW) were traced and 
saved in the ROI Manager (Figure 1 D-F). Images containing both ROI were transformed 
into 8-bit images and the threshold function (percentile) was used to create binary images 
and remove artifact. Measurements were set to calculate “Area Fraction” and this 
measurement was saved for analysis. The density of oxidative stress is reported as a 
percentage of staining following threshold within the ROI defined. 
Densitometry for Iron Histology  
Mounted sections stained with Prussian blue were visualized on a Nikon E600 
light microscope equipped with a motorized stage and Nikon Imaging Software (NIS – 
Advanced Research). Sections spaced every 1200 µm throughout 7 to 10 mm of the 
lesion site were selected for analysis with 6-8 sections selected per animal. The 
investigator was blind to the subject descriptions and experimental conditions. Tiled 
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Large Image Scans of the area of the lesion were acquired using the 10x objective. All 
images were acquired using 750 µsec exposure, AutoWhite balance, and focus surface 
optimized with 5 points on the tissue. The tiled images were overlapped by 10%, stitched 
via blending and image registration, and automatic post-processing for shading 
correction. Once acquired, images as nd2 files were analyzed using the NIS-AR analysis 
software. The polygon tool was used to draw the lesion area ROI as the extent of Prussian 
Blue staining in the lesion area. Then, RGB Threshold was determined by 3- or 6-point 
threshold tool limited to the defined area. ROI Statistics were exported to excel and 
numbers used include “ROI Area,” “Area Fraction,” and “ROI Mean Intensity.” Mean 
Intensity measures were inverted by subtracting numbers from 4095 (maximum for RGB 
intensity) such that the larger numbers represent a darker intensity of staining and the 
lower numbers represent a lighter intensity of staining. Cavalieri principle was used to 
transform area measurements to volume measurements using section thickness and 
spacing. 
LN3 Stereology 
Unbiased stereology was used to quantify LN3 labeled microglia visualized on a 
Nikon Eclipse E600 series light microscope (Nikon; Melville, NY, USA) equipped with a 
motorized stage integrated with StereoInvestigator 9 software (MicroBrightField 
Bioscience; Williston, VT). The Optical Fractionator Workflow on StereoInvestigator 
was used to quantify 5-7 equally spaced sections per monkey throughout the motor 
cortex. ROI (PLG and SLW) were determined at 4x objective. For stereology, sections 
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were visualized at 20x objective with a counting frame of 475µm x 275µm. The sampling 
grid was optimized at 1000µm x 1000µm for the PLG and 1300µm x 1300µm for the 
SLW. However, to gain a sufficient coefficient of error (Gundersen, m=1, CE ≤ 0.10) for 
stereology, the subcortical white matter was recounted in 3 animals (2 control and 1 
treated) using a sampling grid of 800µm x 800µm. To minimize over- or under-
estimation of counts due to sectioning artifacts, counting was performed with 2 µm guard 
zones above and below the counting brick to ensure that lost cell caps could be identified 
and counted or excluded according to the respective face (West, 1991). Inclusion criteria 
included a well-defined cell body located within the counting brick. Markers used for 
stereology categorized each microglia counted as either ramified, hypertrophic, or 
amoeboid using a previously published study as a guide (Karperien, Ahammer and 
Jelinek, 2013) as a guide. Examples of each morphology of LN3 microglia from the 
current study are shown in Figure 2. Ramified microglia included a small, well-defined 
cell body and thin processes (Figure 2A) and were representative of a surveilling 
phenotype. Hypertrophic microglia presented with either a small cell body and thick 
retracted processes or a large cell body with thin processes (Figure 2B) and represent a 
transition state of de-ramifying or re-ramifying. Amoeboid microglia had thick retracted 
processes or no processes extending from an enlarged cell body (Figure 2C) and 
represent mobile, phagocytic cells. All phenotypes were present in the area of the lesion 
in both groups. The estimated total number of LN3 positive microglia by phenotype in 
each ROI were calculated using the optical fractionator formula (West et al., 1991, 2002). 
Parameters were optimized such that Coefficient of Error (Gundersen m=1) (Gundersen 
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et al., 1999) were less than 0.10. The density measures of each phenotype were reported 
in order to account for variability in the volume of traced regions of interest between 
subjects. The density of microglia per mm3 was calculated by dividing the “estimated 
population using number weighted section thickness” by the volume calculated by 
Cavalieri estimator in StereoInvestigator.  
LN3 Total Volume Stained 
The extent of staining of LN3+ cells throughout the brain differed between 
individuals beyond the perilesional and sublesional areas (Figure 3). In order to quantify 
this difference, mounted sections were visualized on a Nikon E600 light microscope 
equipped with a motorized stage and Nikon Imaging Software (NIS – Advanced 
Research) and 1x large tiled image scans were acquired. For each monkey, 6-8 sections 
containing gray matter areas (dorsal and ventral premotor cortices, somatosensory cortex, 
primary motor cortex, caudate, putamen, internal and external globus pallidus, VA/VL of 
the thalamus, substantia nigra, subthalamic nucleus) and white matter areas (corpus 
callosum, frontal white matter, internal capsule, anterior commissure, cerebral peduncle, 
fornix, and temporal lobe white matter) were imaged. All large images from each 
monkey were visualized together. Ratings between 0 and 4 were given to each region 
outlined above in both ipsilesional and contralesional hemispheres with the investigator 
blind to treatment conditions. A rating of 0 indicated no staining present. A rating of 1 
indicated a baseline staining present. A rating of 2 indicated medium staining. A rating of 
3 indicated strong staining. Lastly, a rating of 4 indicated intense staining. These ratings 
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were separated by region and by hemisphere (ipsilesional and contralesional). Once each 
region present was rated and recorded, any regions with a rating of 2, 3, or 4 were 
outlined together to calculate a total area (µm2) stained. Cavalieri principle was used to 
transform area measurements to volume measurements (µm3) using section thickness and 
spacing. Numbers used for comparison between treatment groups included total gray 
matter volume stained, total white matter volume stained, and region ratings. 
Data Analysis and Statistics 
The data were analyzed using R (RStudio Inc, Version 0.99.896, R foundation for 
Statistical Computing, Vienna, Austria). A student’s one-tailed t test (α = 0.05) was used 
to calculate the differences between area fraction of oxidative damage, outcome measures 
from Prussian blue histology, and volume stained of LN3 comparing hUTC treated and 
vehicle control groups. Bonferroni correction was used to adjust p value threshold for 
multiple comparisons. Kruskal Wallis H test was used to compare regional microglial 
ratings as an ordinal scale was used to rate. A two-way ANOVA with repeated measures 
was used to identify significant variables and interactions with group (control or hUTC 
treated) as a between subject variable and cell type (ramified, hypertrophic, and 
amoeboid) as within subject variables. Correlations were assessed using a Pearson’s 
Correlation with an alpha level set at p ≤ 0.05 and df = 6. 
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Results 
Effect of hUTC on Oxidative Damage 
Following lipid peroxidation of cell membranes, both 4-hydroxynonenal (4-HNE) 
and malondialdehyde (MDA) remain in the tissue as evidence of oxidative damage. To 
measure the level of lipid peroxidation, 4-HNE immunohistochemistry was performed. 4-
HNE immunoreactive staining was present throughout the cortex both in the white matter 
between axons and in the gray matter around cell bodies (Figure 4A). 4-HNE was 
specifically localized in the area of the lesion. Densitometry was used to measure levels 
of 4-HNE in the perilesional gray matter and sublesional white matter to compare 
between groups. Levels of 4-HNE staining were significantly lower in the sublesional 
white matter with hUTC treatment (p = 0.033; Figure 4B). However, levels of 4-HNE did 
not differ between groups in the perilesional gray matter (p = 0.169; Figure 4B). These 
results suggest that hUTC treated monkeys had a lower accumulation of oxidative 
damage in the sublesional white matter compared to vehicle controls.  
Effect of hUTC on Iron Accumulation 
On gross inspection, the composition of the lesion was seemingly different 
between groups in that the lesion areas of the vehicle control monkeys were much darker 
in color (Figure 5A-B). Prussian blue histology catalyzes blue pigment in areas of iron 
accumulation.  While a baseline amount of iron is expected in the brain, areas of 
aggregation represent pathological iron accumulations such as hemosiderin. Hemosiderin 
forms when iron ions and cell membrane fragments bind to ferritin accumulations. 
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Prussian blue histology revealed strong iron accumulations both intracellularly in 
macrophages and extracellularly (Figure 5C). Prussian blue was specifically localized in 
the area of the lesion. Prussian blue total volume stained, optical density (intensity) of 
staining, and thresholded percent area stained were measured in the perilesional area. The 
total volume (mm3) of the lesion with Prussian blue staining was not significantly 
different with hUTC treatment (p = 0.416, Figure 5D). However, the percent area of 
Prussian Blue staining above a consistent threshold was significantly lower in the lesion 
area following hUTC treatment (p = 0.045; Figure 5E). Furthermore, the intensity of 
Prussian Blue Staining was significantly lower in the area stained with hUTC treatment 
(p = 0.002; Figure 5F). These results suggest that the amount and concentration of iron 
accumulated in the area of the lesion was lower in hUTC treated monkeys compared to 
vehicle controls. 
Effect of hUTC on Density of Activated Microglia 
Activated microglia were identified using immunohistochemistry for a marker of 
MHC-II (LN3; HLA-DR). Activated microglia were present in the area of the lesion and 
followed white matter pathways. Estimated density of activated microglia in the 
perilesional gray matter and sublesional white matter was estimated using unbiased 
stereology and Cavalieri volume estimation. Density (cells/mm3) was used in order to 
control for variance in total volume of each ROI. The total density of activated microglia 
trended toward a significant higher density in hUTC treated subjects, in the perilesional 
gray matter (p = 0.071) and sublesional white matter (p = 0.093) (Figure 6A). 
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Effect of hUTC on Morphology of Activated Microglia 
While MHC-II positive microglia imply activation, we further subdivided 
microglia into morphological categories to imply surveilling (ramified), transitional 
(hypertrophic), or phagocytic (amoeboid) microglia. All microglial morphologies 
(ramified, hypertrophic, and amoeboid) were present in lesion area including both the 
perilesional gray and sublesional white matter. Stereological analysis revealed no 
significant difference in the density (cells/mm3) of specific microglial morphologies in 
the perilesional gray matter between groups [F(1,6) = 2.87, p = 0.141], but there is a 
significant difference between cell types [F(1,6) = 9.108, p = 0.004] that did not interact 
with group differences (Figure 6B). Similarly, there is no significant difference in density 
by morphology in sublesional white matter between groups [F(1,6) = 2.24, p = 0.185], but 
there is a significant difference between cell types [F(1,6) = 26.307, p = 0.0004] that did 
not interact with group differences (Figure 6C). However, hUTC treated monkeys had a 
consistently higher number of all morphologies in both the perilesional gray matter and 
sublesional white matter.  
Effect of hUTC on Extent of Activated Microglia 
Visually, activated microglia were extensively present in both the lesion area and 
distal white matter pathways. To quantify the level of staining in these areas, visual 
ratings between 0 (no staining) and 4 (intense staining) were given to specific regions of 
the cortical gray matter and underlying white matter pathways. Activated microglia were 
heavily present around the lesion in the ipsilesional primary motor cortex equally in both 
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treated (2.34) and vehicle (2.44) monkeys (Figure 7A). Minimal staining was found in 
most gray matter areas ranging from ratings of an average of 0 to 1.1. Specifically, corpus 
callosum as well as ipsilesional and contralesional frontal white matter, internal capsule, 
and cerebral peduncle exhibited staining in both hUTC and vehicle monkeys. 
Interestingly, staining was also present in ipsilesional and contralesional temporal lobe 
white matter in both treated and vehicle monkeys. Staining intensity was significantly 
higher in hUTC treated monkeys in the contralesional frontal white matter (p = 0.021) 
and contralesional temporal lobe white matter (p = 0.037) compared to vehicle controls 
(Figure 7A). Overall, there was a stronger intensity of activated microglia in distal white 
matter pathways from primary motor cortex with hUTC treatment. 
Effect of hUTC on Volume Stained of Activated Microglia 
To further quantify the extent of staining, sections with regions scoring 2, 3, or 4 
(medium to intense staining) were outlined and total gray and white matter volumes were 
measured. There is a trend toward a greater extent of LN3 staining in gray matter areas 
(primary motor, ventral and dorsal premotor cortices, and somatosensory) with hUTC 
treatment (p = 0.066) (Figure 7B). Further, there is a greater extent of LN3 staining in 
white matter areas (frontal white matter, corpus callosum, internal capsule, cerebral 
peduncle, anterior commissure, optic tract, and temporal white matter) with hUTC 
treatment (p = 0.042) (Figure 7C). 
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Relationship Between Oxidative Damage, Iron Accumulation, Activated Microglia, and 
Lesion Volume 
Previous results in this study were presented comparing the treatment groups. 
However, monkeys in both treatment groups recovered to some degree, with the hUTC 
treatment seemingly enhancing the endogenous recovery mechanisms. Therefore, for 
regression analyses we pooled all subjects (n = 8) together to explore the relationship 
between findings of the current study. 
Based on the known interaction between iron and lipid peroxidation 
(Winterbourn, 1995; Bresgen and Eckl, 2015), we hypothesized that our results of 4-HNE 
and Prussian blue staining in the lesion area may be related. Further, we hypothesized 
that the density of amoeboid (phagocytic) microglia may predict the levels of oxidative 
damage and iron. There was a strong positive correlation between the volume of iron 
accumulation and oxidative damage in the perilesional gray matter (Rp (6) = 0.898 and p 
= 0.002, Figure 8A). However, there was no significant correlation between amoeboid 
microglia and 4-HNE in the perilesional gray matter (Rp (6) = 0.237 and p = 0.572) or in 
the sublesional white matter (Rp (6) = 0.430 and p = 0.288). Further, there was no 
correlation between amoeboid microglia and iron volume in the perilesional gray matter 
(Rp (6) = 0.547 and p = 0.160). These results suggest that the presence of iron increased 
the formation of ROS and lipid peroxidation. The mechanism for lipid peroxidation, 
Fenton reaction, and Haber-Weiss cycle has been summarized in Figure 9D, highlighting 
the contributions of iron ions and reactive oxygen species in perpetuating this cycle.  
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As previously reported, there was no group difference between hUTC treated and 
vehicle control monkeys in reconstructed lesion volume using Nissl stained sections 
(Moore et al., 2013). We hypothesized that the iron accumulation, 4-HNE, and amoeboid 
microglia in the lesion area may be related to the lesion volume. Interestingly, there was a 
positive linear relationship between lesion volume and the volume of iron accumulation 
(Rp (6) = 0.771 and p = 0.048, Figure 8C). Further, there was a trend toward a correlation 
between lesion volume and density of amoeboid microglia in the perilesional gray matter 
(Rp (6) = 0.662 and p = 0.074). Finally, there is no significant correlation with lesion 
volume and perilesional 4-HNE (Rp (6) = 0.581 and p = 0.130). These results suggest that 
a lesion with more iron accumulation may have expanded more via secondary damage 
and resulted in greater activation of amoeboid microglia. 
Discussion 
In this study, we test the hypothesis that hUTC infusion modulates the glial 
response and reduces cytotoxic responses to cortical injury, by interrupting the cycle of 
ROS production and oxidative stress. The overall findings of this study are: (1) Oxidative 
damage is lower in the sublesional white matter with hUTC treatment. (2) The amount 
and concentration of perilesional iron accumulation is lower with hUTC treatment. (3) 
The extent and volume of microglial activation is significantly higher in the downstream 
white matter areas in hUTC treated monkeys compared to vehicle controls. (4) Lesion 
volume and perilesional oxidative damage increase with increased perilesional iron 
accumulation. Overall, these results suggest that hUTC infusion may modulate secondary 
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damage following cortical injury by recruiting microglia and interrupting the cycle of 
ROS production, iron accumulation, and oxidative stress. 
Oxidative Stress Following Cortical Injury 
It is well established that metabolic crisis following cortical injury, such as stroke, 
leads to an increase in reactive oxygen species and oxidative stress (Fumagalli et al., 
2015). The source of reactive oxygen species (ROS) is either through the destruction of 
cells undergoing oxidative stress, thus releasing ROS, or through the release of ROS from 
classically activated microglia or macrophages (Amantea et al., 2015). As a consequence 
of ROS accumulation, lipid peroxidation breaks down both cell membranes and myelin 
resulting in the production of 4-hydroxynonenal (4-HNE) and malondialdyde (MDA) 
(Selim and Ratan, 2004; Mimica-Duki et al., 2012; Ravera et al., 2015). In this study, we 
measure the level of 4-HNE using immunohistochemistry and semi-quantitative analysis. 
We observe lower 4-HNE in the sublesional white matter with hUTC treatment. These 
results are consistent with a previous study that found a reduction of oxidative damage 
with transplantation of mesenchymal stem cells (MSC) in an aged model of stroke (Calió 
et al., 2014). 
Iron Homeostasis Disruption 
Iron homeostasis is an important process in all parts of the body, but especially 
the brain given the large cerebral blood flow. Iron is present in the body in either bound 
ferric iron (Fe3+) or reactive unbound ferrous iron (Fe2+). Following cortical injury, total 
brain iron concentration increases and ferric iron disassociates with its binding proteins, 
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transferrin and ferritin, through an acidic environment or by lysosomal degradation 
(Lipton, 1999; Selim and Ratan, 2004). The expanding pool of dissociated and free iron 
catalyzes formation of ROS (Selim and Ratan, 2004). Further, ferritin accumulates with 
cellular debris forming the protein aggregate, hemosiderin, which binds ferric iron, 
rendering it poorly available (Gutteridge and Hou, 1986). In this study, we use Prussian 
blue histology to quantify the amount and concentration of iron accumulation and found a 
lower extent of iron accumulation in the lesion area with hUTC treatment. To our 
knowledge, no other study has yet quantified iron accumulation in relation to cortical 
injury and cell based therapies. 
However, studies suggest that iron neurotoxicity is associated with a larger lesion 
following stroke (Demougeot et al., 2004; Selim and Ratan, 2004). Our results reveal that 
lesion volume increases with increased perilesional iron accumulation. Studies assessing 
cell based therapies (hUTC) consistently report no change in lesion volume (Zhang et al., 
2011, 2012, 2013; Yang et al., 2012; Moore et al., 2013; Shehadah et al., 2013; Shams 
Ara et al., 2015).  Further the lesion volume does not predict functional recovery. 
However, the reduction in iron and oxidative damage in our model with treatment may 
have reduced secondary injury and enabled more effective reorganization.  
The Relationship Between Oxidative Stress and Iron 
 The positive feedback between unbound iron and ROS is well documented in its 
contribution to stroke pathophysiology (Minotti and Aust, 1989; Selim and Ratan, 2004). 
Initially, lipids are peroxidized in the presence of ROS. Then, unbound reactive ferrous 
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iron reduces any peroxides into hydroxyl free radicals and ferric iron. While ferric iron is 
more stable, it lends its electron to neutralize the abundant ROS present after injury, thus 
returning to ferrous iron. The Fenton and Haber-Weiss reactions perpetuate this cycle, 
disturbing the homeostasis of iron and producing an increasing pool of ROS 
(Winterbourn, 1995). Free radicals may then contribute to the initiation of further lipid 
peroxidation and other oxidative damage in the area of ischemia (Bresgen and Eckl, 
2015). Our results show that perilesional oxidative damage increases with increasing 
perilesional iron accumulation. It follows that interruption of this cycle may interrupt 
damage accumulation and neurotoxicity. 
Microglia in Acute Inflammation 
As the resident immune cells of the brain, microglia connect the central nervous 
system (CNS) to the systemic immune response. In homeostasis, microglia (ramified or 
rod-like) are motile, non-migratory, and morphologically plastic, remaining primed to 
respond quickly to changes in the environment (Kreutzberg, 1996; Eyo and Dailey, 
2013). Following injury, microglia are the first responders in the CNS (Patel et al., 2013), 
undergoing a differential activation and homing to the site of injury through chemotaxis 
(Kreutzberg, 1996; Fumagalli et al., 2015). Neurons at the site of injury undergo 
metabolic stress leading to apoptosis and necrosis and an increase in classically activated 
microglia and macrophages. These cells promote neurotoxicity through the release of 
pro-inflammatory cytokines, proteases, and ROS (Patel et al., 2013). Infiltrating 
peripheral macrophages have a higher tolerance to oxygen deprivation and therefore are 
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found in the core of the lesion in acute injury during metabolic stress (Fumagalli et al., 
2015). Hypertrophic microglia reside in the penumbra (Fumagalli et al., 2015) and 
ramified microglia occupy the external border of the penumbra (Patel et al., 2013). 
Studies report that microglia near the penumbra may be neuroprotective and enhance 
plasticity through the release of neurotrophic factors (Lalancette-Hebert et al., 2007; 
Narantuya et al., 2010; Liguz-Lecznar and Kossut, 2013; Anttila et al., 2016) 
Microglia in the Resolution of Cortical Injury 
It remains unclear how inflammation converts to resolution and neuroprotection 
(Shichita, Ito and Yoshimura, 2014). However, through resolution of inflammatory event, 
microglia and macrophages polarize from classically to alternatively activated 
phenotypes. In alternative activation, microglia secrete growth factors and anti-
inflammatory cytokines promoting lesion repair and removal of cell debris (Fumagalli et 
al., 2015). In the present study, activated microglia are quantified using 
immunohistochemistry, stereology, and densitometry. The marker used for microglia was 
MHC Class II (HLA-DR) and represents activation, but does not further differentiate 
between peripheral macrophages and microglia or these cells into classically or 
alternatively activated (London, Cohen and Schwartz, 2013). Therefore, we further 
quantify activated microglia by morphology (ramified, hypertrophic, and amoeboid) to 
elucidate their functional phenotype (Karperien, Ahammer and Jelinek, 2013). While our 
results show no difference in microglia with hUTC treatment, the density of all 
phenotypes was higher in treated monkeys compared to vehicle controls suggesting 
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widespread microglial activation with treatment. While some studies report a reduction in 
microglia with cell based therapy (Roh et al., 2013; Yoo et al., 2013), other studies report 
a phenotypic switch (beyond morphology) from cytotoxic to cytoprotective with cell 
based therapies (Zanier et al., 2011; Fumagalli et al., 2015), which would support our 
hypothesis. However, further testing is required to determine the exact phenotype of 
microglia in our study. 
Both cell death and white matter disruption contribute to functional deficits 
observed after brain injury. In normal development and following pathological events, 
microglia strip synapses and assist in guiding neurite outgrowth (Eyo and Dailey, 2013). 
While neuronal replacement or new neuron differentiation and migration would 
contribute to recovery of function, small changes in remyelination and reorganization are 
more plausible mechanisms of restored function. Previously, we report an increased 
activation of ventral premotor cortices as a mechanism of reorganization with hUTC that 
was related to improved recovery (publication in review; see chapter 5) confirming with 
results from others (Frost et al., 2003; Nudo, 2007; Nudo and McNeal, 2013). In the 
current study, we observe a marked increase in the extent of microglial activation in the 
white matter pathways downstream from the primary motor cortex with hUTC treatment. 
This may suggest a role of microglia in white matter repair after stroke (Jiang et al., 
2016). Further, white matter degradation via oxidative damage can increase the pool of 
ROS in the white matter areas. In our model, we observe lower levels of oxidative 
damage in white matter and this may reflect a lesser degree of myelin degradation. 
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Potential of Cell Based Therapy 
Studies assessing cell based therapies corroborate the hypothesis that MSCs 
secrete paracrine signals to modulate the inflammatory response to ischemia, reduce 
secondary damage, and enhance reorganization of surviving structures. In vitro, MSC 
secrete signals that polarize microglia to an alternatively activated phenotype (Fumagalli 
et al., 2015) and growth factors that encourage dendritic remodeling and synaptogenesis 
(Alder et al., 2012). In vivo studies report that MSC-based therapies lead to reduction of 
apoptotic cells (Zhang et al., 2011, 2012), necrotic cells (Shams Ara et al., 2015), and 
oxidative stress (Calió et al., 2014; Chen et al., 2016) as well as higher vascular and 
synaptic density in the ischemic boundary zone (Zhang et al., 2011, 2012, 2013; Arbab et 
al., 2012; Jiang et al., 2012; Yang et al., 2012; Shehadah et al., 2013). The current study 
confirms a reduction of oxidative stress and points to the sublesional white matter as a 
region specific to this finding. Further, this study suggests a reduction of iron 
accumulation in the perilesional area and an overall higher recruitment of MHC II 
microglia and macrophages following hUTC treatment. 
The small number of subjects is a significant limitation of this study. However, 
we provide results from a gyrencephalic model that both confirm findings of previous 
studies and add further findings to the current understanding of the mechanism of cell-
based therapies. Future studies are needed to clarify exact changes in the genetic 
signatures of microglia and macrophages influenced by cell based therapies. Further, 
studies are needed to validate the relation of morphology to functional phenotype to 
support our hypothesis. 
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Conclusion 
In this study, we provide for the first time a report of the histopathology observed 
in a non-human primate model of cortical injury with a cell based therapy containing 
hUTC. The major findings of this study are the reduction of secondary damage and 
higher activation of microglia observed with the administration of a cell based therapy. 
These observations provide potential targets for future therapeutics. Further, these 
findings provide confirmation of previous studies and elucidation of the mechanism of 
cell based therapies in recovery from stroke.  
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Figure 1: Regions of interest for densitometry for 4-HNE and stereology for LN3 
Two thionin stained sections through the extent of the lesion are shown here (A-B). 
Representations of ROI tracings are shown (C-D). Regions of interest were traced by 
completing the following: First, sections containing the lesion in the area of the motor 
cortex were chosen for analysis. Sublesional White Matter (SLW) was defined by first 
drawing a straight line from the depths of the cingulate sulcus to the depths of the lateral 
sulcus. Then, lines perpendicular to the cortical surface were drawn from the straight line 
between sulci to the gray-white boundary. Finally, the ROI was completed by connecting 
the lateral and medial boundaries of the SLW by a line following the gray-white 
boundary. Perilesional Gray Matter (PLG) was defined using the lateral and medial 
A
B
C
D
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boundaries of SLW and the gray-white boundary. Next parallel lines to the SLW lateral 
and medial boundaries were continued to the cortical surface. These boundaries were 
connected by lines tracing the cortical surface and the gray-white boundary to complete 
the PLG ROI.   
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Figure 2: MHC-II activated microglia by morphology 
Representative micrographs of the spectrum of MHC II Activated Microglia morphology 
observed and quantified. (A) Ramified microglia exhibit a small, well-defined cell body 
and thin processes and were representative of a surveilling phenotype. (B) Hypertrophic 
microglia present with either a small cell body and thick retracted processes or a large 
cell body with thin processes and represent a transition state of de-ramifying or re-
ramifying. (C) Amoeboid microglia have thick retracted processes or no processes 
extending from an enlarged cell body and represent mobile, phagocytic cells. Scale Bar = 
25µm.   
A B C
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Figure 3: MHC-II activated microglia in downstream white matter pathways from 
primary motor cortex 
Representative micrographs showing thionin stained sections of the lesion hemisphere 
from rostral to caudal. (A) Intense LN3 staining in the sublesional white matter and 
corpus callosum. (B-C) Intense LN3 staining in the sublesional white matter with staining 
present in corpus callosum and internal capsule. (D) Staining present throughout the 
sublesional white matter, corpus callosum, internal capsule, and cerebral peduncle.    
A B C D
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Figure 4: Oxidative damage (4-HNE) 
(A) Calibrated micrographs from the ipsilesional hemisphere comparing 4-HNE in 
perilesional gray matter and sublesional white matter between treatment groups. Scale bar 
= 125 µm (B) 4-HNE staining in the perilesional gray matter did not differ between 
treatment groups. 4-HNE in the sublesional white matter is lower in the hUTC treated 
monkeys compared to vehicle controls * p ≤ 0.05   
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Figure 5: Perilesional iron accumulation (Prussian Blue) 
(A&B) Calibrated photographs showing differences in lesion appearance in motor cortex 
14 weeks post-operatively. (C) Calibrated micrographs of iron accumulation in 
ipsilesional hemisphere comparing both treatment groups. Scale bar = 125 µm (D) Total 
perilesional area occupied by iron does not differ between treatment groups. (E) 
Perilesional iron accumulation percent is lower in the hUTC treated monkeys compared 
to vehicle controls (F) The calibrated color intensity (0-4095) of iron is lower in hUTC 
treated monkeys compared to vehicle controls.    * p ≤ 0.05 and ** p ≤ 0.005   
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Figure 6: Density of MHC II activated microglia 
Density was determined by dividing the estimated cell count from unbiased stereology by 
the Cavalieri volume estimation. All numbers represent cells/mm3. (A) Total density of 
activated microglia did not differ in the perilesional gray matter or sublesional white 
matter between treatment groups. When separated by morphology, there was no 
difference in mean density of activated microglia by morphology in perilesional gray 
matter (B) or sublesional white matter (C) by treatment group, but there is a significant 
difference between cell types ** p ≤ 0.005  
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Figure 7: Staining intensity and total area stained of MHC II activated microglia in 
gray and white matter structures 
Ratings between 0 (no staining) and 4 (intense staining) were given to specific regions. 
Then, sections with regions scoring 2, 3, or 4 were outlined and the total gray and total 
white matter areas were measured.  (A) Staining intensity was significantly higher in 
contralesional frontal and temporal white matter in hUTC treated monkeys compared to 
vehicle controls (B) There was no difference between gray matter areas stained. (C) 
However, the extent of staining in the white matter areas was significantly higher with 
hUTC treatment. * p ≤ 0.05  
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Figure 8: Correlations between markers in the current study and lesion volume 
(A) The volume of the cortex occupied by iron exhibits a positive correlation with 
oxidative damage (4-HNE) in both perilesional gray matter. (B) The volume of the cortex 
occupied by iron exhibits a positive correlation with the reconstructed lesion volume.   
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Figure 9: Summary of relevant mechanisms 
Summary of the lipid peroxidation reaction, Fenton reaction, and Haber-Weiss cycle to 
depict the cyclic nature of free radical formation and iron dysregulation following an 
ischemic event. Lipid peroxidation to cell membranes results in 4-HNE and MDA 
accumulations and increases in the presence of ferrous iron and reactive oxygen species.   
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CHAPTER FOUR: NEURONAL SURVIVAL FOLLOWING hUTC 
TREATMENT 
CELL BASED THERAPY FOLLOWING CORTICAL INJURY ENHANCES 
ENDOGENOUS NEURORESTORATION THROUGH NEUROTROPHIC FACTOR 
EXPRESSION 
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Abstract 
 Cell based therapies derived from stem cells have been producing promising 
results in pre-clinical models of stroke. Most human stroke patients do not fully regain 
function through rehabilitation. However, full recovery of function after stroke has been 
observed in pre-clinical models following physical rehabilitation and cell based therapy. 
Cell based therapies can be given up to 30 days after injury and through an intravenous 
injection, making them translatable to human patients. Studies continue to investigate the 
mechanism by which cell therapies enhance motor recovery. The current hypothesis is 
that cell based therapies modulate the immune response and enhance endogenous 
neurorestorative processes following brain injury. We previously assessed the efficacy of 
cell therapy containing human umbilical tissue derived cells (hUTC) in a non-human 
primate model of cortical injury and observed behavioral recovery. In the current study, 
we investigate the hypothesis that hUTC enhances neurorestorative processes following 
injury by quantifying neuronal survival, synaptic density, and astrocytic complexity in 
the ischemic boundary zone as well as brain derived neurotrophic factor in serum and 
CSF. Overall, results reveal a trend toward significantly higher synaptic density and 
astrocytic complexity in the ischemic boundary zone, but no difference in Betz cell 
numbers. There is no difference with treatment on the level of BDNF in the CSF 16 
weeks after injury. However, there is a trend toward higher BDNF in serum one week 
after injury with hUTC treatment, but no change between treatment groups in level of 
BDNF in serum at weeks 6 and 10. These results suggest that hUTC enhanced 
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neurorestorative processes leading to higher synaptic plasticity that may have been 
mediated through astrocytes in the ischemic boundary zone. Further, the higher level of 
BDNF in the first week represents a rescue of circulating BDNF levels that may suggest 
that hUTC treatment enhances early neurorestorative processes through expression of 
BDNF. 
Introduction 
More than 795,000 Americans suffer a stroke each year, leaving many with 
impairments that persist after irreversible brain damage (Mozaffarian et al., 2015). Pre-
clinical stroke research is focused on identifying neurorestorative treatments that enhance 
recovery of function after ischemic brain injury and the mechanism by which these 
treatments disrupt the pathophysiology of stroke. Cell based therapy is an emerging 
therapeutic that has resulted in consistently positive results in preclinical studies. While 
the mechanism remains unclear, evidence suggests that cell based therapy functions 
through enhancing neurorestorative processes and reducing secondary injury following 
ischemic stroke and other brain injury (Savitz et al., 2014). Studies are needed to assess 
promising cell based therapies in translation models such as non-human primates (Fisher 
et al., 2009; Savitz et al., 2011). To this end, we previously assessed a cell based therapy 
containing human umbilical tissue derived cells (hUTC) in our non-human primate model 
of cortical injury to the hand area of the primary motor cortex (Moore et al., 2013). 
Monkeys treated with hUTC recovered strength sooner and fully regained pre-injury 
grasp patterns. In histological follow up studies (Chapter 3), we found a lower density of 
markers for oxidative damage and iron accumulation (hemosiderin) and more activated 
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microglia with hUTC treatment. However, we have yet to fully elucidate the neuronal 
changes in the ischemic boundary zone with hUTC treatment in our model. 
 In this study, we investigate the effect of hUTC on neuronal survival and 
plasticity in the ischemic boundary zone as well as astrocyte morphology and BDNF 
expression. Cortical injury to the primary motor cortex results in neuronal loss through 
oxidative damage, apoptosis, and inflammation (Brouns and De Deyn, 2009). 
Regeneration of the core of the lesion is uncommon leaving the perilesional structures 
both vulnerable to damage and in the proximity to reorganize surviving structures (Furlan 
et al., 1996; Moustafa and Baron, 2009). As the inflammation in the penumbra area 
resolves, surviving structures contribute to remodeling damaged circuits to restore 
function (Carmichael, 2003; Nudo, 2007). During physical rehabilitation, the motor 
function returns to some degree, but most human patients never fully regain pre-stroke 
motor activity (Carmichael, 2006; Nudo, 2007).  
 Astrocytes are the most abundant glial cells in the human brain and they maintain 
synapses, moderate the blood brain barrier (BBB), and react in inflammatory events 
(Amantea et al., 2015). In acute injury, astrocytes contribute to pro-inflammation while 
also disrupting the BBB and inhibiting axonal outgrowth as protective mechanisms 
(Pekny, Wilhelmsson and Pekna, 2014). Through the progression of injury, astrocytes 
restore the BBB and form the glial scar to prevent spreading injury and to enable 
plasticity in surviving perilesional structures (Li et al., 2014; Pekny, Wilhelmsson and 
Pekna, 2014). A growing body of literature suggests that astrocytes are responsible for 
axonal guidance and enhancing functional recovery after injury (Barker and Ullian, 2010; 
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Li et al., 2014) through release of neurotrophic factors such as brain derived neurotrophic 
factor (BDNF) (Béjot, Mossiat, et al., 2011). Serum levels of BDNF in stroke patients 
initially decrease significantly compared to control patients and eventually increase to 
contribute to post-stroke recovery (Santos et al., 2016; Stanne et al., 2016; Wang et al., 
2016). Increasing these levels acutely may lead to a more successful functional recovery. 
 Cell based therapies may enhance functional recovery through the modulation of 
astrocytes (Li et al., 2014) and promoting the secretion of neurotrophic factors (Alder et 
al., 2012; Hsuan et al., 2016) to enhance innate neurorestorative responses. Specifically, 
hUTC enable dendritic differentiation through the production of BDNF (Alder et al., 
2012). Consistently, pre-clinical studies report increased perilesional synaptic density 
(Zhang et al., 2011, 2012, 2013; Arbab et al., 2012; Jiang et al., 2012; Yang et al., 2012; 
Shehadah et al., 2013) and reduced perilesional necrotic cells (Shams Ara et al., 2015). In 
the current study, we present data on the effect of cell based therapy containing hUTC on 
the survival of Betz cells, the synaptic density in the ischemic boundary zone, astrocytic 
morphology, and BDNF levels in serum and CSF in our non-human primate model of 
cortical injury. Our hypothesis is that hUTC functions through enhancing 
neurorestorative processes following injury thereby interrupting neuronal death and 
enabling synaptic plasticity through BDNF secretion. 
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Methods 
Blood Draw 
 For blood draws, monkeys were sedated with Ketamine (10 mg/kg IM) and blood 
was sampled from the saphenous vein between 11:00 and 15:00. These samples were 
collected one week before cortical injury and one week, four to six weeks, and nine to ten 
weeks after cortical injury. A final blood sample was acquired on the day of sacrifice 
between 11:00 and 12:00, sixteen weeks after cortical injury. For the final sample, 
monkeys were deeply anesthetized with sodium pentobarbital (25 mg/kg IV) and arterial 
blood was collected.  
CSF Draw 
CSF was collected on the day of sacrifice between 11:00 and 12:00. For CSF 
draws, monkeys were sedated with Ketamine (10 mg/kg IM), deeply anesthetized with 
sodium pentobarbital (25 mg/kg IV), and CSF was sampled from the cisterna magna.  
Thionin Histology 
A series of 60 μm sections spaced 1200 μm stained with thionin was used to 
quantify Betz cells in the primary motor cortex. For thionin histology, sections were 
mounted on subbed microscope slides immediately after cutting on the frozen microtome 
and allowed to dry completely. All microscope slides were placed in each solution 
together in a rack. First, sections were incubated in a 1:1 mixture of Chloroform and 
100% Ethanol for 3 hours to remove lipids and increase penetration of the stain in 
subsequent steps. Then slides were rehydrated through a graded series of ethanol for 30 
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seconds each (100%, 100%, 95%, 70%, 50%) and one round of reverse osmosis H2O 
(dH2O). Next, slides were incubated for 3 minutes in filtered 0.05% thionin solution (pH 
4.8) containing sodium acetate and glacial acetic acid. Following, slides were moved 
through two rounds of dH2O and dehydrated through a graded series of ethanol (70%, 
95%, 100%, 100%). Finally, slides were cleared in Xylene (Fisher Scientific, Pittsburgh, 
PA) and coverslipped using Permount (Fisher Scientific, Pittsburgh, PA) mounting 
medium.  
Immunohistochemistry 
Markers chosen for immunohistochemistry were synaptophysin representing pre-
synaptic vesicles and glial fibrillary acidic protein (GFAP) representing reactive 
astrocytes. One series of 30 μm sections spaced 1200 μm apart (synaptophysin) or 2400 
μm (GFAP) containing the motor cortex in both hemispheres was removed from storage 
and thawed to room temperature for immunohistochemistry. Sections were batch-
processed for each experiment in the same reagents per the following steps.  First, 
sections were rinsed in 0.05M Tris-buffered saline (TBS) to remove the glycerol. To 
quench endogenous peroxidases, sections were incubated for 30 minutes in TBS 
containing 3% H2O2 followed by washes in TBS. Sections were then incubated for one 
hour in a blocking solution of 10% Normal Goat Serum (NGS) and 0.4% Triton-X in 
TBS. Then, sections were incubated for 48 hours at 4ºC with gentle agitation in a 
monoclonal primary antibody to synaptophysin (anti-synaptophysin IgG in mouse, 
1:100000, Millipore, Billerica, MA) or GFAP (anti-GFAP in rabbit; 1:1000, DAKO, 
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Carpinteria, CA) in a solution containing 2% NGS and 0.1% Triton-X in TBS. Several 
sections of brain tissue were left out of the primary antibody to control for 
immunoreactivity. Following incubation with the primary antibody, the sections were 
washed in a solution containing 2% NGS and 0.1% Triton-X in TBS, followed by a 2-
hour incubation in biotinylated secondary antibody (1:600; Vector Laboratories, 
Burlingame, CA) in TBS containing 2% NGS, and 0.4% Triton-X. The sections were 
then washed in TBS and subsequently incubated with an avidin biotinylated horseradish 
peroxidase complex (ABC Elite; Vector Laboratories, Burlingame, CA) for 1 hour. The 
sections were then washed in TBS followed by rinses in 0.175M sodium acetate solution. 
For visualization, all sections were incubated together in sodium acetate containing 0.55 
mM 3-3’-diaminobenzidine (DAB; Sigma-Aldrich, St. Louis, MO), nickel sulfate 
(0.095M), and 0.0025% H2O2. The sections were washed in sodium acetate to stop the 
DAB reaction, followed by washes in TBS. Finally, sections were mounted on gelatin-
coated slides, air dried, and cover-slipped using Permount mounting medium (Thermo 
Fisher Scientific, Waltham, MA).  
Regions of Interest for Stereology and Densitometry 
Regions of interest (ROI) were determined on a Nikon E600 light microscope at 
the 4x objective (Betz cells and synaptophysin) or the 10x objective (GFAP). For Betz 
cell stereology, the regions of interest were ipsilesional-medial, ipsilesional-lateral, and 
contralesional. On the ipsilesional hemisphere, layer V of the primary motor cortex was 
outlined from the sagittal sulcus to the lesion (ipsilesional-medial) and from the lesion to 
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the lateral sulcus (ipsilesional-lateral). On the contralesional hemisphere, layer V of the 
primary motor cortex was outlined from the sagittal sulcus to the lateral sulcus 
(contralesional). Layer V was defined by the presence of Betz cells. Measures for 
synaptophysin were taken in both the perilesional area and the ischemic boundary zone 
(IBZ). The perilesional area was defined as the intact cortex from 1 mm medial to the 
lesion to 1 mm lateral to the lesion. IBZ was defined as the irregularly stained boundary 
of the lesion. For GFAP densitometry, the perilesional gray matter (PLG) and sublesional 
white matter (SLW) areas were outlined as previously described in Chapter 3. Briefly, 
SLW was defined by first drawing a straight line from the depths of the cingulate sulcus 
to the depths of the lateral sulcus on sections containing the lesion. Next, lines 
perpendicular to the cortical surface were drawn from the straight line between sulci to 
the gray-white boundary. Finally, the ROI was completed by connecting the lateral and 
medial boundaries of the SLW by a line following the gray-white boundary. PLG was 
defined using the lateral and medial boundaries of SLW and the gray-white boundary. 
Next parallel lines to the SLW lateral and medial boundaries were followed to the cortical 
surface. These boundaries were connected by lines tracing the cortical surface and the 
gray-white boundary to complete the PLG ROI. 
Betz Cell Stereology 
Unbiased stereology was used to quantify the number thionin stained Betz cells in 
Layer V of the Primary Motor Cortex in three ROI: ipsilesional-lateral, ipsilesional-
medial, and contralesional. For stereology, Betz cells were visualized on a Nikon Eclipse 
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E600 series light microscope (Nikon; Melville, NY, USA) equipped with a motorized 
stage integrated with StereoInvestigator 9 software (MicroBrightField Bioscience; 
Williston, VT). The Optical Fractionator Workflow on StereoInvestigator was used to 
quantify 8-9 equally spaced sections per monkey throughout the motor cortex. ROI were 
determined at 4x objective. For stereological counting, sections were visualized at 20x 
objective with a counting frame of 350 µm x 250 µm. The sampling grid was optimized 
at 350µm x 250µm for ipsilesional-lateral, 750 µm x 750 µm for ipsilesional-medial, and 
1000 µm x 1000 µm for contralesional. Counting was performed allowing a minimum of 
1 µm guard zones above and below the counting brick to ensure that lost caps could be 
identified and counted or excluded according to the respective face (West, Slomianka and 
Gundersen, 1991). Betz cells of layer V of the primary motor cortex have distinct 
morphological features including a prominent nucleolus and dendritic branches sprouting 
from the entire soma that were used as inclusion criteria (Rivara et al., 2003). The 
estimated total number of Betz cells in each ROI were calculated using the optical 
fractionator formula (West et al., 1991, 2002). Parameters were optimized such that 
Coefficient of Error (Gundersen m=1) (Gundersen et al., 1999) was less than 0.10.   
Densitometry for Synaptophysin and GFAP 
Densitometry was used to quantify synaptophysin and GFAP. For synaptophysin 
densitometry, mounted sections from the area of the lesion were visualized on a Nikon 
E600 light microscope equipped with a motorized stage and Nikon Imaging Software 
(NIS – Advanced Research). Sections spaced every 1200 µm throughout 7 to 10 mm of 
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the lesion site were selected for analysis with 4-6 sections selected per animal. Tiled 
Large Image Scans of the area of the lesion were acquired using the 4x objective. All 
images were acquired with 625 µsec exposure, AutoWhite balance, and focus surface 
optimized to 5 points on the tissue. The tiled images were overlapped by 15%, stitched 
via blending and image registration, followed by automatic post-processing for shading 
correction. Once acquired, images as nd2 files were analyzed using the NIS-AR analysis 
software. The polygon tool was used to draw the IBZ. Then, Intensity Threshold was set 
to a low of 15 and high of 150. ROI Statistics were exported to excel and numbers used 
for analysis include “ROI Area,” “Area Fraction,” and “ROI Mean Intensity (Optical 
Density).” Mean intensity measures were inverted by subtracting numbers from 255 such 
that the larger numbers represent a darker staining and the lower numbers represent a 
lighter intensity of staining. 
For GFAP densitometry, mounted sections from the area of the lesion were 
visualized on a Nikon E600 light microscope equipped with a motorized stage and 
Surveyor software (Objective Imaging, Kansasville, WI). Two equally spaced sections 
near the site of the lesion were selected per animal. The ipsilesional hemisphere was 
visualized in Surveyor using the 10x objective, bright field correction, and manual focus. 
Using TurboScan Stepped, tiled images were acquired and saved as TIFF files. These 
images were imported into Fiji software (NIH, version 1.50i), (Schindelin et al., 2012) 
and scale was set using distance in pixels determined for the specific objective on the 
specific microscope. ROIs (PLG and SLW) were traced and saved in the ROI Manager. 
Images containing both ROI were transformed into 8-bit images and the threshold 
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function (default) was used to remove artifact and create binary images. Measurements 
were set to calculate “Area” and “Area Fraction” and these measurements were saved for 
analysis. The density of astrocytes is reported as a percentage of staining following 
threshold within the ROI defined. 
Sholl Analysis for Reactive Astrocytes 
 The complexity of GFAP+ astrocytes was quantified on manually traced 
astrocytes by Sholl and Branched Structure Analysis. Mounted sections stained for GFAP 
were visualized on a Nikon E600 light microscope equipped with a motorized stage and 
Neurolucida software (MicroBrightField Bioscience, Williston, VT). Two sections near 
the site of the lesion were selected per animal. The reference point was chosen at 4x as 
the point most central to the lesion area on the specific section, specifically where the 
GFAP+ astrocytes infiltrated from cortical surface to the white matter without 
interruption. The grid function was used to determine systematic sampling sites. One 
astrocyte was reconstructed using the 60x oil immersion objective at 30 different sites 
chosen at 250µm intervals from the lesion reference point (250µm, 500µm, 750µm, and 
1000µm) based on a pre-determined grid. A total of 30 astrocytes per section and 60 
astrocytes per animal were reconstructed. Astrocyte reconstructions were opened in 
Neurolucida Explorer (MicroBrightField Bioscience, Williston, VT) where a Sholl 
analysis was completed using a starting point of 0 µm and an interval of 5 µm. The sum 
of the number of intersections used for analysis. A branched object analysis was also run 
for the Cell Summary and Soma Details. 
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ELISA for BDNF 
Enzyme Linked Immunosorbent Assay (ELISA) was performed using blood and 
CSF samples from all 8 monkeys to quantify BDNF peripherally and centrally. The 
Human BDNF ELISA Kit (ELH-BDNF, RayBiotech, Norcross, GA) was optimized to 
ensure a reliable standard curve and a sufficient concentration of sample. All samples 
were run in triplets to account for variability in absorbance and in two plates 
simultaneously to fit all samples. Sandwich ELISAs were performed according to 
manufacturer’s instructions. Briefly, samples and standards were diluted and loaded into 
the wells of the pre-coated 96-well plates and incubated for 2.5 hours. The plate is then 
washed with wash solution. and incubated with biotinylated antibody to the target protein 
for 1 hour. Next, following another wash with wash buffer, the plate was incubated with 
streptavidin solution for 45 minutes and then washed with wash buffer. Finally, TMB 
One solution was used for color development for 30 minutes and the color development 
was stopped with the addition of stop solution. The absorbance of all wells was measured 
at 450 nm on a plate reader within 30 minutes of color development. All values of total 
protein concentrations were calculated using the standard curve and four-parameter 
logistic regression. 
Data Analysis and Statistics 
Statistical analyses were performed using R (RStudio Inc, Version 0.99.896, R 
foundation for Statistical Computing, Vienna, Austria). Student’s t tests (α = 0.05) with 
Bonferroni correction were used to assess differences between treatment groups. 
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Significance level was set to p ≤ 0.05. A two-way ANOVA with repeated measures was 
used for BDNF serum analysis to identify significant variables and interactions with 
group (vehicle or hUTC treated) as a between subject variable and time point (post-
operative 1 week, 6 weeks, and 10 weeks) as within subject variables. Regression 
analyses were performed with subjects from both groups together. For correlations 
relating to the mean grasp (an ordinal scale, 0-8), Spearman’s Correlation was used, and 
all other correlations were assessed using a Pearson’s Correlation with an alpha level set 
at p ≤ 0.05. 
Results 
Effect of hUTC on Betz Cell Survival 
Betz cells are the upper motor neuron of the primary motor cortex involved in fine 
motor movements of the hand. Following injury to the primary motor cortex, Betz cells 
are one population of neurons damaged. Therefore, we quantified the number of Betz 
cells in the ipsilesional and contralesional hemispheres (Figure 10A). Cells with a 
prominent nucleolus and branching from all parts of the soma were counted (Figure 10B). 
Group comparisons were assessed in the ipsilesional (addition of lateral and medial 
portions) and contralesional primary motor cortex ROI. There was no significant 
difference in Betz cell numbers between groups [F(1,6) = 0.345, p = 0.579], but there is a 
significant difference between hemispheres [F(1,6) = 20.91, p = 0.0038] (Figure 10C). This 
suggests that while a significant number of Betz cells were lost following cortical injury, 
there is no effect of hUTC treatment on this loss. To assess if the Betz cells were lost 
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simply as a consequence of the lesion or whether secondary injury lead to further loss, we 
calculated the percent loss of Betz cells and of gray matter volume in the primary motor 
cortex from reconstructed lesion volumes. In both cases, we subtracted the value of the 
ipsilesional hemisphere from that of the contralesional hemisphere and determined a 
percentage by dividing by the contralesional value. While there was no difference 
between groups, there was a significantly higher percent loss of Betz Cell numbers 
compared to percent loss of gray matter volume in the primary motor cortex (p = 0.0002) 
(Figure 10D). These results suggest that significant secondary injury lead to loss of Betz 
cells beyond the lesion core.  
Effect of hUTC on Synaptic Remodeling 
To investigate the changes in synaptic density in the perilesional area, 
synaptophysin immunohistochemistry and densitometry was performed. Synaptophysin is 
a pre-synaptic vesicle protein. Measures for synaptophysin were taken in the IBZ, which 
was defined as the irregularly stained boundary of the lesion (Figure 11A-B). The volume 
measured of the IBZ ROI trended toward a significant increase with treatment (p = 0.092) 
(Figure 11C), meaning synapses were present in the perilesional area in a larger area of 
damage. There was no significant difference in area fraction with hUTC treatment (p = 
0.279) (Figure 11D). However, the optical density of staining trended toward a 
significant increase in the hUTC treated monkeys compared to vehicle controls (p = 
0.090) (Figure 11E). Overall, there was a trend toward a significant increase in the 
ischemic boundary zone volume and synaptophysin staining with hUTC treatment. 
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Effect of hUTC on Astrogliosis 
Reactive astrocytes express GFAP. Percent area of binary images was used to 
measure astrogliosis in the perilesional gray matter and sublesional white matter (Figure 
12A-B). Overall, there was no measured difference in the percent area of staining of 
GFAP positive astrocytes between groups in either perilesional gray matter (p = 0.440) or 
sublesional white matter (p = 0.651) (Figure 12C). These results suggest that hUTC 
treatment did not affect the level of perilesional and sublesional astrogliosis. 
Effect of hUTC on Astrocytic Complexity 
Individual astrocytes were identified (Figure 13A) and manually traced. The 
tracings were used to determine the sum of intersections through Sholl Analysis and 
soma size through Branched Structure Analysis. Sholl Analysis of lesion area astrocytes 
(50-150 µm from lesion center) show a trend toward significantly higher sum of 
intersections (p = 0.083) with hUTC treatment (Figure 13B). This difference was not 
observed in deeper white matter astrocytes (750-1000 µm from lesion center) (p = 0.76). 
The soma size of lesion area astrocytes does not differ between treatment groups (p = 
0.35) and approached a decrease in soma size with hUTC treatment in white matter 
astrocytes (p = 0.14) (Figure 13C). These results suggest that the lesion area astrocytes 
were more complex in their branching in hUTC treated compared to vehicle control 
monkeys.  
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Effect of hUTC on Circulating BDNF Levels 
BDNF levels were measured in serum samples taken at the time points 1 week, 6 
weeks, 10 weeks, and 16 weeks with the pre-operative samples as a baseline. Using 
ELISA, the concentration of BDNF was estimated in serum samples. The average 
concentration of BDNF (ng/mL) for both treatment groups and every time point are 
shown in (Figure 14A). For analysis, the serum concentrations were normalized to 
baseline values. For the two monkeys without baseline samples, the average of all others 
was used. Then the difference was calculated between the time point and baseline 
samples and divided by the baseline value to determine the percent difference following 
cortical injury and with or without hUTC treatment. For six of the eight samples from the 
week 16, there was no detectable level of BDNF, so these numbers were left out of the 
analysis. Overall, there is a no significant difference in BDNF level by group [F(1,6) = 
0.168, p = 0.694], but there is a significant difference between time points [F(1,6) = 6.687, 
p = 0.009]. Further, there is a trend toward a significant interaction between group and 
time point [F(1,6) = 2.523, p = 0.116], in that the hUTC treated monkeys have a higher 
level of BDNF at 1-week post-operative (Figure 14B). Overall, these results suggest an 
increase in peripheral BDNF in the first week of injury with hUTC treatment followed by 
levels more similar to the vehicle treated controls.  
Effect of hUTC on Terminal CSF BDNF Levels 
BDNF levels were measured in CSF samples taken at 16 weeks. Using ELISA, 
the concentration of BDNF was estimated in CSF samples. For CSF, only one sample 
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was available and therefore the data could not be normalized to baseline levels. There 
was no significant difference in BDNF levels in the CSF at 16 weeks with hUTC 
treatment (p = 0.182) (Figure 14C). Overall, these results suggest that there is no 
observable difference in the BDNF level in CSF 16 weeks after injury with or without 
hUTC treatment. 
Relationship Between Markers 
Previous results in this study were presented comparing the treatment groups. 
However, monkeys in both treatment groups recovered to some degree, with the hUTC 
treatment seemingly enhancing the endogenous recovery mechanisms. Therefore, for 
regression analyses we pooled all subjects (n = 8) together to explore the relationship 
between findings of the current study and behavioral results published previously (Moore 
et al., 2013).  
As previously reported, hUTC treated monkeys returned to pre-operative levels of 
performance on fine motor tasks in significantly fewer days compared to monkeys that 
received vehicle (Moore et al., 2013). Interestingly, there is a trend toward a significant 
negative correlation between recovery time (in days) and number of ipsilesional Betz 
cells (Rp = -0.688, p = 0.066) (Figure 15A). Alternatively, recovery time was not 
correlated with change in BDNF levels at post-operative week 1 (Rp = -0.432, p = 0.285). 
These results suggest that increased ipsilesional Betz cell may be a significant predictor 
of improved recovery time following cortical injury. 
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As previously reported, there was no group difference between hUTC treated and 
vehicle control monkeys in reconstructed lesion volume using Nissl stained sections 
(Moore et al., 2013). However, there was a trend toward a significant negative 
relationship with lesion volume and number of ipsilesional Betz cells (Rp = -0.676, p = 
0.059) (Figure 15B). Similarly, there is a trend toward a significant negative linear 
relationship with lesion volume and percent change in serum BDNF in week 1 (Rp = -
0.635, p = 0.091). Finally, there was a positive linear relationship between lesion volume 
and the soma size of lesion area astrocytes (Rp = 0.768, p = 0.026) (Figure 15C). These 
results suggest that more hypertrophied astrocytes and a decreased number of ipsilesional 
Betz cells accompany a larger lesion. 
Discussion 
Summary of Results 
(1) While there is no difference in ipsilesional Betz cell numbers with hUTC 
treatment, the number of ipsilesional Betz cell numbers approached a significant positive 
association with faster recovery. (2) Percent loss of Betz cells is significantly higher than 
percent loss of gray matter volume, suggesting significant secondary injury beyond the 
lesions core. (3) There is a trend toward an increase in synaptophysin staining in the IBZ 
with hUTC treatment. (4) There is no observable difference in overall astrogliosis or 
astrocyte soma size with hUTC treatment. (5) Soma size of astrocytes in the lesion area is 
positively correlated with lesion volume. (6) Lesion area astrocytic branching is more 
complex with hUTC treatment. (7) Peripheral BDNF percent change from baseline values 
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show a trend toward a significant increase with hUTC treatment at 1 week. Further, with 
a higher percent change at 1 week the lesion area is smaller. (8) There is no overall 
difference in BDNF level in the CSF 16 weeks after injury with hUTC treatment. Overall 
hUTC treatment spared synaptic density in the lesion area, but not the total number of 
ipsilesional Betz cells. This was accompanied by increased lesion area astrocyte 
complexity. Finally, peripheral BDNF levels were higher within a week of injury with 
hUTC treatment and then BDNF leveled off. 
Betz Cells in Primary Motor Cortex 
Betz cells are large pyramidal neurons found only in layer V of the primary motor 
cortex. Dendrites emanate from multiple locations on the cell body and large diameter 
axons project to join the fibers in the corticospinal tract, making up 10% of its fibers 
(Rivara et al., 2003). Clusters of Betz cells are found in distinct areas of the somatotopic 
map (Rivara et al., 2003). A previous study found that 5.5% of all Betz cells are clustered 
in the hand area of the primary motor cortex (Rivara et al., 2003), suggesting a location 
to influence control of fine motor functions. The large diameter axons from Betz cells 
directly or indirectly innervate lower motor neurons initiating activity of reaching and 
grasping. In the current study, we found no difference in the number of ipsilesional Betz 
cells after cortical injury with hUTC treatment. This may be due to these unique large 
cells having a higher resistance to an ischemic environment as observed in a previous 
study of human patients with hypoxic-ischemic encephalopathy (Murayama, Bouldin and 
Suzuki, 1990). However, we report that the number of Betz cells approach a significant 
 92  
increase with faster recovery to pre-operative grasp patterns, which is consistent with the 
Betz cells contributing to fine hand movements. hUTC treatment has been implicated in 
decreasing secondary damage and therefore may have acted indirectly through limiting 
spreading damage of both neurons and glia. Our result that the percent loss of Betz cells 
was significantly higher than percent loss of gray matter in the primary motor cortex 
suggests that secondary injury played a significant role. Future studies will determine 
where this secondary injury occurred and if there is a treatment effect on secondary 
injury. 
Synaptic Density in the Ischemic Boundary Zone 
The ischemic boundary zone borders the lesion core where irreversible damage 
takes place. The ischemic boundary zone, also known as the penumbra, is defined by the 
decreased level of blood flow to the area (Astrup, Siesjö and Symon, 1979) in an 
ischemic event and the area of secondary damage (Stoffel et al., 1997) in a traumatic 
event. It is within the IBZ that increased synaptic plasticity occurs resulting in functional 
improvements after stroke (Carmichael, 2003; Nudo, 2007). In our model without 
reperfusion, there is no true ischemic penumbra, however the IBZ is an area of 
opportunity as the brain cells are vulnerable, but not yet irreversibly damaged. In the 
current study, we defined IBZ based on the area of inconsistent synaptic density to 
represent an area that could have been subject to secondary damage. In this area, we 
found a trend toward an increase in the synaptophysin staining and volume of staining in 
the IBZ with hUTC treatment. This is consistent with other studies assessing hUTC as a 
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treatment for ischemic stroke, who consistently find an increase of synaptic density in the 
IBZ (Zhang et al., 2011, 2012, 2013; Arbab et al., 2012; Jiang et al., 2012; Yang et al., 
2012; Shehadah et al., 2013).  
Hypertrophied Astrocytes Following Injury 
Astrocytes become reactive and exhibit hypertrophy of processes and cell bodies 
in response to pro-inflammatory cytokines (Pekny, Wilhelmsson and Pekna, 2014). 
Reactive astrogliosis limits damage acutely through elimination of glutamate and reactive 
oxygen species and thus protecting of the penumbra (Li et al., 2014; Pekny, Wilhelmsson 
and Pekna, 2014). However, if not resolved, chronic gliosis inhibits innate 
neurorestorative processes to revascularize and reinnervate the areas bordering damage 
(Pekny, Wilhelmsson and Pekna, 2014). In the current study, we found no observable 
differences in the extent of astrogliosis or soma size with hUTC treatment. This may be 
due to observing astrogliosis later in the recovery process (16 weeks after injury). The 
astrogliosis in the lesion area represents the residual glial scar, which forms to physically 
quarantine the area of injury and allows for endogenous regeneration (Suzuki et al., 2012; 
Li et al., 2014). The area of the glial scar is typically the area of irreversible cell damage 
and death. The increased soma size in lesion area astrocytes is positively correlated with 
lesion volume. This may reflect the that the morphological phenotype of reactive 
astrocyte is dependent on the severity of injury (Pekny, Wilhelmsson and Pekna, 2014). 
With a decrease in secondary injury due to an earlier resolution as seen with hUTC 
treatment (see chapter 3), this may have decreased the lesion and glial scar size and 
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increased overall neuronal survival. Interestingly, previous studies have found that MSC 
treatment decreases the glial scar formation after stroke (Li et al., 2005; Pavlichenko et 
al., 2008). 
Astrocytes in Axonal Guiding 
Due to the diverse functions of reactive astrocytes following injury, we isolated 
specific morphological features to better understand function, both soma size as discussed 
above and branching complexity. In the developing brain, astrocytes assist in neurite 
guidance and synaptogenesis (Powell, Fawcett and Geller, 1997). After stroke, astrocytes 
remain reactive during chronic neurorestoration and contribute to neurite outgrowth and 
synaptic plasticity (Li et al., 2014). Significant evidence suggests that astrocytes mediate 
functional improvements occurring after cell based therapy (Li et al., 2014). Astrocytes 
in the presence of MSC are enhanced in their ability to promote brain plasticity as shown 
from in vitro studies (Gao, Li and Chopp, 2005; Barzilay et al., 2013). Astrocytes modify 
the plasticity of synapses and form new synapses (Barker and Ullian, 2010), specifically 
astrocytic processes are plastic and may stabilize newly formed synapses (Li et al., 2014). 
In the current study, we report an increase in branching complexity of astrocytes in the 
lesion area near the IBZ. In previous studies, increased branching complexity of 
astrocytes in the hippocampus has been shown to be associated with enhanced learning 
(Viola et al., 2009). Thus, it is possible that the astrocytes in the IBZ were contributing to 
synaptogenesis through branched processes guiding neurite outgrowth. Further work to 
assess interactions between astrocytes and synapses will be important. 
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Circulating BDNF Levels After Injury 
BDNF levels in blood and serum have been measured as a biomarker of the brain 
functioning for various neurological disorders. BDNF is secreted both by glutamatergic 
neurons and peripheral cells (Santos et al., 2016) and can cross the blood brain barrier 
(Karege, Schwald and Cisse, 2002). Infusion of BDNF after cerebral ischemia has been 
found to reduce cell death and infarct size, stimulate adult neurogenesis, enhance synaptic 
plasticity, and improve long term recovery of function (Schäbitz et al., 2000, 2004, 2007; 
Ploughman et al., 2009; Santos et al., 2016; Cook et al., 2017). Studies in human patients 
have found that low BDNF serum levels are related to incomplete outcome following 
TBI (Korley et al., 2016). Further, after ischemic stroke, low circulating BDNF levels in 
the acute phase are associated with poorer outcome (Stanne et al., 2016; Wang et al., 
2016) and post-stroke patients continue to have decreased circulating levels of BDNF in 
the chronic phase compared to control patients (Santos et al., 2016). In the current study, 
we report an initial increase in BDNF levels at week 1 compared to baseline with hUTC 
treatment that is not observed in the vehicle treated monkeys. This increase is different 
from all reports of lower levels in the acute phase and may suggest that hUTC increased 
circulating BDNF levels in the phase most predictive of functional outcome. Percent 
change of BDNF from baseline at 6 and 10 weeks were not different between groups. 
Interestingly, increased percent change of serum BDNF at week 1 is related to a smaller 
lesion volume. While these results are exciting, the treatment was given systemically and 
samples were from peripheral blood vessels pointing to the importance of having a 
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measurement more directly related to the brain such as from CSF (Zetterberg, Smith and 
Blennow, 2013). 
Central BDNF Levels After Injury 
CSF is preferable to identify biomarkers following brain injury due to its 
proximity to the brain and a decrease in confounding factors such as systemic infections 
(Zetterberg, Smith and Blennow, 2013). Many biomarkers have been identified in the 
CSF including GFAP, S100B, and pro-inflammatory cytokines (Mrozek et al., 2014), but 
less is known about the levels of BDNF after stroke and with injury severity. However, 
BDNF is assessed for a biomarker in traumatic brain injury (Failla, Conley and Wagner, 
2016; Meirelles, Simon and Regner, 2017) and hypoxia (Korhonen et al., 1998) in human 
patients. Following CNS injury, studies have found an increase in acute CSF BDNF 
levels compared to controls (Chiaretti et al., 2003; Failla, Conley and Wagner, 2016) and 
that CSF BDNF negatively correlates with acute serum BDNF (Failla, Conley and 
Wagner, 2016). These results are consistent with studies that measured of mRNA of the 
perilesional cortex and again found an increase in BDNF acutely after injury (Oyesiku et 
al., 1999). The initial increase in CSF or cortical BDNF expression may a compensatory 
mechanism to protect the brain after injury (Kim and Zhao, 2005; Shulga et al., 2008) to 
enable regeneration and reorganization (Felderhoff-Mueser et al., 2002; Shetty et al., 
2004). Further, in vitro, hUTC secrete BDNF to enhance dendritic differentiation (Alder 
et al., 2012), suggesting its role in post-injury plasticity. In the current study, we 
quantified CSF BDNF in the chronic period, 16 weeks after injury. We found no overall 
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difference in CSF BDNF concentration with hUTC treatment. Future studies should 
quantify BDNF in CSF as a biomarker in the acute period with a comparison to baseline 
CSF measures. 
Conclusion 
In this study, we provide evidence for enhanced endogenous restorative processes 
observed in a non-human primate model of cortical injury with a cell based therapy 
containing hUTC. The major findings of this study are higher synaptic density and 
complexity of astrocytes in the ischemic boundary zone, but no difference in Betz cell 
numbers, as well as increased circulating BDNF one week after injury with the 
administration of a cell based therapy. These observations provide potential targets for 
future therapeutics. Further, these findings confirm previous studies and contribute to the 
literature on the mechanism of cell based therapies in recovery from stroke.   
 98  
 
Figure 10: Regions of interest, stereology criteria, and estimations of Betz cells  
Representative micrographs of thionin histology. (A) Regions of interest for Betz cell 
Stereology including layer V in contralesional (green), in medial ipsilesional (yellow), 
and in lateral ipsilesional primary motor cortex (orange.) (B) Betz cells were counted 
based on the presence of a prominent nucleolus and dendritic branches sprouting from the 
entire soma with representative Betz cells are shown. (C) Number of Betz cells in 
contralesional and ipsilesional were estimated using stereology. There was no significant 
difference of Betz cells in the contralesional or ipsilesional hemispheres in the hUTC 
treated monkeys compared to vehicle treated controls. (D) Percent loss of gray mater 
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volume and Betz cell numbers were calculated using the values from ipsilesional and 
contralesional hemispheres. There were no significant group differences, but here was a 
significantly higher percent loss of Betz Cell numbers compared to percent loss of gray 
matter volume in the primary motor cortex. Scale bar: 100 µm ** p ≤ 0.005 *** p ≤ 
0.001 
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Figure 11: Synaptophysin densitometry 
(A&B) Calibrated micrographs showing synaptophysin immunohistochemistry (A) and 
the ischemic boundary zone (IBZ) identified by the irregularly stained boundary of the 
lesion. (B). (C) Total volume of the IBZ trends toward a significant increase with hUTC 
treatment. (D) The percent area of synaptophysin does not differ between treatment 
groups. (E) The optical density of synaptophysin staining in the IBZ trends toward a 
significant increase with hUTC treated monkeys compared to vehicle controls.   
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Figure 12: Astrogliosis (GFAP) in the perilesional area 
(A) Representative micrographs of GFAP immunohistochemistry through the lesion in 
primary motor cortex with an overlay of ROI tracings used for densitometry. ROI are 
perilesional gray matter and sublesional white matter and were defined using boundaries 
of the depths of the cingulate and lateral sulcus were used as boundaries as well as the 
cortical surface and the gray-white boundary. (B) Calibrated micrographs of 
representative GFAP staining in both ROI. Scale bar = 20 µm (C) Percent area of the 
GFAP staining does not differ between treatment groups in either ROI.  
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Figure 13: Astrocyte complexity in lesion area and deeper white matter 
(A) Calibrated micrographs of GFAP astrocytes from the lesion area (0-75 µm from 
lesion center) and white matter (750-1000 µm from lesion center) from both treatment 
groups. Scale bar = 15 µm (B) The sum of all intersections from Sholl Analysis per cell 
was averaged for each subject. Lesion area astrocytes trend toward a significantly greater 
sum of intersections with hUTC treatment compared to vehicle controls, but does not 
differ in deeper white matter. (C) Soma area does not differ between treatment groups in 
either the lesion area or deeper white matter.   
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Figure 14: BDNF concentration in serum and CSF. 
(A) Concentrations of serum at baseline, 1 week, 6 weeks, 10 weeks, and 16 weeks are 
shown. Due to variability in baseline measures, the percent change from baseline was 
calculated for serum values for each subject. (B) Percent change from baseline values are 
shown comparing treatment groups. There is a trend toward a significant increase in 
serum BDNF at 1 week with hUTC treatment. (C) Concentrations of CSF BDNF levels at 
16 weeks are shown.  
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Figure 15: Correlations between markers in the current study and outcome 
measures 
(A) The number of ipsilesional Betz cells exhibits a trend toward a significant negative 
correlation with days to recovery and (B) lesion volume. (C) The soma area of lesion area 
astrocytes exhibits a positive correlation with lesion volume.  
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CHAPTER FIVE: REORGANIZATION FOLLOWING hUTC TREATMENT 
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Abstract 
Stroke results in enduring damage to the cerebral cortex which is followed by 
innate neurorestorative processes, such as reorganization of surviving circuits and 
stimulation of neurogenesis. Nevertheless, patients are often left with permanent residual 
impairments. Cell based therapy is an emerging therapeutic that may function to enhance 
the innate neurorestorative capacity of the brain. We previously evaluated human 
umbilical tissue-derived cells (hUTC) in our non-human primate model of cortical injury 
limited to the hand area of primary motor cortex. Injection of hUTC 24 hours after injury 
resulted in significantly enhanced recovery of fine motor function compared to vehicle 
treated controls (Moore et al., 2013). Moreover, hUTC treatment resulted in lower 
oxidative damage and iron accumulation as well as higher density of markers for 
microglial activation and synaptic remodeling in perilesional areas (Chapters 3 and 4). 
Here we investigate the hypotheses that hUTC treatment enhanced recovery through 
increasing cortical reorganization and neurogenesis. Monkeys received an injection of 
Bromodeoxyuridine (BrdU) 8 days after cortical injury to label newly generated cells. 
This was followed by 12 weeks of behavioral testing, which culminated in a final 
behavioral testing session 3 hours prior to perfusion using only the impaired hand to 
upregulate the immediate early gene c-Fos in activated cells. Following perfusion-
fixation of the brain, sections were processed using immunohistochemistry to label c-Fos 
activated cells, pre-synaptic vesicle protein synaptophysin, and BrdU labeled cells, in 
adjacent premotor cortices known to play a role in motor control. Quantitative analysis 
revealed that c-Fos activated cells were significantly increased in the ipsi- and contra-
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lesional ventral premotor cortex in the hUTC treated monkeys compared to vehicle 
controls. Furthermore, the increase in c-Fos activated cells in the ipsi- and contra-lesional 
ventral premotor cortex correlated with a decrease in recovery time and improved grasp 
topography. Interestingly, there was no difference in the number of synaptophysin puncta 
in either ipsi- or contra-lesional ventral or dorsal premotor cortices between treatment 
groups. The density of BrdU labeled cells in the subgranular zone of the hippocampus 
approached a significant increase with hUTC treatment, but did not differ between groups 
in the subventricular zone. These findings support the hypothesis that hUTC treatment 
enhances the capacity of the brain to reorganize after cortical injury. Specifically, these 
results suggest that bilateral ventral premotor cortex takes over some of the function of 
the lost neurons in the primary motor cortex. Given the observation that the total number 
of synapses in ventral premotor is not different between treatment groups, this 
reorganization may be accomplished through enhanced activation of pre-existing circuits 
between ventral premotor and the primary motor cortex or cortical projections to the 
brainstem or spinal cord.  
Introduction 
Stroke is the leading cause of long-term disability in the United States and 
approximately 795,000 Americans experience a new or recurring stroke each year. The 
only current FDA-approved therapy for ischemic stroke is intravenous administration of 
tissue plasminogen activator (tPA) to return blood flow to the blocked artery, but this is 
only effective if administered within hours following onset of stroke (Wang et al., 2004; 
Ebinger et al., 2015). Many patients are unable to receive the tPA treatment due to the 
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narrow therapeutic window, or other contraindications (Fugate and Rabinstein, 2015) and 
even those who do receive tPA often are left with varying amounts of irreversible brain 
damage and significant residual impairment. Accordingly, neurorestorative treatments are 
needed to enhance neuroplasticity and facilitate recovery of function following stroke or 
other traumatic events.  
In both animal models and human stroke patients with motor impairments, 
physical therapy involving rehabilitative motor tasks can lead to significant improvement 
in motor function over a period of months following stroke (Calautti and Baron, 2003; 
Frost et al., 2003). Nevertheless, in humans, complete recovery to pre-stroke function is 
rare (Gowland, 1987). The central nervous system (CNS) has a limited ability to repair or 
regenerate neurons due to inhibitory factors released by CNS parenchyma and glial 
scarring (Yiu and He, 2006). As a result, functional recovery following CNS damage is 
not a result of neuronal regeneration, but more likely due to a variety of neuroplasticity 
mechanisms such as axonal sprouting, synaptic reorganization, and changes in 
myelination (Pascual-Leone et al., 2012; Fields, 2015; Mensch et al., 2015; Armstrong et 
al., 2016). In fact, there is evidence for cortical neuroplasticity and reorganization 
following CNS lesions in both humans and animal models (Pons et al., 1988; Kaas, 1991; 
Seitz et al., 1995). Specifically, there is evidence of increasing cortical reorganization of 
undamaged motor areas including premotor cortices (Frost et al., 2003; Nudo, 2007; 
Nudo and McNeal, 2013) and evidence of enhanced neurogenesis (Zhang et al., 2013; 
Marlier et al., 2015). Hence, targeting plasticity and reorganization mechanisms with new 
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therapeutic agents may be one way to enhance more complete functional recovery after 
cortical injury. 
Cell based therapies are an attractive avenue of neurorestorative treatments that 
have shown largely promising results in preclinical models of stroke. While the 
mechanism remains unclear, studies suggest that cell based therapies enhance 
endogenous repair mechanisms through increasing brain plasticity and synaptic 
remodeling (Savitz et al., 2014). While such neurorestorative treatments for stroke have 
been assessed preclinically, none have successfully translated to human patients. The 
Stroke Therapy Academic Industry Roundtable (STAIR) (Fisher et al., 2009) and Stem 
Cells as an Emerging Paradigm in Stroke (STEPS) (Savitz et al., 2011) committees 
assessed ways to enhance translation between preclinical and clinical studies. Both the 
STAIR (Fisher et al., 2009) and STEPS (Savitz et al., 2011) reports recommended the 
use of non-human primate models to validate and further assess efficacy and safety of 
promising therapies including cell based approaches. Further, STEPS recommends 
performing appropriate histological studies to examine the effects of the cell based 
therapy on the remodeling of surviving structures (Savitz et al., 2011). 
To that end, this report is a histological follow-up to our earlier study that a cell 
based therapy of human umbilical tissue derived cells (hUTC) enhanced recovery of fine 
motor function in our reproducible non-human primate model of cortical injury (Moore et 
al., 2013). Specifically, it was demonstrated that intravenous administration of hUTC, 24 
hours after cortical damage, significantly improved function and strength of the impaired 
hand in the first two weeks of recovery and improved finger-thumb grasp rating during 
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the 12-week post-operative assessment as compared to vehicle treated controls. Our 
previous histological studies show that hUTC treatment resulted in a lower oxidative 
damage and iron accumulation as well as higher density of markers for microglial 
activation and synaptic remodeling in perilesional areas (Chapters 3 and 4). However, it 
is unknown whether these changes in markers of damage, repair, and remodeling indeed 
lead to structural reorganization of circuits that support recovery of function. 
We hypothesized that the recovery of function observed with hUTC treatment 
may be due to reorganization of undamaged motor areas and enhancement of general 
neuroplasticity as reflected by adult neurogenesis. To evaluate this hypothesis, we report 
here quantitative analysis of markers of cell activation and synaptic density in bilateral 
premotor cortices. Further, we evaluated generalized stimulation of neuroplasticity by 
quantifying neurogenesis in the subventricular zone and subgranular zone. 
Methods 
BrdU Administration 
Seven (3 treated and 4 vehicle) monkeys received a single intraperitoneal 
injection of 200 mg/kg Bromodeoxyuridine (BrdU), prepared in a 15 mg/mL solution of 
warm, sterile Tris-buffered saline at pH 7.4. The BrdU solution was injected exactly eight 
days after surgically induced cortical injury. BrdU survival time ranged from 92 to 138 
days and is shown in Table 2. 
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Pre-perfusion Testing and Immediate Early Gene Activation 
Three hours prior to the onset of perfusion-fixation of the brain, monkeys were 
tested on the fine motor task for one hour. For this last testing session 100% of the trials 
were given to the impaired hand to maximize activation of neurons participating in 
function of the impaired hand since we hypothesized that testing only the impaired hand 
would activate the neurons supporting whatever recovery of function might have 
occurred. After this testing the monkey was returned to the home cage for 2 hours to 
allow for expression of c-Fos protein resulting from activation before perfusion-fixation 
of the brain. 
c-Fos and Synaptophysin Immunohistochemistry 
Quarter series of 30 μm sections (i.e. sections spaced 1200 μm apart) through the 
premotor cortices were removed from storage and thawed for c-Fos and synaptophysin 
immunohistochemistry. All the sections for each experiment were batch-processed in the 
same reagents at the same time, according to the following steps.  First, sections were 
rinsed in 0.05M Tris-buffered saline (TBS) to remove the glycerol. To quench 
endogenous peroxidases, sections were incubated for 30 minutes in TBS containing 1% 
sodium borohydride (c-Fos) or 3% H2O2 (synaptophysin) followed by washes in TBS. 
Sections were then incubated for 1 hour in a blocking solution of 10% Normal Goat 
Serum (NGS) and 0.4% Triton-X in TBS. The sections were then incubated for 48 hours 
at 4ºC with gentle agitation in monoclonal primary antibodies to c-Fos (anti-c-Fos IgG in 
rabbit, 1:10000; Calbiochem, Billerica, MA) and synaptophysin (anti-synaptophysin IgG 
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in mouse, 1:100000, Millipore, Billerica, MA) in a solution containing 2% NGS and 
0.1% Triton-X in TBS. Several sections of brain tissue were left out of the primary 
antibody to control for immunoreactivity. Following incubation with the primary 
antibody, the sections were washed in a solution containing 2% NGS and 0.1% Triton-X 
in TBS, followed by a 2-hour incubation in biotinylated secondary antibody (1:600; 
Vector Laboratories, Burlingame, CA) in TBS containing 2% NGS, and 0.4% Triton-X. 
The sections were then washed in TBS and subsequently incubated with an avidin 
biotinylated horseradish peroxidase complex (ABC Elite; Vector Laboratories, 
Burlingame, CA) for 1 hour. The sections were then washed in TBS followed by washes 
in 0.175M sodium acetate solution. For visualization, all sections were incubated together 
in sodium acetate containing 0.55 mM 3-3’-diaminobenzidine (DAB; Sigma-Aldrich, St. 
Louis, MO), nickel sulfate (0.095M), and 0.0025% H2O2. The sections were then washed 
n sodium acetate to stop the DAB reaction, followed by rinses in TBS. Finally, sections 
were mounted on gelatin-coated slides, air dried, and cover-slipped using Permount 
mounting medium (Thermo Fisher Scientific, Waltham, MA).  
BrdU Immunohistochemistry 
A half series of 30 μm sections (i.e. sections spaced 600 μm apart) containing 
lateral ventricle and hippocampus was removed from storage and thawed for 
immunohistochemistry. All sections were batch-processed in the same reagents for BrdU 
according to the following steps. First, sections were washed in 0.05M Potassium 
Phosphate-Buffered Saline (KPBS) to remove the glycerol. For antigen retrieval, sections 
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were incubated at 65ºC for 2 hours in 50% formamide in 2x saline sodium citrate (SSC), 
followed by washes in SSC. Sections were then incubated in 2N Hydrochloric Acid 
(HCl) for 30 minutes at 37ºC to create single-stranded DNA and expose the incorporated 
BrdU, then rinsed in a 0.1M Borate buffer (pH 8.5) for 10 minutes to neutralize the HCl. 
Sections were washed in KPBS and placed in SuperBlock (Thermo Fisher Scientific, 
Waltham, MA) for 30 minutes. Then, sections were incubated in the monoclonal primary 
antibody to BrdU (anti-BrdU IgG in rat; 1:500; Accurate Chemical & Scientific 
Corporation, Westbury, NY) in KPBS containing 0.4% Triton-X for 1 hour at room 
temperature, followed by 48 hours at 4ºC with gentle agitation. Several sections of brain 
tissue were left out of the primary antibody to control for immunoreactivity. Next, the 
sections were washed in KPBS, then incubated in biotinylated secondary antibody 
(1:600, goat-anti-rat; Vector Laboratories, Burlingame, CA) in a solution containing 
0.4% Triton-X in KPBS buffer for 1 hour at room temperature. The sections were washed 
in KPBS, incubated in an avidin-biotin peroxidase complex (ABC Elite; Vector 
Laboratories, Burlingame, CA) for 1 hour, then rinsed in KPBS. For visualization, all 
sections were incubated simultaneously for 8 minutes in KPBS containing DAB and 
0.0025% H2O2, followed by washes in KPBS. Free floating sections were mounted on 
gelatin-coated slides and air dried. Sections were then lightly counterstained with a 
0.05% thionin solution (pH 5.5), dehydrated through a graded series of alcohols, cleared 
with xylene, and coverslipped using Permount mounting medium (Thermo Fisher 
Scientific, Waltham, MA).  
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Regions of Interest for Stereology 
Unbiased stereology was used to quantify c-Fos labeled neurons, synaptophysin 
puncta, and BrdU labeled cells visualized on a Nikon Eclipse E600 series light 
microscope (Nikon; Melville, NY, USA) equipped with a motorized stage integrated with 
StereoInvestigator 9 software (MicroBrightField Bioscience; Williston, VT).  All regions 
of interest (ROI) were outlined using the 4X objective.  
For c-Fos and synaptophysin stereology, ROIs were created for the ipsilesional 
and contralesional dorsal premotor cortex (iPMd and cPMd) and the ipsilesional and 
contralesional ventral premotor cortex (iPMv and cPMv) on 6-10 equally spaced sections. 
ROIs spanning all cortical layers were outlined as shown in Figure 17 using the Paxinos 
rhesus monkey stereotaxic atlas as a guide (Paxinos et al., 2008). Specifically, PMd 
(areas 6DR and 6DC) was sampled from its first appearance near the rostral aspect of the 
superior limb of the arcuate sulcus, past the region of the arcuate sulcus to its 
disappearance at the rostral aspect of M1. PMv (areas 6VR and 6VC) was sampled from 
its first appearance near the inferior arcuate sulcus to its disappearance at the rostral 
aspect of M1.  
For BrdU analysis, ROIs were created for the ipsilesional and contralesional 
subventricular zone (iSVZ and cSVZ) on 7-8 equally spaced sections and the ipsilesional 
and contralesional subgranular zone of the dentate gyrus (iSGZ and cSGZ) on 16-25 
equally spaced section. Specifically, the SVZ was restricted to the frontal and anterior 
parietal lobes and included an area extending 2500 µm above the most inferior portion of 
the ventricle and 250 µm out from the ependymal layer bordering the lumen of the 
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ventricle. Representative sections and ROI contours for SVZ are shown in Figure 18 (A-
H). The SGZ, a subdivision of the dentate gyrus, was sampled through its rostral-caudal 
extent as shown in representative sections and contours in Figure 18 (I-P) and as 
previously described (Ngwenya et al., 2015). 
Stereological Parameters and Inclusion Criteria 
The Optical Fractionator Workflow in StereoInvestigator 9 software 
(MicroBrightField Bioscience; Williston, VT) was used to optimize and quantify all 3 
markers and stereological parameters are summarized in Table 3. To avoid counting 
errors due to sectioning artifacts, counting was performed with a minimum of 2 µm guard 
zones above and below the optical dissector counting brick to ensure that lost caps could 
be identified and counted or excluded according to the respective face (West, Slomianka 
and Gundersen, 1991). c-Fos labeled cells were also identified based on nuclear staining 
intensity but were further classified as heavily or lightly labeled. Nuclei filled with dark 
black reaction product were classified as heavily labeled and stained nuclei filled only 
partially were classified as lightly labeled. Inclusion criteria for synaptophysin puncta 
included a circular, dark profile located within the counting frame. BrdU-immunostained 
(BrdU+) cells are relatively rare, therefore accurate estimates of numbers required use of 
an exhaustive sampling scheme. BrdU labeled cells were counted if more than one-third 
of the nucleus was darkly labeled and if the labeled nucleus did not belong to a cell 
within a blood vessel. This counting method omitted very lightly stained cells and 
endothelial cells from the count. 
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Stereology Object Estimates 
The estimated total number of c-Fos labeled cells, synaptophysin labeled puncta, 
and BrdU labeled cells in each ROI were calculated using the optical fractionator 
formula: N=Q−×1/ssf×1/asf×t/h (West, Slomianka and Gundersen, 1991; Sutula and 
West, 2002), where N is the estimate of the total number of objects, Q− is the number of 
objects counted, ssf is the section sampling fraction, asf is the area sampling fraction, and 
t/h is the actual section thickness (t) divided by the height (h) of the dissector. Parameters 
were optimized such that Coefficients of Error (Gundersen, m=1) were less than 0.10 
(Gundersen et al., 1999). Estimated activated cell (c-Fos) numbers were used for 
analysis. Estimated BrdU cell density and synaptophysin puncta density measures were 
used for analysis (estimated cell number divided by Cavalieri estimated volume in mm3).  
Statistical Analysis 
Statistical analyses were performed using R (RStudio Inc, Version 0.99.896, R 
foundation for Statistical Computing, Vienna, Austria). Two-way analysis of variance 
(ANOVA) with repeated measures was used to identify significant variables and 
interactions with treatment group (hUTC treated or vehicle) as a between subject variable 
and hemisphere (ipsilesional and contralesional) as a within subject variable. Separate 
two-way ANOVAs with repeated measures (six total) were used to analyze c-Fos (PMv 
and PMd), synaptophysin (PMv and PMd), and BrdU (SVZ and SGZ). Significance level 
was set to p ≤ 0.05. Tukey Post-hoc tests were used to identify significant variables. 
Regression analyses were performed with subjects from both groups together. For 
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correlations relating to the mean grasp (an ordinal scale, 0-8), Spearman’s Correlation 
was used, and all other correlations were assessed using a Pearson’s Correlation with an 
alpha level set at p ≤ 0.05 
Results 
Effect of hUTC on c-Fos Activation to Localize Foci of Plasticity  
To localize regions that were activated during recovered hand performance, 3 
hours prior to perfusion monkeys were behaviorally tested using only the impaired hand 
to increase expression of the immediate early gene c-Fos. Subsequently, c-Fos 
immunohistochemistry, was used to identify activated cells and they were quantified with 
unbiased stereology. Estimated numbers of lightly and darkly labeled c-Fos labeled cells 
were identified and counted as shown in Figure 19. Overall, there were no significant 
differences observed between the numbers of lightly and heavily labeled cells, therefore 
these were combined (lightly + heavily labeled) into a total estimate of c-Fos labeled cells 
for each region of interest in each subject. Total estimated numbers of c-Fos labeled cells 
were used for comparisons between hUTC treated and vehicle treated monkeys. Two-
way ANOVAs were performed on c-Fos data from PMv and PMd with treatment (hUTC 
vs. vehicle) as a between subject variable and hemisphere (ipsilesional vs. contralesional) 
as a within subject variable. Results showed that in PMv, the total number of c-Fos 
labeled cells was significantly increased in hUTC monkeys compared with the vehicle 
monkeys in both hemispheres [F(1,6) = 12.82, p = 0.0116] but did not differ by hemisphere 
[F(1,6) = 0.162, p = 0.701] . The number of c-Fos labeled cells did not differ in PMd 
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between groups [F(1,6) = 0.028, p = 0.873] or by hemisphere [F(1,6) = 4.742, p = 0.072]. As 
shown in Figure 20, these results demonstrate an upregulation of c-Fos activation in 
ventral premotor cortex of both the ipsilesional and contralesional hemispheres 
suggesting that this region may be an important substrate for hUTC stimulated 
neuroplasticity following damage to primary motor cortex.  
Effect of hUTC on Synaptic Density 
To investigate the changes in synaptic density in premotor cortices, synaptophysin 
immunohistochemistry and unbiased stereology was performed to quantify synaptophysin 
labeled puncta as shown in Figure 21 and density measures were calculated using 
Cavalieri estimated volume in mm3.  Two-way ANOVAs were performed on 
synaptophysin data from PMv and PMd with treatment (hUTC vs. vehicle) as a between 
subject variable and hemisphere (ipsilesional vs. contralesional) as a within subject 
variable. Results showed that the number of synaptophysin puncta did not differ 
significantly in PMv between groups [F(1,6) = 0.784, p = 0.41] or hemisphere [F(1,6) = 
1.118, p = 0.331] (Figure 22). Similarly, synaptophysin puncta did not differ significantly 
in PMd between groups [F(1,6) = 0.436, p = 0.533], or hemisphere [F(1,6) = 2.709, p = 
0.151] (Figure 22). Overall, these results suggest that synaptic density in the ventral and 
dorsal premotor cortices did not differ with hUTC treatment. 
Effect of hUTC on Neurogenesis 
To determine if hUTC affected general neuroplasticity, we quantified 
neurogenesis in response to cortical injury. For this, monkeys received an injection of the 
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thymidine analog bromodeoxyuridine (BrdU) 8 days after injury. Following, unbiased 
stereology was used to quantify estimated numbers of BrdU labeled cells in cortical 
sections containing the subventricular zone (SVZ) and subgranular zone (SGZ) in both 
the ipsilesional and contralesional hemispheres as shown in Figure 23. Due to a large 
variance in the volumes of ROI used for BrdU stereology, estimated BrdU cell density 
measures were used for analysis (estimated cell number divided by Cavalieri estimated 
volume in mm3).  Two-way ANOVAs were performed on BrdU data from SVZ and SGZ 
with treatment (hUTC vs. vehicle) as a between subject variable and hemisphere 
(ipsilesional vs. contralesional) as a within subject variable. The density of BrdU labeled 
cells did not differ significantly in the SVZ between groups [F(1,5) = 0.803, p = 0.411] or 
hemispheres [F(1,5) = 0.450, p = 0.532] (Figure 24). However, the density of BrdU labeled 
cells approached a significant difference between groups in SGZ [F(1,5) = 4.259, p = 
0.094] and differed significantly between hemispheres [F(1,5) = 18.63, p = 0.0076] Figure 
24, revealing a greater density of BrdU labeled cells in cSGZ compared to iSGZ. Overall, 
these results suggest that neurogenesis did not differ in ipsilesional or contralesional SVZ 
with hUTC treatment. However, we observed a potential increase of BrdU labeled 
neurogenesis in the SGZ with hUTC treatment and an increase in neurogenesis in the 
cSGZ compared to the iSGZ. Overall, this suggests higher general neuroplasticity in 
ipsilesional and contralesional hemispheres after primary motor cortex damage. 
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Relationship of Markers of Plasticity to Functional Recovery 
As previously reported, hUTC treated monkeys returned to pre-operative levels of 
performance on fine motor tasks in significantly fewer days compared to monkeys that 
received vehicle (Moore et al., 2013). Interestingly, reduced recovery time (in days) was 
predicted by increased numbers of c-Fos labeled cells in iPMv [Rp = -0.716, p = 0.046] 
and cPMv [Rp = -0.783, p = 0.022] (Figure 25). Thus, subjects with a higher number of c-
Fos activated neurons in PMv at the end of testing had shown more rapid recovery of 
function. This relationship between fewer days to recovery and increased c-Fos activation 
was not observed in either the iPMd or cPMd (data not shown). Further, there was no 
relationship between recovery time and density of synaptophysin puncta or BrdU labeled 
cells in any region of interest (data not shown). These results suggest that increased c-Fos 
activation in iPMv and cPMv may be a significant predictor of improved recovery time 
following cortical injury.  
Another measure of recovery is the recovery of accurate pinch between finger and 
thumb. Mean grasp was rated over the post-operative period on a scale of 0 (no 
movement) to 8 (full recovery). As previously reported, recovery toward improved grasp 
topography was significantly enhanced in hUTC treated monkeys compared to vehicle 
controls (Moore et al., 2013). Interestingly, enhanced grasp assessment (closer to full 
recovery) was predicted by increased numbers of c-Fos activated neurons in iPMv [Rs = 
0.970, p = 0.00006] and cPMv [Rs = 0.946, p = 0.0004] (Figure 26). Thus, subjects with a 
higher number of c-Fos activated neurons in PMv at the end of testing had enhanced 
grasp topography over the recovery period. This relationship between enhanced grasp 
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topography and more c-Fos activation was not observed in either the iPMd or cPMd (data 
not shown). Further, there was no relationship between mean grasp and density of 
synaptophysin puncta or BrdU labeled cells in any region of interest (data not shown). 
This suggests increased numbers of c-Fos activated cells may be a significant predictor of 
grasp topography recovery. 
Discussion 
Summary of Results 
The overall findings of this study are that following injury to the primary motor 
cortex: (1) Cellular activation is increased bilaterally in the ventral premotor cortex in 
monkeys treated with hUTC compared to vehicle treated controls, but is not altered in 
dorsal premotor cortex. (2) The number of activated cells in both the ipsi- and contra-
lesional ventral premotor cortices is positively associated with improved recovery time 
and grasp topography, pointing to ventral premotor cortex as a potential locus of 
reorganization. (3) In contrast, the synaptic density, in both ventral and dorsal premotor 
cortices, does not differ between hUTC treated and vehicle controls. (4) Neurogenesis in 
the subventricular zone does not differ between hUTC treated and vehicle controls, but 
hippocampal neurogenesis in the subgranular zone bilaterally approached a significant 
increase with hUTC treatment. Overall, these results suggest that the effect of hUTC cell 
therapy on improved motor performance may be mediated in part by activating the 
ventral premotor cortex but that there may also be enhancement of general neuroplasticity 
in the injured brain as evidenced by hippocampal neurogenesis. 
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Previous Studies of Cell Based Therapy 
Spontaneous recovery of motor function following stroke in the motor cortex has 
been shown to involve reorganization through activation of cell repair, axonal growth, 
dendritic remodeling, and synaptic plasticity leading to the formation of functional 
connections (Wieloch and Nikolich, 2006; Minger et al., 2007). This reorganization 
occurs most notably in the perilesional area, though changes also occur throughout the 
brain after stroke (Ward and Cohen, 2004; Cotrina et al., 2016). Recent studies in rodents 
have demonstrated enhanced motor recovery using human umbilical tissue derived cell 
(hUTC) infusion following stroke-induced motor impairment (Zhang et al., 2011, 2012, 
2013; Jiang et al., 2012; Yang et al., 2012; Shehadah et al., 2013; Shams Ara et al., 
2015). The enhanced motor recovery following hUTC treatment in rodents was 
accompanied by increased vascular and synaptic density in the perilesional area (Zhang et 
al., 2011, 2012, 2013; Arbab et al., 2012; Jiang et al., 2012; Yang et al., 2012; Shehadah 
et al., 2013) and an increase in neurogenesis in the subventricular zone (Yang et al., 
2012; Zhang et al., 2012, 2013). Recently, we assessed the same hUTC therapy in 
monkeys with damage limited to the hand representation of motor cortex and showed 
enhancement of functional recovery (Moore et al., 2013). In the present study, we 
analyzed brain tissue sections from monkeys in that study and quantified neuronal 
reorganization in perilesional motor areas and general neuroplasticity through 
neurogenesis. 
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Motor and Premotor Cortices 
While the primary motor cortex is involved in the control and execution of motor 
movements, precision grasping of an object during goal directed hand movements is 
further mediated by the PMd and PMv. Specifically, the PMd is involved in the direction 
and amplitude of reaching toward an object to be grasped. In contrast, the PMv mediates 
the actual grasping component of goal directed hand movements including the 
appropriate shaping of the hand posture to grasp objects (Rizzolatti et al., 1988, 1990; 
Rizzolatti, Fadiga, Matelli, et al., 1996; Murata et al., 1997). Interestingly, PMv has been 
identified as a potential locus of reorganization to enable functional recovery following 
an insult to the primary motor cortex in both human patients and animal models. 
Specifically, through stimulation, studies in non-human primates observed an enlarged 
hand representation in ipsilesional PMv (iPMv) related to the size of M1 injury and that 
only stimulation in iPMv, but not M1, evoked a hand response following recovery (Nudo 
and Milliken, 1996; Frost et al., 2003; Dancause et al., 2006). Further, in imaging of 
human patients recovering from stroke affecting hand movements, studies observed 
bilateral recruitment of premotor cortices while performing fine motor functions with the 
impaired hand, which was not seen in performance with their unaffected hand or in 
healthy controls (Cao et al., 1998; Calautti and Baron, 2003). Therefore, functional 
recovery may depend on reorganization and plasticity of brain regions adjacent to the 
injury site, rather than a change in neuronal survival or regeneration of the lesion site. 
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Regions Supporting the Recovery of Function 
To identify the role of premotor cortices involved in hUTC enhancement of 
recovery, we used motor testing and c-Fos immunohistochemistry. Activation of the c-
Fos immediate early gene occurs because of influx through voltage gated calcium 
channels activated during neuronal depolarization. Activation of the c-Fos gene leads to 
production of the c-Fos nuclear protein, a transcription factor that initiates a cascade of 
other gene activations. The c-Fos protein production peaks at two to four hours after c-
Fos gene activation (Morgan and Curran, 1989, 1991; Harris, 1998; Rosene et al., 2004). 
In the current study, subjects were perfused 3 hours after the start of motor testing with 
the impaired hand for one hour to activate the c-Fos protein in neurons functioning during 
testing. Subsequently, immunohistochemistry and stereology were used to quantify c-Fos 
expression as a marker for the location and number of neurons activated during the final 
testing session with the impaired hand. 
We observed widespread c-Fos activation in dorsal and ventral premotor cortices 
bilaterally in all subjects but subjects that had hUTC treatment and demonstrated 
enhanced recovery showed increased activation in the ventral premotor cortex bilaterally. 
In contrast, there was no effect of hUTC treatment on dorsal premotor cortex activation, 
compared to vehicle controls. Furthermore, results demonstrated that the number of 
activated neurons in bilateral PMv predicted a more successful grasp topography and a 
shorter time to recover pre-operative levels of performance on fine motor tasks. This 
finding is consistent with studies, which have demonstrated reorganization in PMv after 
M1 lesions restricted to the digit representation (Frost et al, 2003). It is also consistent 
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with the theory that the PMv is part of the parietofrontal circuit that mediates fine motor 
function of the hand and digits (G Rizzolatti and Luppino, 2001). We conclude that 
hUTC treatment may have enhanced and facilitated the reorganization of the ventral 
premotor cortex of the hUTC treated animals and that this may underlie recovery of 
function in response to M1 injury. 
Synaptic Density and Neuroplasticity 
Distinct changes in the premotor cortices with treatment observed through 
neuronal activation further raised the question of whether there was also change in 
innervation of these neurons. To explore synaptic remodeling in premotor cortices, we 
quantified synaptic density by calculating density of synaptophysin puncta. 
Synaptophysin is a glycoprotein found in pre-synaptic vesicles (Wiedenmann et al., 
1986) that is commonly used to quantify synaptic density (Zhang et al., 2011, 2012, 
2013; Arbab et al., 2012; Jiang et al., 2012; Yang et al., 2012; Shehadah et al., 2013). In 
the current study, there was no observable difference in synaptic density when comparing 
hUTC treated subjects to controls in bilateral ventral or dorsal premotor cortices. Studies 
assessing hUTC treatment have consistently found increased perilesional synaptic density 
with treatment (Zhang et al., 2011, 2012, 2013; Arbab et al., 2012; Jiang et al., 2012; 
Yang et al., 2012; Shehadah et al., 2013). Further, studies in vitro revealed that hUTC 
treatment enhanced synaptic formation and function through paracrine factors (Koh et al., 
2015). Our finding that synaptic density remains stable does not preclude the possibility 
that synaptic efficacy has been altered by pre- or post-synaptic mechanisms such that the 
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functional connections that compensated for the damaged cortex were strengthened or 
unmasked rather than completely rebuilt (Pons et al., 1988; Jacobs and Donoghue, 1991; 
Liguz-Lecznar et al., 2014).  
Adult Neurogenesis 
In addition to remodeling of adjacent motor areas, we investigated the effect of 
hUTC treatment on neurogenesis. We did not hypothesize the formation and migration of 
new neurons into the lesion or perilesional sites but rather we measured neurogenesis to 
assess overall levels of plasticity in the injured brain. We speculate that neurotrophic 
factors released by the hUTC into the blood may alter neurogenesis. Previous studies 
investigating cell based therapy for stroke in rats have shown that administration of 
human mesenchymal stem cells increased neurotrophic factor expression, which in turn 
augmented host brain plasticity (Li et al., 2002; Zhang et al., 2011). Here, we injected 
bromodeoxyuridine (BrdU) 8 days after cortical injury to label proliferating cells in the 
hippocampal SGZ and in the SVZ of the lateral ventricles during the S-phase of the cell 
cycle (Taupin, 2007). Studies have reported that adult neurogenesis is enhanced after 
cortical injury in the rodent brain in SGZ and SVZ (Anderson, 2001; Arvidsson et al., 
2002; Jin et al., 2006; Minger et al., 2007; Zhang et al., 2011, 2013; Lindvall and Kokaia, 
2015).  
Previous studies assessing hUTC (Yang et al., 2012; Zhang et al., 2012, 2013) 
and other cell based therapies (Bachstetter et al., 2008; Yoo et al., 2013) have reported an 
increase in neurogenesis in the iSVZ. In the current study, we found no significant 
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difference in neurogenesis in the iSVZ and cSVZ between the treatment and vehicle 
groups. However, neurogenesis in the SGZ bilaterally approached a significant increase 
with hUTC treatment. Possible explanations for this include the relatively small size of 
our cortical lesion in the hand representation compared to the widespread cortical and 
subcortical damage produced by middle cerebral artery occlusion (MCAO) in the rodent. 
Additionally, the rodent studies performed BrdU injections daily throughout the recovery 
period, while we performed one injection eight days after injury. Thus our data on 
neurogenesis represent a snapshot of the capacity for plasticity in the injured brain on the 
eighth day of recovery.  Finally, it is worth noting that our subjects survived for 3 months 
following BrdU injection and it’s possible that newly generated cells may have continued 
to divide, diluting the label. 
Therapeutic Possibilities of Cell Based Therapy 
Cell based therapies are a promising therapeutic option following stroke and our 
results add to the existing literature on the possible mechanisms by which the exogenous 
cell treatments might enhance recovery. Previous studies have corroborated that hUTC 
infusion after stroke results in enhanced motor recovery (Zhang et al., 2011, 2012, 2013; 
Jiang et al., 2012; Yang et al., 2012; Moore et al., 2013; Shehadah et al., 2013; Shams 
Ara et al., 2015), increased perilesional vascular and synaptic density (Zhang et al., 2011, 
2012, 2013; Arbab et al., 2012; Jiang et al., 2012; Yang et al., 2012; Shehadah et al., 
2013), increased neurogenesis (Yang et al., 2012; Zhang et al., 2012, 2013), but does not 
alter lesion volume (Zhang et al., 2011, 2012, 2013; Yang et al., 2012; Moore et al., 
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2013; Shehadah et al., 2013; Shams Ara et al., 2015) or perilesional apoptosis (Zhang et 
al., 2011, 2012), Overall, our results support that cell based therapies function through 
enhancement of endogenous restorative mechanisms, some of which include 
reorganization of intact adjacent motor areas and enhanced neuroplasticity. 
Conclusions 
In this study, we provide for the first-time evidence that cell based therapy 
containing hUTC enhanced motor recovery after cortical injury by stimulating bilateral 
reorganization of ventral premotor cortex. These observations identify ventral premotor 
cortex as a target for therapeutic interventions. However, further studies are needed to 
determine whether cortical neurons activated were primarily excitatory or inhibitory as 
well as to assess reorganization in downstream pathways of the basal ganglia, brainstem, 
and spinal cord, which may also contribute to supporting recovery of function.   
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 Region of 
Interest 
Stereology 
Objective 
Section 
Interval 
Counting 
Frame 
(µm) 
Grid 
Spacing 
(µm) 
Dissector 
Height 
(µm) 
Guard 
Zone 
Above 
(µm) 
c-Fos 
PMd 
40x 1/40 250 x 250 
1200 x 
1200 15 2 
PMv 950 x 950 
Synaptophysin 
PMd 100x oil 
immersion 
1/80 5 x 5 
1000 x 
1000 
5 1 
PMv 
BrdU 
SVZ 60x oil 
immersion 
1/20 150 x 90 150 x 90 15 1 
SGZ 
Table 2: Stereological parameters for optical fractionator   
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Figure 16: Regions of interest for stereological estimation of c-Fos and 
synaptophysin 
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The entire extent of dorsal and ventral premotor cortices was evaluated. Schematic 
representations of rhesus monkey coronal sections adapted from Paxinos (2008) are 
shown from rostral to caudal (A-H) showing the boundaries of the dorsal and ventral 
premotor area regions of interest that were sampled for stereological analysis. The 
sagittal view (I) shows the rostral and caudal boundaries from which the sections sampled 
were taken.   
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Figure 17: Regions of interest for stereological estimation of BrdU 
The subventricular zone and granule cell layer of the dentate gyrus were evaluated. (A-H) 
The boundaries of the subventricular zone ROI that was sampled for stereological 
analysis are shown as representative micrographs (A, C, E, G) and schematic illustrations 
(B, D, F, H) of coronal sections. (I-P) The boundaries of the dentate gyrus, including the 
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granule cell layer that was sampled for stereological analysis, are shown as representative 
micrographs (I, K, M, O) and schematic illustrations (J, L, N, P) of coronal sections.  
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Figure 18: Differential activation of c-Fos positive cells 
Representative micrographs of c-Fos activation in ipsilesional ventral premotor cortex in 
vehicle (A) and hUTC treated (B) sections are shown. At a higher magnification, 
individual c-Fos positive cells of differential activation levels are discernable in vehicle 
(C) and hUTC treated (D) sections. An example of a heavily labeled cell is shown with 
the black arrow and a lightly labeled cell is shown at the unfilled arrow in D. Scale bar: 
100 µm   
C D
PLACEBO hUTC TREATED
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Figure 19: c-Fos positive cells in Ventral Premotor Cortex increase following hUTC 
treatment 
Numbers of c-Fos positive cells in the dorsal and ventral premotor cortex were estimated 
using unbiased stereology. There were significantly more c-Fos positive cells in the iPMv 
and cPMv in the hUTC treated monkeys compared to vehicles [F(1,6) = 12.82, p = 
0.0116].   
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Figure 20: Uniform expression of synaptophysin puncta in the premotor cortices 
Representative micrographs of synaptophysin puncta in ipsilesional ventral premotor 
cortex in vehicle (A) and hUTC treated (B) sections are shown. An example of a 
synaptophysin puncta is shown at the white arrow in both A and B. Scale bar: 10 µm   
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Figure 21: Synaptophysin puncta in bilateral premotor cortices remain unchanged 
following hUTC treatment 
Numbers of synaptophysin puncta in the dorsal and ventral premotor cortex were 
estimated using unbiased stereology and are represented here (in millions). There was no 
significant difference between groups in any region.   
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Figure 22: BrdU positive cells in the subventricular zone and subgranular zone 
A representative micrograph of the iSVZ is shown (A). At a higher magnification (B), an 
example of a BrdU positive cell is shown at the black arrow and an endothelial cell 
(excluded from the current study) is shown at the red arrow. A representative micrograph 
of the ipsilesional dentate gyrus is shown (C). At a higher magnification (D), examples of 
two BrdU positive cells in the iSGZ are shown at the black arrows. 
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Figure 23: BrdU positive cells in Subgranular Zone increase following hUTC 
treatment 
The densities of BrdU positive cells in the subventricular zone and subgranular zone were 
estimated using unbiased stereology. There was no significant difference between groups 
in any region. However, there are significantly more BrdU positive cells in cSGZ 
compared to iSGZ. [F(1,5) = 18.63, p = 0.0076].    
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Figure 24: Increased c-Fos activation is correlated with improved recovery time 
Recovery time is defined as days following cortical injury to return to asymptotic 
performance in a 120-day period. There is a significant negative correlation between 
recovery time and the level of c-Fos activation in the iPMv (A) and cPMv (B).   
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Figure 25: Increased c-Fos activation is correlated with improved grasp topography 
The mean grasp assessment score is reported on a scale from 0 (no movement) to 8 (pre-
operative finger/thumb opposition). There is a significant positive correlation between the 
mean grasp assessment score and the level of c-Fos activation in the iPMv (A) and cPMv 
(B).     
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CHAPTER SIX: CONCLUSIONS AND FUTURE DIRECTIONS 
Summary of Results 
This dissertation follows up on the striking finding of significantly enhanced 
motor recovery after primary motor cortex injury in rhesus monkeys and an overall 
different composition of the lesion following hUTC treatment. In this dissertation, we 
tested the overall hypothesis that hUTC infusion reduces cytotoxic responses and 
enhances neurorestorative processes following cortical injury. To accomplish this, brain 
sections were processed using histological techniques to quantify oxidative damage, 
hemosiderin accumulation, microglial activation, Betz cell numbers, synaptic density, 
and astrocytic complexity in the perilesional area. Beyond the lesion area, microglial 
activation in white matter pathways, cell activation in premotor cortices, and 
neurogenesis in the hippocampus and lining of the lateral ventricle were analyzed. 
Finally, blood samples were assessed for BDNF levels throughout the recovery period 
and CSF samples were assessed for BDNF at the completion of the study. 
 In Chapter 3, we tested the specific hypothesis that hUTC infusion modulated the 
glial response and reduced cytotoxic responses to cortical injury, by interrupting the cycle 
of ROS production and oxidative stress. Overall, our results revealed less oxidative 
damage in the sublesional white matter and less perilesional iron accumulation with 
hUTC treatment. Interestingly, lesion volume as well as perilesional oxidative damage 
increased with increased perilesional iron accumulation, suggesting an interaction 
between iron and oxidative damage that relates to the final lesion volume. Next, while the 
density of microglia in the perilesional area did not differ with hUTC treatment, the 
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extent and area of microglial activation was significantly higher in the downstream white 
matter areas in hUTC treated monkeys compared to vehicle controls. The increase in 
downstream microglial activation may suggest a reparative role of microglia. Overall, 
these results suggest that hUTC infusion may reduce secondary injury by recruiting 
microglia and interrupting the cycle of ROS production, iron accumulation, and oxidative 
stress. 
In Chapter 4, we tested the hypothesis that hUTC functions through enhancing 
neurorestorative processes following injury thereby interrupting cell death and enabling 
synaptic plasticity through BDNF secretion. Overall, results revealed no significant group 
differences in presumably corticospinal projecting Betz cells, but that Betz cells were 
positively associated with more rapid recovery. Additionally, there was higher synaptic 
density in the IBZ with hUTC treatment. While there was no observable difference in 
overall astrogliosis, the lesion area astrocytes have significantly more complex branching 
with hUTC treatment. Next, peripheral BDNF percent change from baseline values 
exhibited a trend toward a significant increase with hUTC treatment at 1 week, however 
there was no difference with hUTC treatment after the first week. Finally, there was no 
difference in BDNF level in the CSF 16 weeks after injury with hUTC treatment. Overall, 
compared to vehicle, hUTC treatment resulted in a greater synaptic density in the lesion 
area, greater lesion area astrocyte complexity, and higher peripheral BDNF levels within 
a week of injury, but overall no difference in ipsilesional Betz cell numbers with hUTC 
treatment. 
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 In Chapter 5, we tested the hypothesis that the recovery of function and changes 
in markers for damage, repair, and remodeling observed with hUTC treatment may be 
associated with reorganization in undamaged motor areas and enhancement of general 
neuroplasticity as reflected by adult neurogenesis. Results revealed cell activation is 
greater bilaterally in the ventral premotor cortex in monkeys treated with hUTC 
compared to vehicle treated controls, but was not altered in dorsal premotor cortex. 
Interestingly, the number of activated cells in both the ipsi- and contra-lesional ventral 
premotor cortices was positively associated with improved recovery time and grasp 
topography, pointing to ventral premotor cortex as a potential locus of reorganization. In 
contrast, the synaptic density, in both ventral and dorsal premotor cortices, did not differ 
between hUTC treated and vehicle controls, suggesting that the connections taking over 
for lost function were not completely rebuilt. Next, neurogenesis in the subventricular 
zone did not differ between hUTC treated and vehicle controls, but there was a trend 
toward a greater degree of hippocampal neurogenesis in the subgranular zone bilaterally 
with hUTC treatment. Overall, these results suggest that the effect of hUTC cell therapy 
on improved motor performance may be mediated in part by activating the ventral 
premotor cortex but that there may also be enhancement of general neuroplasticity in the 
injured brain as evidenced by hippocampal neurogenesis. 
Therapeutic Potential of UTC 
Overall, the results of the current study suggest that hUTC treatment modulated 
immune responses, thus limiting perilesional damage and cell death, enabling 
neuroplasticity and reorganization, and enhancing neurotrophic factor secretion. These 
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results are consistent with the pre-clinical studies using hUTC treatment for stroke 
(Zhang et al., 2011, 2012, 2013; Arbab et al., 2012; Jiang et al., 2012; Yang et al., 2012; 
Shehadah et al., 2013) and retinal degeneration (Lund et al., 2007; Cao et al., 2016). 
Specifically, enhanced recovery is observed with hUTC in ischemic brain injury in young 
animal models (Zhang et al., 2011, 2012; Jiang et al., 2012; Moore et al., 2013; Shehadah 
et al., 2013) and aged animal models (Zhang et al., 2013). Histological results from these 
pre-clinical stroke studies reveal no change in the lesion volume (Zhang et al., 2011, 
2012, 2013; Yang et al., 2012; Moore et al., 2013; Shehadah et al., 2013; Shams Ara et 
al., 2015), a decrease in apoptotic cells (Zhang et al., 2011, 2012) an increase in vascular 
density and synaptic density in the ischemic boundary zone (Zhang et al., 2011, 2012, 
2013; Arbab et al., 2012; Jiang et al., 2012; Yang et al., 2012; Shehadah et al., 2013), 
and an increase in cell proliferation in the subventricular zone (Yang et al., 2012; Zhang 
et al., 2012, 2013) with hUTC treatment. These consistent and striking results in pre-
clinical models have led to safety and efficacy clinical trials. 
Of MSCs sourced from extraembryonic tissues or adult bone marrow assessed in 
clinical trials (Trounson et al., 2011), intravenous infusion of BM-MSC are the most 
common for ischemic stroke patients (Doeppner and Hermann, 2014) resulting in positive 
clinical outcomes, increased neural plasticity, and no adverse effects (Bang et al., 2005; 
Lee et al., 2010; Bhasin et al., 2011, 2013; Honmou et al., 2011; Taguchi et al., 2015). 
These clinical improvements have been observed both when treatment is given in the 
acute phase (Lee et al., 2010) and the chronic phase (Bhasin et al., 2013). One phase I 
clinical trial has assessed the safety of hUTC (CNTO 0007) as a treatment for ischemic 
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cerebral infarction and was completed in March 2014 (NCT01273467), but no results 
have been published. Similar treatments containing hUTC (CNTO 2476) have been 
assessed for safety in patients suffering from age-related macular degeneration 
(NCT01226628), advanced retinitis pigmentosa (NCT00458575), geographic atrophy of 
the retina (NCT02659098) with positive clinical outcomes (Bharti et al., 2014; Ho et al., 
2017). The mechanism of hUTC based therapy continues to be investigated in preclinical 
models to aid in further advances in the clinical realm of treatment and their results are 
briefly summarized here. 
Optimizing Dose, Timing, and Route of hUTC Treatment 
Following isolation and characterization of hUTC, studies assessed the optimal 
conditions by which the treatment is given. The first study reports that behavioral 
recovery is dose-dependent and that hUTC treatment is effective in behavioral 
enhancement even if given at delayed time points such as 1, 7, or 30 days (Zhang et al., 
2011). The next study found that injection through multiple routes, including 
intravenously, intra-arterially, into the striatum, into the cisterna magna, or intra-thecal at 
L4-5, promoted successful recovery (Zhang et al., 2012). A third study reports that there 
is no difference in behavioral outcome when giving a single IV injection of hUTC 24 
hours after injury compared to multiple injections at 24 hours and 3 or 7 days after injury 
(Shehadah et al., 2013). In the current study, we administered hUTC in one infusion 24 
hours after stroke through an intravenous route. Taken together, these results suggest that 
hUTC based therapy may be given a single time and through intravenous injection up to 
30 days after injury and result in enhanced recovery. These findings are important as they 
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present an administration route and timeline options that enhance recovery, while also 
being a feasible clinical protocol for human patients who may not be able to seek 
treatment within hours of stroke onset. 
hUTC Immune System Modulation Through the Spleen 
Studies assessing cell based therapies corroborate the hypothesis that MSCs 
secrete paracrine signals to modulate the inflammatory response to ischemia. In vitro, 
MSCs secrete signals that polarize microglia to an alternatively activated phenotype in a 
pro-inflammatory environment (Zanier et al., 2014; Fumagalli et al., 2015) and hUTC 
directly modulate activation of natural killer cells (Noone et al., 2013), lymphocytes 
(Zhou et al., 2011), and phagocytes (Cao et al., 2016). In the current study, we observed 
a profound activation of microglia in downstream white matter pathways. While the 
microglia in the current study express HLA-DR, a marker for MHC class II, antigen 
presenting cells have important roles in the immune responses that are both cytotoxic and 
cytoprotective. Importantly, administration of hUTC does not result in immune rejection 
or response in vitro (Mistry et al., 2005) or through intravenous injection in rodent 
models (Weiss et al., 2006) or in our non-human primate model (unpublished data). 
The spleen is an important regulator of the peripheral immune system. Following 
stroke, the spleen atrophies through apoptosis to reduce T cell proliferation and secretion 
of inflammatory cytokines (Offner et al., 2006). This immunosuppression can result in a 
reduced infarct volume, demonstrated in studies performing splenectomy before MCAO 
and observing a neuroprotective effect (Pennypacker and Offner, 2015). While 
encouraging, these are difficult to translate to the clinical setting and may not be 
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beneficial in the long term (Zierath et al., 2017). An alternative approach is to modulate 
the immune response of the spleen. When injected intravenously, hUTC enter the venous 
system (through a distal superficial vein) that returns to the heart. From the heart, the 
cells enter and congregate in the lungs, liver, and spleen (Arbab et al., 2012). Within days 
of injection, hUTC migrate to the brain targeting the perilesional area (Arbab et al., 
2012), but very few human cells are found in the ischemic cortex 60 days after stroke 
(Zhang et al., 2011, 2012, 2013; Shehadah et al., 2013). 
Exogenous cell based therapies migrating to the spleen within days of injury onset 
(Yoon et al., 2010; Arbab et al., 2012; Yang et al., 2017) may allow for peripheral 
immune modulation through the spleen. A recent study found that intravenously 
administered BM-MSC after MCAO modulated gene expression of splenocytes after 
stroke to reflect the gene expression of sham operated controls such that immune 
activation genes were downregulated (Yang et al., 2017). Further, BM-MSC upregulated 
serum expression of anti-inflammatory cytokines (IL-10) and downregulated expression 
of pro-inflammatory cytokines (IL-1β) (Yang et al., 2017). Interestingly, the enhanced 
behavioral outcomes after BM-MSC infusion were not observed in splenectomized 
animals (Yang et al., 2017) suggesting that the effect of cell based therapy on 
immunomodulation relies on the spleen. When comparing UTC to BM-MCS, UTC are 
less immunogenic and have greater immunosuppression in an in vivo model of arthritis 
(Bárcia et al., 2015), but spleen modulation by UTC following stroke has yet to be 
directly assessed. Future studies building on the current findings should assess pro- and 
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anti-inflammatory cytokine expression profiles in serum and spleen from the hUTC and 
vehicle treated monkeys to test this hypothesis. 
hUTC Reorganization through Thrombospondin Family Proteins 
Thrombospondin proteins are one potential pathway involved in the mechanism 
by which hUTC enhances neuronal reorganization. Thrombospondins (TSPs) are a family 
of extracellular matrix proteins found throughout the body. TSPs are expressed on 
astrocytes during brain development when they modulate formation and remodeling of 
synapses (Christopherson et al., 2005; Risher and Eroglu, 2012).  In vitro, astrocytes co-
cultured with retinal ganglion cells (RGC) secrete thrombospondin 1 and 2 (TSP-1 and 
TSP-2) that induce synaptogenesis, remodeling, and stability of excitatory synapses 
(Christopherson et al., 2005). Further, astrocytic TSP-1 stimulates the migration of 
oligodendrocyte precursor cells in cultures originating from myelinated areas of the 
cortex (Scott-Drew and Ffrench-Constant, 1997). After stroke, the expression of TSP-1 
and TSP-2 is significantly increased (Zhou et al., 2010) and is necessary for synaptic 
remodeling and axonal sprouting leading to the spontaneous functional recovery observed 
in pre-clinical stroke models (Liauw et al., 2008). 
hUTC secrete TSP-1, TSP-2, and TSP-4 in culture to support and promote neurite 
outgrowth of RGC (Koh et al., 2015). TSP-4 is most likely associated with neurite 
outgrowth in the peripheral nervous system (Risher and Eroglu, 2012), but TSP-1 and 
TSP-2 are expressed on endothelial, glial, neuronal, and macrophage cells in the central 
nervous system and peripheral system (Lin et al., 2003). MSC-based therapies have been 
shown to increase synaptic density in the ischemic boundary zone (Zhang et al., 2011, 
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2012, 2013; Arbab et al., 2012; Jiang et al., 2012; Yang et al., 2012; Shehadah et al., 
2013) and increase the expression of genes involved with synaptic plasticity in the 
perilesional area (Yang et al., 2017). While the secretion of TSP-1 and TSP-2 from 
hUTC has yet to be assessed in vivo, these findings suggest that hUTC may directly affect 
synaptogenesis following stroke. 
A growing body of literature suggests that astrocytes mediate the enhanced 
outcome of cell based therapy after brain injury through axonal guidance (Barker and 
Ullian, 2010; Li et al., 2014) and the release of neurotrophic factors (Béjot, Mossiat, et 
al., 2011). Astrocytes modify the plasticity of synapses, form new synapses (Barker and 
Ullian, 2010), and may stabilize newly formed synapses (Li et al., 2014). Following 
cortical injury, the upregulation of TSPs is primarily driven by astrocytes (Tran and 
Neary, 2006) and TSP-1 and TSP-2 are highly expressed in the lesion area, most 
frequently on astrocytes (Liauw et al., 2008). TSP-1 and TSP-2 are necessary and 
sufficient for astrocyte mediated excitatory synaptogenesis (Christopherson et al., 2005) 
through the receptor calcium channel subunit α2δ-1 found on neurons (Eroglu et al., 
2009), but do not affect astrocyte mediated inhibitory synaptogenesis (Hughes, Elmariah 
and Balice-Gordon, 2010).  Following stroke, there is a significant loss of dendritic 
spines, which are rescued and remodeled through cytoskeletal reorganization via TSP 
pathways (Risher and Eroglu, 2012). Taken together, the upregulation of TSP-1 and TSP-
2 by astrocytes following cortical injury enhances excitatory synaptogenesis through α2δ-
1 receptors on neurons. This astrocyte mediated synaptogenesis through TSPs may be 
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enhanced through hUTC treatment, but further studies are needed to clarify the role of 
hUTC in expression of astrocytic TSPs. 
hUTC may also indirectly act through upregulation of TSPs on microglia or 
macrophages resulting in synaptogenesis and modulation of the neuroimmune system. 
Microglia and macrophages express TSP-1 after ischemia and promote axonal outgrowth 
and phagocytosis of degraded material (Chamak, Morandi and Mallat, 1994; Möller et 
al., 1996; Lin et al., 2003). Further, TSP-1 expression enhances the release of IL-6 and 
IL-10, which are involved in synaptic plasticity as well as inflammation (Balschun, 2004; 
McAfoose and Baune, 2009), from microglia and macrophages through the CD36 
receptor (Risher and Eroglu, 2012). The CD36 receptor for TSP-1 also enables 
modulation of monocyte recruitment and phagocytosis after injury (Yamauchi et al., 
2002; Abumrad et al., 2005). Studies report that microglia near the penumbra may be 
neuroprotective and enhance plasticity through the release of neurotrophic factors 
(Lalancette-Hebert et al., 2007; Narantuya et al., 2010; Liguz-Lecznar and Kossut, 2013; 
Anttila et al., 2016). Overall, TSP-1 expressed on microglia and macrophages functions 
through the CD36 receptor to enable synaptic plasticity, monocyte recruitment, and 
phagocytosis that may allow for reorganization in the lesion area. As mentioned, co-
culture of hUTC with RGC enhance protective and necessary phagocytosis (Cao et al., 
2016), suggesting a potential for hUTC to act directly on phagocytes. The direct effect of 
hUTC to TSP-1 expressed on macrophages and microglia requires further study. 
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hUTC Reorganization through Neurotrophic Factors 
hUTC function in part through the secretion of neurotrophic and angiogenic 
factors. Notably, hUTC secrete higher levels of IL-6, FGF2, and BDNF than other stem 
cell sources (Lund et al., 2007). In post-natal development, BDNF and its action on the 
TrkB receptor regulates dendritic structure, synaptic connectivity of neurons, neuronal 
size, and cell proliferation and survival (Gorski et al., 2003; Yoshii and Constantine-
Paton, 2010; Meirelles, Simon and Regner, 2017). TrkB receptors for BDNF are found 
on progenitor cells in neurogenic niches (Tonchev, 2011), as well as in the membrane of 
growth cones (Martins et al., 2017). Studies suggest that in an ischemic environment 
astrocytes express TrkB and are thus activated through BDNF (Tonchev, 2011). 
Unilateral stroke results in higher BDNF expression in both hemispheres, which 
persists in the ipsilesional hemisphere (Béjot, Prigent-Tessier, et al., 2011). The 
expression of BDNF is localized on neurons, ependymal cells, microglia, endothelial 
cells, and astrocytes in the lesion hemisphere (Béjot, Prigent-Tessier, et al., 2011). In 
brain injury patients, studies have found an increase in acute CSF BDNF levels compared 
to controls (Chiaretti et al., 2003; Failla, Conley and Wagner, 2016). This initial increase 
in central BDNF expression may act as a compensatory mechanism to protect the brain 
after injury (Kim and Zhao, 2005; Shulga et al., 2008) to enable regeneration and 
reorganization (Felderhoff-Mueser et al., 2002; Shetty et al., 2004). Interestingly, BDNF 
has also been implicated as the mediator of hUTC and HUCPVC enhanced dendritic 
remodeling, axonal outgrowth, and synaptic formation in cultured neurons (Alder et al., 
2012; Martins et al., 2017). Studies suggest that BDNF expression after injury is required 
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for neurite sprouting in the spinal cord after motor cortex injury (Ueno et al., 2012) and 
activation of the phagocytic phenotype in peripheral macrophages (Asami et al., 2006). 
This activity may be enhanced through cell based therapy.  
Increased BDNF in CSF negatively correlates with acute serum BDNF in TBI 
(Failla, Conley and Wagner, 2016) and post-stroke patients continue to have decreased 
circulating levels of BDNF in the chronic phase compared to control patients (Santos et 
al., 2016). To counteract the reduction in circulating BDNF, pre-clinical studies have 
assessed the efficacy of administration of BDNF following cerebral ischemia and have 
found it reduces cell death and infarct size, stimulates adult neurogenesis, enhances 
synaptic plasticity, increases myelin basic protein production, and improves long term 
recovery of function (Schäbitz et al., 2000, 2004, 2007; Ploughman et al., 2009; Harris et 
al., 2016; Santos et al., 2016; Cook et al., 2017). Following attempts to downregulate the 
immune system through microglia, there is a greater reduction in circulating BDNF that 
is related to a long term reduction in synaptophysin and growth associated protein 43 
(GAP-43) (Madinier et al., 2009). Overall, this suggests that BDNF is expressed in all 
brain cells after injury and positive outcomes are observed after enhancing or polarizing 
these cells to express more BDNF. The central hypothesis around the mechanism of 
hUTC based therapy relies on increased expression of growth factors, such as BDNF, 
leading to neurorestorative processes outlined above.  
Anesthesia Effects 
Anesthetic agents used commonly during experimental stroke surgery and clinical 
endovascular thrombolysis act in a neuroprotective role (Schifilliti et al., 2010; Archer et 
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al., 2017), which is a potential confounding factor that must be considered when 
interpreting pre-clinical results. Intravenous anesthetics are the most commonly used in 
experimental and clinical settings (Schifilliti et al., 2010). In the current study, three 
anesthetics were used including intravenous sodium pentobarbital (25 mg/kg) and 
Propofol (0.3-0.4 mg/kg/min) as well as intramuscular Ketamine (10 mg/kg). Ketamine 
was used as a sedative in short procedures or before other anesthetics. Propofol was used 
as the anesthesia during MRI scans for approximately two hours. Sodium pentobarbital 
was used for anesthesia during surgery to induce cortical injury for approximately five to 
six hours and at sacrifice for approximately one hour. The timeline of the anesthetics for 
the current study is briefly summarized here. Before injury, all monkeys received 
Ketamine/Propofol for a pre-operative MRI scan (-60 ± 11 days) and Ketamine for a pre-
operative blood draw (-10 ± 3 days). During surgery (0 days), all monkeys received 
Ketamine and sodium pentobarbital. In the first month following surgery, all monkeys 
received Ketamine for treatment infusion 1 day after injury and for blood draw 8 days 
after injury. Two additional blood draws were performed using Ketamine sedation in the 
following months after surgery (39 ± 5 and 66 ± 2 days). Monkeys received 
Ketamine/Propofol for a post-operative MRI scan (107 ± 6 days). Finally, at the 
completion of the study (122 ± 16 days), all monkeys received Ketamine and sodium 
pentobarbital for blood draw, CSF draw, and perfusion. One monkey (SM024j) received 
an additional two MRI scans during the study using Ketamine/Propofol, one pre-
operatively (-11 days) and one post-operatively (+9 days). In the following paragraphs, 
the effect on the brain of anesthetics related to this study is reviewed.   
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 Barbiturates, such as sodium pentobarbital, induce anesthesia by activating 
GABAA receptors and inhibiting the uptake of adenosine which in turn reduces excitatory 
synaptic transmissions and neurotransmitter release (Karmarkar, Bottum and Tischkau, 
2010; Schifilliti et al., 2010). In vitro, sodium pentobarbital reduces neurotoxicity 
induced by kainic acid (Schifilliti et al., 2010) and following serum deprivation 
(Morimoto et al., 2000). In vivo, sodium pentobarbital is neuroprotective after global 
ischemia (Ishimaru et al., 1995) and reduces infarct volume in focal cerebral ischemia in 
rats (Warner et al., 1996). However, sodium pentobarbital also has detrimental effects 
after injury including greater disruption of blood brain barrier permeability after MCAO 
(Chi et al., 2017) and higher intracranial pressure following TBI (Pérez-Bárcena et al., 
2008). Overall, while sodium pentobarbital is neuroprotective through inhibiting 
excitatory synaptic transmissions, it is also cytotoxic by increasing BBB permeability and 
intracranial pressure. During surgery in the current study, sodium pentobarbital may have 
reduced initial neurotoxicity after injury, however all monkeys (both hUTC and vehicle 
treated) received anesthesia for similar duration and volumes. Therefore, the effect of 
sodium pentobarbital on the current results is likely equal in both groups thus not 
affecting treatment outcomes. 
Propofol, 2, 6-disopropylphenol, is a global CNS depressant that functions 
through activation of GABAA receptor and also inhibition of NMDA receptors (Schifilliti 
et al., 2010). During brain ischemia, Propofol protects against excitotoxicity through 
modulating calcium influx and reducing glutamate concentration (Schifilliti et al., 2010; 
Fan et al., 2015). Further, Propofol has a robust anti-inflammatory effect on microglia 
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through suppression of pro-inflammatory cytokine expression (Kubo, Inada and Shingu, 
2011) and is antioxidant through scavenging ROS, inhibiting ROS production, and 
inhibiting lipid peroxidation (Fan et al., 2015). Propofol has been shown to be 
neuroprotective in models of ischemic stroke, subarachnoid hemorrhage, and TBI. 
Specifically, following MCAO, Propofol reduces neuronal apoptosis (Ito et al., 1999; 
Wang et al., 2009) and decreases autophagy proteins (Cui et al., 2012), leading to 
reduction in infarct volume, brain edema, and neurological deficits (Shu et al., 2012). 
Following subarachnoid hemorrhage, Propofol leads to reductions in edema, BBB 
permeability, inflammation, lipid peroxidation, and neurological deficits (Shi et al., 
2015). Finally, in TBI, Propofol improves behavioral outcomes while decreasing pro-
inflammatory cytokine (IL-1β, IL-6, and TNF-α) mRNA and protein expression (F. Liu et 
al., 2016). Taken together, the neuroprotective, anti-inflammatory, and antioxidant 
properties of Propofol may be significant. However, in the current study, Propofol was 
not given in the acute phase either immediately before or after injury. The only exception 
is SM024j, who received Propofol twice within days of injury, but no obvious changes 
were observed in behavioral, lesion volume, or histological data. 
Ketamine is a non-competitive NMDA antagonist that lessens excitotoxicity 
through reducing calcium influx and glutamate release (Bell, 2017). Due to its direct 
activity on NMDA receptors, Ketamine has been associated with a decrease in spreading 
depolarizations after injury such as stroke or TBI (Hertle et al., 2012). In ischemic injury 
models, Ketamine is protective against oxygen-glucose deprivation leading to a 
maintenance of neuronal and astrocyte viability (Schifilliti et al., 2010) and reduction of 
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apoptosis, infarct volume, brain edema, and neurological deficits (Shu et al., 2012). 
Following immune system activation, Ketamine administration leads to an inhibition of 
pro-inflammatory cytokines (TNF-α, IL-6, and IL-8) in both peripheral immune cells and 
microglia (Chang et al., 2005, 2009; Shibakawa et al., 2005). Also, Ketamine given daily 
for one week after TBI results in a reduction of IL-6 and TNF-alpha, autophagy, and 
secondary injury (Wang et al., 2017) and prevention of downregulation of dendritic 
spines (Miller et al., 2014; Wang et al., 2017). Interestingly, in a depression model, 
Ketamine has been implicated in upregulation of BDNF production, which in turn 
increases uptake of glutamate thus alleviating depression symptoms (W. X. Liu et al., 
2016), but this interaction has not been looked at in injury models. Overall, Ketamine 
acts on NMDA receptors thus decreasing excitotoxicity and acts on immune cells thus 
decreasing the pro-inflammatory response. Ketamine was the anesthetic given most 
frequently during the current study, but low doses were used for a short duration of time. 
In summary, the three anesthetics used in the current study may have resulted in some 
neuroprotective, anti-inflammatory, and antioxidant processes, but anesthesia was given 
to all monkeys as consistently as possible thus controlling for the effects and not entirely 
confounding treatment effects. 
Alterations in Stroke and Treatment Between Sexes and Across Age 
The subjects of the current study were young male rhesus monkeys. However, we 
acknowledge that age is a significant risk factor for stroke and is an important 
consideration when modeling stroke (Bacigaluppi, Comi and Hermann, 2010). Studies 
show that older animals are more susceptible to damage resulting from inflammation and 
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oxidative stress occurring in response to ischemia (Buga et al., 2008). Using our non-
human primate model of ischemia, we have demonstrated that there is a significant 
decrease in recovery on motor dexterity tasks for middle-aged monkeys compared to 
younger monkeys (Moore et al., 2012). However, intravenous hUTC treatment in aged 
rats resulted in improved recovery of function (Zhang et al., 2013). While exciting, these 
results need to be replicated in aged NHPs and the differential effect of hUTC on post-
injury processes in aged subjects elucidated. 
There are also differences in recovery from stroke between sexes, but most pre-
clinical studies of stroke use only male animals (Hall, Pazara and Linseman, 1991). 
Studies in female models are important to pursue, especially considering that women 
have greater disability following stroke on average (Go et al., 2013). While estrogen is 
neuroprotective against ischemia, the protective effect diminishes after reproductive 
senescence in a time when risk for stroke is higher (Alkayed et al., 2000). While no study 
has investigated hUTC in female subjects, intravenous BM-MSC enhanced recovery of 
function in young female rats (Chen et al., 2003) and aged female rats (Shen et al., 2007). 
Future studies assessing hUTC in mechanism and efficacy should address both the age 
and sex differences. 
Future Directions: Angiogenesis  
Angiogenesis, the formation of new blood vessels, is an important restorative 
mechanism after stroke that occurs in parallel with synaptic plasticity in the perilesional 
area. For this reason, promoting angiogenesis is an important target for neurorestorative 
treatments after stroke. When comparing gene expression of cell based therapies, UTC 
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express more angiogenic factors than BM-MSC (Panepucci et al., 2004). Specifically, 
hUTC secrete angiogenic factors in vitro including HGF, MCP-1, bFGF, and IL-8 
(Mistry et al., 2005; Lund et al., 2007). Further, as hUTC upregulate TSPs and act via the 
CD36 receptor, as mentioned above, angiostasis is regulated through this pathway (Lin et 
al., 2003; Adams and Lawler, 2004). In vivo, studies have consistently found a higher 
vascular density following experimental stroke and treatment with hUTC (Zhang et al., 
2011, 2012, 2013; Arbab et al., 2012; Jiang et al., 2012; Yang et al., 2012; Shehadah et 
al., 2013). Follow up studies of the current work should assess vascular density in the 
perilesional area as well as the effect of TSP and CD36 receptors on this vascular 
proliferation.  
Conclusion 
In summary, we previously assessed the efficacy of hUTC on motor recovery 
after primary motor cortex injury in rhesus monkeys. After a striking observation of 
improved recovery, we assessed the effect of hUTC on the pathophysiology and 
neurorestorative processes after cortical injury through quantifying proteins in brain 
sections, serum, and CSF from 4 rhesus monkeys treated with hUTC and 4 treated with 
vehicle. In the perilesional area, hUTC treatment was associated with a reduction of 
damage, enhanced neuronal survival, and higher synaptic plasticity. In distal white matter 
pathways, hUTC leads to profound immune activation, suggesting an anti-inflammatory 
pathway. Activation of ventral premotor cortex was higher with hUTC treatment and may 
have enabled recovery of hand movements through projection neurons. Finally, 
peripheral BDNF levels are higher with hUTC treatment one week after injury, 
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suggesting a benefit to early increased BDNF through hUTC. Taken together, these 
results suggest that hUTC treatment modulates immune responses, limits perilesional 
damage and cell death, enables neuroplasticity and reorganization, and enhances acute 
neurotrophic factor secretion. While our results do not directly implicate a mechanism, 
previous studies have suggested that hUTC enhances functional recovery through 
expression of TSPs and BDNF, which in turn activate neurons and glia to enable 
neurorestorative processes. While many cell therapies are currently undergoing clinical 
trials for a variety of neurological disorders, this study advances our understanding of the 
mechanism of cell based therapies. 
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